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Abstract 
 
Replication-selective adenoviruses are promising anti-cancer therapies 
(virotherapy). Viruses can be engineered to selectively target cancer cells by 
deleting viral genes involved in cell cycle regulation. These deletions impair 
replication in normal cells, as the virus cannot overcome cellular checkpoints and 
pro-apoptotic pathways triggered by the infection. In cancer cells, however, these 
pathways are often deregulated hence viral propagation is not affected by these 
deletions. Despite the efforts to maximise potency and selectivity of adenoviruses 
as therapeutic agents, efficacy was poor when evaluated alone in clinical trials. 
Enhancement of efficacy was demonstrated in combination with chemotherapy 
and radiotherapy. A requirement for virus-mediated sensitisation to chemotherapy 
and enhancement of efficacy is the expression of the early viral gene E1A. 
However, the exact E1A regions required for increased cell death have not yet 
been identified. The E1A proteins bind to a variety of cellular factors, including 
the transcriptional and cell cycle regulators p300/CBP and pRb. This thesis 
describes the use of replication-selective and replication-defective adenoviruses 
expressing different mutation of the E1A gene in order to identify regions 
involved in chemosensitisation of prostate cancer cell lines to two cytotoxic 
drugs, mitoxantrone and docetaxel. Synergistic interactions were observed with 
all replication-selective adenoviruses and mitoxantrone in a cell dependent 
manner. The results obtained indicate that mutations in the p300/CBP binding 
site, but not pRb, impaired the sensitising activity of E1A to the cytotoxic drugs. 
Expression of E1A enhanced the arrest in the G2/M phase induced by 
mitoxantrone and increased the percentage of apoptotic cells in a process 
dependent on E1A binding to p300/CBP. Deletion of this binding site also 
attenuated the potency of replicating adenoviruses, indicating that binding to 
p300/CBP plays a central role in sensitisation to chemotherapy and control of 
viral cycle in prostate cancer cells. 
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1Chapter 1 
 
 
 
Introduction: Adenoviruses and E1A in 
gene therapy for prostate cancer 
 
 
1.1 Prostate cancer 
 
Prostate cancer is the most common malignancy in men and second 
leading cause of cancer related death in men in Western countries. In the United 
Kingdom (UK) there are approximately 34000 new cases detected per year, and 
10000 death patients per year would die from the disease, making a mortality of 
30% (6). It also accounts for 25% of all the malignancies diagnosed in men and 
approximately the 12% of male deaths from malignant diseases (6). Prostate 
cancer is a malignancy affecting mostly elder men, with 60% of the cases 
diagnosed in men aged over 70 years (6).  This implies that patients diagnosed 
with metastatic disease often die from causes not related to prostate cancer. In 
addition to age, ethnicity is recognised as an important factor in prostate cancer 
risk. African Caribbean men are more susceptible to this malignancy than 
Caucasian men, while men of Asian origin have the lowest risk (6, 7). In addition, 
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black men have a higher risk with development at a younger age, hence increasing 
the risk of dying from this malignancy. Interestingly, the incidence is 10 times 
higher in Western industrialised countries than in East Asian countries (8). 
Therefore the lifestyle, ethnicity and probably diet might contribute to prostate 
cancer development. 
 
The prostate is a secretory gland, located just below the bladder, 
surrounding the urethra. Its secretions facilitate sperm mobility and also protects 
the male urinary and reproductive systems from pathogens (9). Development of 
the prostate is dependent on androgens, hormones that activate the androgen 
receptor (AR) expressed in the urogenital mesenchyme, inducing development of 
the gland (8, 10). In the adult prostate, AR is highly expressed in the stromal and 
secretory epithelial cells (8, 10).  
 
The prostate is composed of a fibromuscular stroma and a glandular 
epithelial compartment. The glandular epithelium is composed of three different 
cell types: basal, secretory luminal and neuroendocrine. Anatomically, the 
glandular compartment can be divided into a large peripheral area and a small 
central zone. About 70% of prostatic cancers occur in the peripheral zone (8).  
 
 
1.1.1 Development of prostate cancer 
 
Most prostate cancers are classified as adenocarcinomas, as they occur 
more frequently in the glands of the peripheral area (8). The earliest precursor of 
prostate cancer is the prostatic intraepithelial neoplasia (PIN). It is defined as a 
neoplastic growth of the epithelial layer of cells within the prostatic acini. It is 
characterised by a loss of the layer of basal cells, although it expressed markers of 
basal and secretory cells (8). Prostate carcinoma develops due to abnormal cell 
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growth in PIN thought to be caused by a decrease in the apoptotic rate, since cells 
still show slow proliferation rates (8). Some reports suggest that only 1.3% of 
prostate cancer cells enter S-phase per day (11). At this stage, expression of AR 
and the prostate specific antigen (PSA) are increased. PSA is hence used as a 
marker for early diagnosis of the malignancy.  
 
Prostate carcinoma is first localised within the gland; usually several foci 
can be found, varying in their degree of dysplasia and heterogeneity (8).  At an 
early stage, the growth of prostate carcinomas is dependant on androgens, as AR 
controls growth. The AR is active after binding to hormones such as testosterone. 
However, the disease becomes androgen independent as it progresses, even 
though AR is still expressed (8). At a late stage, AR can be activated in the 
absence of androgens, increasing the growth rate of the tumour. This occurs 
approximately two years after diagnosis of a localised carcinoma (6). AR can be 
activated in this case by growth factors or become hypersensitive to androgens 
(7). In other cases, mutations in the AR alter the affinity or specificity to its 
ligands and can bind coactivators in a ligand-independent fashion. Gene 
amplification of the AR has also been reported (8). As a result of these alterations, 
the malignancy becomes more aggressive (7, 8, 10).  
 
At this late stage, prostate cancers metastasise to local lymph nodes and 
spread to distal organs in 90% of the cases. A third of prostate carcinomas become 
invasive, most frequently invading organs such as lung, liver and bone (8). These 
metastasic tumours are aggressive, with a doubling time faster than that of early 
stage localised carcinoma. 
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1.1.2   Current treatments for prostate cancer 
 
Treatments depend on the progression of the cancer. A widespread 
detection of PSA levels has contributed to earlier detection (6, 8). Active 
surveillance, also called active monitoring or watchful waiting, is now often done 
after early diagnosis in the UK. Treatment with more invasive therapies can cause 
side effects and might not increase survival when detection is at an early stage due 
to the slow growth of prostate cancer and the normally advanced age of the 
patients (6). If further growth of the tumour is observed, the next treatment could 
be radiotherapy or surgery. Surgery, also called radical prostatetomy, implies the 
surgical removal of part or the whole gland. However, this procedure has severe 
side effects including impotence and urinary dysfunctions (6). Radiotherapy can 
be administered by external beam irradiation or brachytherapy, also known as 
sealed source radiotherapy (6). Brachytherapy consists of seeds, small radioactive 
rods implanted in he prostate that release radiation locally at the tumour site. New 
therapies are also available for localised prostate cancer, including cryotherapy 
and high frequency ultrasound therapy, although they are not yet considered 
standard procedures (6). 
 
Treatments for localised prostate carcinoma are often combined with 
hormone treatments; prostate carcinoma cells depend on androgens to proliferate, 
hence hormone depletion reduces the growth rate of tumours. Patients that are not 
fit enough to receive invasive therapies might be treated by hormone deprivation 
on its own (6). Androgen deprivation is achieved by orchiectomy or, most 
commonly, chemical castration. Combination of both treatments can also be used, 
called total androgen blockade. Orchiectomy is the surgical procedure of 
castration, while chemical castration is the use of androgen agonists and 
antagonists to block AR activity. Some chemicals (pituitary downregulators, 
including goserelin, buserilin and leuprorelin) target the production of 
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testosterone induced by the luteinising hormone  and gonadotropin produced in 
the pituitary gland while anti androgens stop the testosterone produced in the 
testicles from getting into cancer cells (6, 12). Flutamide and bicalutamide are 
examples of anti androgens used currently in the clinic (6). Pituitary down 
regulators are better known as luteinising hormone releasing hormones (LHRH).  
 
Hormone therapies are the only treatment when prostate carcinoma 
becomes more aggressive and metastasises to other organs (6). However, it is 
unclear whether androgen depletion is curative at this stage. At late stage, prostate 
cells can become hormone independent, so androgen deprivation would only 
eliminate those hormone dependent, less aggressive cells (8). Chemotherapy can 
be used as therapy in these cases and has been found efficient in some cases, 
although ultimately, tumours become resistant to these agents. 
 
 
1.1.2.1 Chemotherapy in prostate cancer 
 
Chemotherapy has shown efficacy in the treatment of high-risk hormone 
refractory prostate carcinoma.  Most commonly used cytotoxic drugs include 
mitoxantrone and docetaxel. 
 
Mitoxantrone is a synthetic anthracenedione, was originally synthesised in 
1979 as a doxorubicin analogue. The FDA approved mitoxantrone for the 
treatment of adult acute myeloid leukaemia in 1987, for hormone-refractory 
prostate cancer in 1996 and for the treatment of multiple sclerosis in 2000 (13). 
Mitoxantrone has a circulating half-life ranging from 8.9 hours to 9 days and is 
rapidly taken up by the tissues, persisting in the body for as long as 272 days (13).   
 
Mitoxantrone is a topoisomerase II inhibitor (14) and also intercalates in 
the DNA, causing cross-linking that together with topoisomerase II inhibition 
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results in defective DNA repair and apoptosis. Recent studies have shown that 
mitoxantrone also has an inhibitory effect on microtubule assembly and induces 
G2/M phase arrest (15). Other biological effects have been described, including 
electrostatic interactions with DNA, DNA-protein cross-links, prostaglandin 
byosynthesis and calcium release (16). Mitoxantrone affects both dividing and 
non-dividing cells and has immunomodulatory effects by suppressing 
proliferation of macrophages, T and B cells (13). It also decreases the secretion of 
cytokines, impairs antigen presentation (13) and controls caspase-2 mRNA levels 
(14). Mitoxantrone is usually administered by rapid intravenous infusion at 3-
weekly intervals, although it can also be administered by continous infusion or 
daily or weekly repeated doses (16). Side effects have been reported after 
mitoxantrone administration; the most common side effects include drop in the 
number of white and red blood cells, resulting in higher risk of infections, 
tiredness and anaemia. Some patients have experienced diarrhoea, loss of hair and 
mild liver damage (6). 
 
Docetaxel is a taxane that stabilises microtubules and arrests their 
depolymerisation by binding principally to ?-tubulin monomers (17). 
Consequently, mitosis is impaired and cells are arrested in the G2/M phase. In 
addition, it inactivates Bcl-2 by phosphorylation. Docetaxel has been shown to 
induce mitotic catastrophe, an alternative path to cell death (17). Rather than a 
mode of cell death, mitotic catastrophe is considered an irreversible trigger for 
cell death, characterised by chromosome missaggregation and imperfect cell 
division. Adverse effects have been reported after docetaxel treatment, including 
hypersensitivity reactions, bone marrow suppression, peripheral neuropathy, fluid 
retention, alopecia and others (18).  
 
Docetaxel is administered in the clinic in combination with prednisolone, 
or its pro-drug prednisone and is replacing mitoxantrone as the chemotherapy of 
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choice for prostate cancer, mainly due to cost-benefit ratios rather than other 
reasons. (18). 
 
 
1.1.3 Alterations in prostate cancer at the cellular level 
 
Chromosomal alterations are not frequent in early stage prostate 
carcinomas; although deletions of chromosomal segments are observed in early 
stages, amplifications become predominant at a late stage (19). Decreased copy 
numbers and loss of heterozygosity of chromosome 8p and 13q are frequently 
observed in prostate carcinomas, while the most commonly amplified region is 
8q, often in metastatic tumours. Loss of 17p and 10q are also observed in late 
stage carcinomas (8, 19). 
 
At the gene level, loss and mutation of p53 and PTEN have been reported 
to be involved in the progression of the disease to a more aggressive stage. In 
addition, loss of 13q implies loss of the retinoblastoma protein (pRb) gene (8). 
However, there are indications that the role of pRb in prostate cancer progression 
might not be decisive, as one allele is usually intact. Some reports indicate loss of 
expression of pRb as prostate carcinomas become more aggressive, although there 
was not a statistically significant correlation between malignancy and pRb 
expression (20). Interestingly, other reports showed that loss of expression of 
p130, a pRb family member, correlated with progression of the disease and that 
the pRb/p130 ratio could be used as a prognostic tool for prostate carcinoma (21). 
 
Together with loss of these tumour suppressor genes, up-regulated 
expression of oncogenes has also been observed. Bcl-2, a p53 repressor, is 
overexpressed in approximately half of the prostate carcinomas (8). Bcl-2 is 
detected in the epithelium of PIN, but not in normal secretory cells; there are 
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indications that the AR activity could control expression of Bcl-2 in PIN and early 
stage carcinomas, suggesting a mechanism that partially explains the dependance 
on hormones in prostate cancer (8). This is also observed in prostate cancer cell 
lines; the expression of Bcl-2 in the LNCaP cell line is androgen dependent (8). 
Overexpression of Ki-67, a known marker for proliferation, has also been reported 
in prostate carcinomas, showing that its expression correlates with the expression 
of AR (10). However, it has also been observed that Bcl-2 is deregulated in the 
absence of AR activity in more advance carcinomas, indicating further alterations 
in the expression of the oncogene that do not depend on androgens (22). 
 
 MYC is another oncogene that is often overexpressed in prostate tumours. 
Interestingly, MYC is a negative regulator of p27, also found to be down-
regulated in prostate cancer (8). The p27 protein is a cyclin-dependent kinase 
(cdk) inhibitor that blocks phosphorylation of cyclin D1, hence controlling the G1 
cell cycle checkpoint (21). Overexpression of MYC together with down-
regulation of p27 would therefore inactivate this checkpoint and allow 
progression to S-phase. In addition, androgen independence of prostate 
carcinomas correlates with overexpression of MDM2 and cyclin D1 (8, 23).  
 
Other changes at the molecular level correlate with the progression to an 
androgen independent stage. The expression profiles of different AR coregulators 
change as the disease progresses to a more undifferentiated and aggressive stage 
(20, 24). The expression of the transcription factor p300 increases during prostate 
carcinogenesis and it has been related to an increase in proliferation in androgen 
independent carcinomas (20, 25). The steroid receptor coactivator Src-1 is also 
commonly overexpressed in prostate carcinomas; it induces the activation of the 
AR, promoting proliferation (24).  
 
Gene silencing by methylation is also altered in prostate cancer. 
Methylation of DNA at cytosines of CpG dinucleotides alters the interactions of 
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DNA with transcription factors, inhibiting transcription of methylated genes (8). 
There is evidence that genes such as GSTP1 encoding the glutathione-S-
transferase ? isozyme, are silenced in prostate cancer by methylation (8). Another 
example of downregulation by aberrant methylation is the CDKN2 (p16/MTS1), a 
negative regulator of the G1/S checkpoint; this downregulation is only partially 
explained by methylation as loss of the 9p chromosome, where this gene is 
allocated, is also found in prostate carcinomas (8, 26).  
 
 
 
1.2 Adenoviruses 
 
Adenoviruses were first isolated in 1953 by Rowe and colleagues, who 
were searching for etiologic agents of acute respiratory infections (1). However, 
adenoviruses are not the etiologic agents for the common cold and only account 
for a small portion of respiratory morbidity in the general population (1). Soon it 
was discovered that there were multiple serotypes with a common complement 
fixation antigen (27). They were first called adenoid degeneration agents, but in 
1956 the name of adenoviruses was adopted, given after the tissue (adenoid) in 
which they were discovered (1, 27). Today, more than 100 members of the 
adenovirus group have been identified (1); 51 serotypes are known to infect 
humans (27). The use of adenoviruses in research led to important discoveries. 
First, Ad12 was demonstrated to be oncogenic in rodents. Secondly, the splicing 
of messenger RNA (mRNA) was first observed in adenoviruses (1, 28). In 
addition, the adenoviral E1A gene has been widely used to investigate cellular 
mechanisms controlling the cell cycle and its regulation by proteins such as pRb.  
 
Adenoviruses are non-enveloped, icosahedral particles encapsidating a 
linear, double-stranded DNA genome (29). They constitute the Adenoviridae 
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family, which is divided into 4 genera Mastadenovirus, Aviadenovirus, 
Atadenovirus and Siadenovirus; a fifth genus is likely to be added (28). This 
division is based on the hosts for the viruses within each genus; mastadenovirus 
infect mammals, aviadenoviruses are found in birds and the other two genera 
infect a broader range of hosts, including reptiles and amphibians (28). Within 
each genus, viruses are subdivided into species according to their specific hosts 
and supplemented with a letter; in the cases of human viruses, they are divided in 
6 species: HAdV-A, HAdV-B, HAdV-C, HAdV-D, HAdV-E and HAdV-F, all 
belonging to the Mastadenovirus genus (28). Each species contains several 
serotypes of adenoviruses; serotype Ad12 belongs to the HAdV-A species, while 
Ad2 and Ad5 are classified as HAdV-C viruses.  
 
Although adenoviruses are not responsible for the common cold, infection 
can lead to acute febrile respiratory disease, pertussis-like syndrome, eye 
infections, meningoencephalitis and some gastrointestinal disorders (27).  
 
 
1.2.1 Structure of adenovirus 
 
1.2.1.1 The viral capsid 
 
The icosahedral protein shell or capsid measures 70 to 100 nm in diameter 
(1). It comprises 252 capsomeres, of which 240 are hexons and 12 are pentons 
situated at the vertices of the icosahedral capsid. From each penton a fiber is 
projected, composed of proteins and traces of carbohydrates (1). There are 11 
known proteins forming the viral particle, 7 constituting the capsid and 4 proteins 
in the core, organising the genomic structure and bridging between capsid and 
genome (1). The capsid constitutes approximately the 87% of the mass of the 
adenovirus (1). A diagram of an adenovirus particle can be found in Fig. 1. 
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The hexon capsomere is composed of three molecules of poplypeptide II 
(1). The hexon is stabilised by three different proteins: polypeptides VI, VIII and 
IX. In addition, polypeptides VI and VIII are thought to act as bridges between 
the capsid and the core components of the virus (1). The structure of the hexon 
capsomere forms a structure with a hexagonal base with a triangular top facing the 
outside of the capsid (1). Along the hexagonal bases of each capsomere in the 
same facet, polypeptide IX stabilises interactions between adjacent hexons. 
Hexons of adjacent facets are joined by the polypeptide IIIa and polypeptide VI 
anchors the ring of peripentonal hexons on the inside surface (1). 
 
Fig. 1. Structure of an adenovirus. The viral DNA is packed with polypeptide VII and stabilise 
by polypeptide mu and V. The capsid is formed by polypeptide II (hexon capsomeres) and 
polypeptide III (penton base); polypeptides IIIa, VI, VIII and IX stabilise the capsid structure. A 
fiber of polypeptide IV, together with the penton base, forms the penton capsomere. Adapted 
from Shenk, 2001 (1). 
 
 23 
 The penton capsomere is formed by a penton base and a fiber. The penton 
base is also an association of a polypeptide. Five molecules of polypeptide III 
form the penton base. The fiber protein is composed of a trimeric association of 
polypeptide IV, than in the case of Ad5 is later modified by addition of 
glucosamine (1). The 40 residues at the amino-terminus of the fiber are embedded 
in the penton base. 
 
 
The core of the viral particle contains four known proteins. The structure 
and organisation of the core remains unclear, and so is the function of some 
proteins in the core. Protein mu is a small arginine-rich protein found in the core, 
but its function remains unknown (1). Polypeptide V can bind to the penton base, 
probably acting as a bridge between the capsid and the core (1). Polypeptide VII 
is the most abundant protein of the core and acts as a histone-like centre around 
which viral DNA is wrapped (1). It is also involved in viral chromatin 
organisation in particles composed of DNA and polypeptide VII (1). The last 
protein found in the virion core is the terminal protein, attached to the ends of the 
viral DNA. This protein serves as a primer for DNA replication and mediates 
attachment of the viral genome to the nuclear matrix (1). 
 
 
1.2.1.2 Genome organisation 
 
The genome organisation of adenoviruses varies among virus genera; 
genes common to all modern adenoviruses are located centrally in the genome and 
are involved in replication, DNA packaging and capsid formation (28). The linear 
genome of Ad5 contains two identical origins of replication at each terminal 
repeat (1). A diagram representing the genome organisation of Ad5 can be found 
in Fig. 2 and a detailed list of genes and proteins coded in Table 1. Near the 
genome left terminus there is a cis-acting packaging sequence that interacts with 
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the structural proteins of the capsid during the formation of new virions after 
infection (1). Viral genes can be classified according to their time of expression 
after infection, being early, delayed early or late genes. Early genes include E1A, 
E1B, E2, E3 and E4 coding for different proteins with functions that involve 
preparation of the infected cell for efficient viral replication and modulation of the 
host immune response targeting infected cells. Delayed early genes are expressed 
early after infection but after the expression of early genes; they code for protein 
IX and IVa2, both involved in transcription of late genes. Late genes are the last 
viral genes to be expressed, coding for structural proteins and polypeptides that 
facilitate assembly of new virions. The late genes are divided in five families, 
termed L1 to L5 (1). Two genes, called virus-associated genes (VA genes I and II) 
that express short RNA molecules during the translation of viral mRNA (30). The 
function of all genes will be discussed later in this chapter. 
Fig. 2. Graphic representation of the Ad5 transcription map. Viral genes are classified in 
early (E1A, E1B, E2A, E2B, E3 and E4) and late units (L1 to L5); arrows indicate the 
direction of transcription of each gene. Adapted from Russell, 2000 (2). 
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 Transcription of viral genes is executed by the RNA polymerase II, with the 
exception of the VA genes, that are transcribed by RNA polymerase III (1). Both 
strands of the viral DNA are transcribed; the rightward reading strand codes for 
E1A, E1B, IX, late genes, VA RNA and E3, and the leftward strand codes for E2, 
E4 and IVa2 genes. The E1B-19K, E1B-55K and protein IX genes are single exon 
structures (28). Other viral genes, however, are transcribed by splicing; all late 
genes, including all genes from the L1-52K unit to pVIII and fiber located in the 
rightward strand, are spliced from the tripartite leader sequence (28). All late 
mRNA share this sequence, as it facilitates translation (1). Preterminal protein 
(pTP), the viral DNA polymerase, E1A, E1B, E3 and E4 genes are also spliced. 
However, transcription of E1A, E1B and E4 is more complex; these genes give 
rise to several mRNAs and proteins by alternative splicing with different 
biological functions (28).  
  
  
1.2.2 Viral cycle 
 
1.2.2.1 Infection and entry into the cell 
 
Viral infection starts with entry of virus into the cell. This is accomplished 
by interactions of the viral fiber knob with a cellular protein of the 
immunoglobulin superfamily, the coxsackie and adenovirus receptor (CAR) (31). 
CAR is a transmembrane protein that is involved in formation of tight-junctions 
and cell-cell adhesion complexes (32). Once the fiber knob is bound to CAR, the 
penton base binds to integrins ?v?3 and ?v?5 allowing internalisation by 
endocytosis (1). Internalisation of the virus is a very efficient event, with 
approximately 85% of the virus that binds to CAR being internalised within 10 
minutes (1). The accepted model implies that binding to CAR only serves to 
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attach the virus particle to the cell, facilitating the interaction with integrins. It 
was reported that modifications in the CAR binding domain of the fiber impaired 
infection, while modification of the penton site interacting with the integrins did 
not affect infection in one study (33). Other researchers showed that the virus 
cannot be internalised in the absence of ?v integrins (34).  
 
 The penton and integrin interaction might not be the only mechanism for 
viral internalisation. It is possible that the penton base could interact with other 
integrins through sites that were not mutated in the study. In addition, heparan 
sulfate glycosaminoglycan and the ?v?1 have been implicated in viral attachment 
and internalisation (35, 36). On the other hand, infection is proportional to CAR 
expression; overexpression of CAR in transgenic mouse models resulted in an 
increased infectivity of tissue that was normally poorly infectable (37). The 
suggestion that CAR only functions as an anchorage protein for adenovirus is 
based on manipulation of the cytoplasmic and transmembrane domains of CAR. If 
CAR was also involved in internalisation, truncation of these domains would have 
an effect on viral entry. However, was demonstrated that expression of the 
extracellular domain of CAR attached to the cell surface by a glycolipid was 
sufficient to allow viral infection (38, 39). One of these reports suggested that the 
absence of cytoplasmic and transmembrane domains actually increased the 
efficiency of the internalisation, even though the mechanisms remained unclear 
(38). In addition, alternative modes of infection have been described in vivo. It 
was reported that coagulation factors like Factor X can bind to hexon capsomeres 
and that this interaction modulates infection of hepatocytes in vivo (40). 
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Table 1. List of viral proteins coded by the different adenoviral genes and their functions during 
infection. Viral genes are divided into early, delayed early and late genes; early and early 
delayed genes are involved in transcription, replication of the viral genome and escape from the 
host’s immune system, while late genes are involved in viral mRNA translation and assembly of 
new viral particles.  
 
 Protein Function 
E1A (5 isoforms) Activation of transcription 
55K Inhibition of apoptosis; mRNA transport 
E1B 
19K Bcl-2 homolog 
E2A DBP DNA binding protein 
Pol Viral polymerase 
E2B pTP Primer for DNA replication; attachment to nuclear 
matrix 
12.5K Unknowm 
6.7K Signal-anchor protein; inhibitor of TRAIL 
gp19K Inhibition of MHC class I presentation 
ADP Virus release 
RID Protection from TNF-mediated apoptosis 
E3 
14.7K Protection from TNF-mediated apoptosis 
E4 Orfs1-6/7 Activation of transcription; mRNA transport 
IX Stabilisation of hexon capsomeres 
Delayed early 
IVa2 Activation viral late transcription 
52K Encapsidation proccess 
L1 
IIIa Bridge between penton and hexon 
pVI Stabilisation: bridge between core and capsid 
L2 
II Hexon capsomere 
III Penton base 
pVII Viral DNA packaging protein L3 
V Packaging and stabilisation 
100K Translation of viral mRNA; encapsidation 
33K Transcription of late viral genes L4 
pVIII Bridge between core and capsid 
L5 IV Fiber protein 
VA VA RNAs Interferon antagonism, cellular mRNA block 
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After internalisation, the endosome containing the virion is rapidly 
disrupted and the virus moves quickly to the nucleus by interactions of hexon with 
microtubules, before the formation of an endosome (1).  The virion is dismantled 
in the lysosome in an organised sequence of event to ensure successful delivery of 
viral DNA to the nucleus. The regulation of this process is unknown; virions 
escape the endosome when acidification of this compartment occurs, but this is 
not related to disassembly of the capsid (1). First, polypeptides IIIa and IV are 
lost, followed by degradation of polypeptide III and polypeptide VI by viral 
proteases. At this point, hexon is still bound to viral DNA through polypeptides 
VI and VIII that are consequently degraded to prepare transport of DNA to the 
nucleus. Finally, polypeptide IX, the last of the capsid proteins is lost, leaving 
Fig. 3. Diagram showing an adenovirus infection cycle. After attachment to CAR and integrins, 
the viral particle is internalised in an endosome. The particle escapes from the endosome and 
viral DNA reaches the nucleus of the infected cell. Early viral genes prepare the cell for viral 
transcription and replication, resulting in the production of new viral particles that are release 
after lysis of the cell. Adapted from Kanerva et al, 2004 (5). 
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viral DNA free from the hexon (1). Viral DNA is transported to the nucleus 
through the nuclear pores entering the nucleus in a complex with polypeptide VII. 
It was thought that polypeptide VII was replaced by cellular histones to form a 
structure similar to cellular chromatin. However, there is yet no evidence of 
cellular histones binding to viral DNA. Currently it is believed that polypeptide 
VII forms a chromatin-like structure with the viral DNA. The terminal protein 
associates the viral DNA with the nuclear matrix, in a event that is essential for 
viral replication, as the terminal protein is necessary to activate viral gene 
expression (1). 
 
 
1.2.2.2 Activation of viral transcription 
 
Transcription of viral genes is initiated after viral DNA entry to the 
nucleus and attachment to the nuclear matrix. First, the early viral genes are 
transcribed and expressed to induce S-phase in the infected cells and enable viral 
replication by protecting the infected cell from the host immune system and to 
synthesise viral proteins required for viral DNA replication (1). The first gene to 
be transcribed is E1A; it is controlled by a constitutively active promoter and 
codes for five products generated by alternative splicing (1). The two main 
proteins coded are 13S and 12S that are identical except for an additional 46 
amino acid region present only in the 13S protein. All E1A proteins are named 
based on their respective sedimentation coefficients. The other three proteins 
coded by the E1A gene (11S, 10S and 9S) are expressed later in the cycle, but 
their function remains unclear (1). Expression of E1A-9S has only been observed 
in vitro (4). E1A proteins bind to cellular proteins and modulate their function to 
induce cellular S-phase entry and activation of the transcriptional machinery. 
More details about the function and role of E1A in adenovirus infection will be 
discussed in the next section of this chapter. The expression of E1A and its 
interactions with cellular proteins induce p53-dependent and p53-independent 
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apoptosis (1, 3, 41, 42). This is overcome by expression of E1B and E4 proteins; 
the E1B gene codes for two main proteins, E1B-19K and E1B-55K both with 
antiapoptotic properties (41, 43).  
 
The E1B-55K protein inhibits p53-dependent apoptosis, while the E1B-
19K protein blocks both p53-independent and p53-dependent apoptosis by 
interacting with BAX and BAK (41, 43). E1B-55K protein inhibits p53-mediated 
apoptosis by binding directly to p53 and blocking its transcriptional activation 
(43, 44). In addition, E1B-55K interacts with the E4orf6 viral protein to control 
viral mRNA export and viral ubiquitin ligase activity (41, 45). E1B-55K acts as a 
substrate-binding subunit that promotes degradation of p53, a second mechanism 
of downregulation of p53 by E1B-55K (41, 45). E1B-19K can block apoptosis 
induced by tumour necrosis factor (TNF), Fas ligand (FasL) or TNF related 
apoptosis inducing ligand (TRAIL) (41, 43). Deletions of the E1B-19K 
significantly reduced the viral yield in normal primary cells after TNF treatment 
(44). E1B-19K can functionally substitute for Bcl-2; activation of E1B-19K 
differs from Bcl-2 in that E1B-19K is not phosphorylated to be active (43). 
Although the sequence homology between the E1B-19K and Bcl-2 is weak, there 
are conserved residues that are common to both the viral and the cellular proteins 
(43). E1B-19K binds to the proapoptotic members of the Bcl-2 family BAX, 
BAK, BIK, BNIP1 and BNIP3 (30). The antiapoptotic properties of E1B-19K can 
mostly be attributed to the ability to bind BAK and BAX; E1B-19K binds BAK 
and abrogates the interaction with BAX, preventing activation of BAX, 
mitochondrial pore formation and release cytochrome c (Cyt c) (43). In addition, 
the E1B-19K protein has been shown to bind the intermediate filaments of the 
cytoskeleton in the cytoplasm and the nuclear lamina (46); this suggested a role of 
E1B proteins in regulation of the cytoskeleton that somehow promotes cell 
survival independent of anchorage, although these mechanisms remain unclear. 
 
 
 31 
1.2.2.3 Viral DNA replication 
 
Viral replication starts when the E2a promoter is activated by E2F and E2 
protein is accumulated (1). Viral DNA replication can be divided in two stages; 
first, replication starts from the terminus of the double-stranded DNA, displacing 
one of the original strands. Next, the displaced strand is circularised by annealing 
of the complementary termini; a complementary sequence is synthesised, forming 
a duplex of parental and daughter strands (1). Cis-Acting sequences within the 
inverted terminal repeats (ITRs) act as origin of replication (1). The ITRs are 
formed by three domains; domain A is essential for viral DNA replication, while 
domains B and C are not required but increase the efficiency of the process. 
Domains B and C bind to nuclear factor I (NFI) and nuclear factor III (NFIII) 
respectively and these interactions stabilise the replication complexes bound to the 
domain A (1). This replication complex is formed by an association of viral 
proteins coded by the E2 gene, the preterminal protein (pTP) and the DNA 
polymerase. The pTP binds to the origin of replication, where it is processed by 
proteolysis to generated the E2-coded terminal protein (TP). In addition, pTP is 
thought to preserve the integrity of the viral chromosome’s terminal sequence 
during multiple rounds of replication (1). It forms a complex with the E2-coded 
DNA polymerase to allow replication of the DNA. The pTP binds to a 
deoxycytidine monophosphate (dCMP) after the polymerase is in place. The pTP-
CMP serves a prime start for the polymerase to synthesise the new DNA strand. 
Another E2-coded protein is needed for chain elongation, the single-stranded 
DNA-binding protein; its polymerisation is essential for viral DNA strand 
separation (1).   Polymerisation is also necessary for efficient elongation; the 
polymerase can travel the entire length of the viral chromosome after it has 
separated from pTP (1). Another nuclear factor, NFII, has been reported to 
contribute to viral DNA replication; it does not enhance the synthesis of new 
DNA, hence it must be needed to overcome DNA structural problems after 
extensive replication (1). 
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1.2.2.4 Viral mRNA export and translation 
 
One of the consequences of E1A expression is the release of free E2F 
transcription factor that binds to the promoter of the E2 viral gene, activating 
transcription of this gene and viral DNA replication. Other viral genes are also 
able to induce transcription of the viral genome by directing E2F to the E2 
promoter (1, 47). Adenoviruses lacking E4orf6/7 do not show attenuated 
replication, hence this gene is not essential for initiation of transcription (47). 
However, viruses expressing E4orf6/7 under the control of the CMV promoter in 
the absence of E1A showed that E4orf6/7 expression was sufficient to displace 
E2F from pRb and re-direct it to the E2a viral promoter (47). This indicates that 
E4orf6/7 could act as an auxiliary gene to E1A, to ensure efficient binding of E2F 
to the E2a promoter. In addition, the E4 gene has shown to modulate apoptosis 
and control of mRNA export (45, 48-50).  Apoptosis by p53-independent 
mechanisms has been described after expression of E4orf4 (49-51).  Apoptosis by 
E4orf4 does not involve caspase activation but can be reversed by the anti-
apoptotic protein Bcl-2 (49) and binding to the phosphatase 2A (PP2A) is a 
requirement for the induction of apoptosis (50, 51). Interestingly, there is 
evidence that the E4orf6 can inhibit p53-mediated apoptosis, but not p53-
independent, and is able to cooperate with E1A in the transformation of baby rat 
kidney cells (44, 48). Additional research has shown similar properties for E4orf1 
and E4orf3 (50). Some groups have suggested that inhibition of p53-mediated 
apoptosis by E4orf6 might be caused by the ability of this protein to control 
mRNA export from the nucleus (44, 52). E4orf6 control the mRNA interacts with 
pp32/leucine-rich acidic nuclear protein (pp32/LANP) and the complex is 
exported to the cytoplasm, where binds an AU-rich element (ARE) present within 
many proto-oncogenic mRNAs (52). E4orf3 and E4orf6 are known to play a role 
in mRNA export and the control of the alternative splicing of the three major late 
tripartite leader (51). E4orf6 binds to E1B-55K to control mRNA export; together, 
they allow nuclear export of late viral mRNAs, block export of cellular mRNA 
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and induce degradation of proteins like p53 by ubiquitination by E4orf6 ubiquitin 
ligase activity (45, 53). In fact, an adenovirus expressing a mutant E4orf6 lacking 
ligase activity was impaired for both ubiquitination of p53 and mRNA export 
from the nucleus, suggesting that degradation of a specific substrate is responsible 
for E4orf6/E1B-55K nuclear mRNA export (45). 
 
Expression of adenovirus late genes starts during viral DNA replication, 
controlled by the major late promoter, activated by E1A proteins late during the 
infection (1). Late genes are organised into a single large transcription unit that is 
processed by poly-A site utilisation and alternative splicing by E4 proteins (1). 
This generates mRNAs classified into 5 families based on the poly-A addition 
sites, called L1 to L5 (1). Transcription of the late genes is achieved by the 
contribution of a cellular transcription factor called USF and a viral transcription 
factor coded by the viral delayed early gene IVa2, also involved in capsid 
assembly (1, 28). At this point, cellular mRNA fails to accumulate in the 
cytoplasm, while viral mRNAs are exported from the nucleus by the process 
mediated by E1B-55K and E4orf6 mentioned earlier in this chapter. Viral mRNA 
is then translated, but not cellular mRNA; selective translation of viral mRNA is 
facilitated by the inactivation of protein kinase R (PKR) and the expression of 
virus-associated RNAs (VA RNAs) (1, 30). VA RNAs are small RNA molecules 
that accumulate in the cytoplasm and protect viral mRNA from degradation, in 
addition to other functions, such as protection of the infected cell from interferon-
mediated cell death (54). Another mechanism for selective translation of viral 
mRNA is the inactivation of the helicase activity of eIF-4F. Late viral mRNAs 
contain a sequence called the tripartite leader sequence, that allows translation by 
the ribosome in the absence of the helicase activity provided by eIF-4F, essential 
for translation of cellular mRNA (1). Another viral protein, the 100 K protein of 
the L4 family, also selectively activates late viral protein synthesis, as viruses 
with defects in this protein fail to produce viral proteins, even though they are 
able to block cellular mRNA translation (1). 
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1.2.2.5 Assembly of new virions 
 
The L4 100K protein is also involved in the assembly of new viral 
particles. It acts as a scaffold to assemble the three molecules of polypeptide II. 
Hexon capsomeres and penton base bound to the fiber accumulate in the nucleus 
to start the assembly of new capsids in a process that could involve L3 proteins. 
L3 proteins have shown protease activity that could be involved in the 
modification of structural proteins (1). Empty capsids are formed in a manner that 
requires interaction with the packaging signal located within the viral DNA. DNA 
is then encapsidated, beginning with the left end of the viral DNA, in a process 
that could involve the L152/55K proteins (1).  
 
Viral particles are released after assembly through destruction of 
intermediate filaments of the cytoskeleton, leaving the cell prone to lysis (1). The 
action of the E3 11.6Kd protein, known as the adenovirus death protein (ADP), 
also plays a role in the destruction of the cell and consequent release of the virus, 
although the exact underlying mechanisms remain unknown (1, 41, 55, 56). E3 
genes have also been reported to down-regulate E1A (57, 58). Two E3 proteins, 
E3-14.5K and E3-10.4K have been described to decrease E1A translation, but not 
mRNA levels. Consequently, E3 genes appear to be involved in both regulation of 
the viral cycle and evasion from the immune system (58). 
 
 
1.2.2.6 Escape from the host’s immune system 
 
The E3 genes code for 7 proteins involved in protection of the infected cell 
from the immune system and in viral release (30). Deletion of these genes has no 
adverse effect on viral toxicity and replication in vitro, but attenuates viral 
potency in vivo (35, 56, 59). The E3 promoter contains binding sites for several 
transcription factors, one of which is nuclear factor ?B (NF?B). NF?B is induced 
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by TNF, so E3 is expressed in this context (30). It has been shown that the E3-
14.7K protein protects from TNF-mediated apoptosis by a mechanism that 
involves down-regulation of the NF?B transcriptional activity mediated by 
several cytokines (60). However, other reports showed that E3-14.7K binds to 
NF?B antagonist to repress apoptosis and induce a NF?B-dependent survival 
pathway (1, 30). Probably, E3 proteins modulate NF?B activity to promote 
survival mechanisms and repress apoptosis induced by cytokines. Another E3 
complex called RID also protects from TNF-mediated apoptosis; this complex is 
formed by two E3-coded proteins: RID? and RID? (30). This complex avoids 
FasL and TRAIL related apoptosis by clearing the corresponding receptors from 
the cell surface. Another main protein encoded by E3 genes is the E3-gp19K 
protein that inhibits MHC class I presentation by direct binding and blocking of 
its transport to the cell surface (30, 61). However, some reports suggest that E3-
mediated decreases in MHC class I cell surface presentation is not efficient, cell-
dependent and does not prevent from MHC class I recognition at early times of 
infection (62). Expression of all E3-coded proteins after infection in 
immunocompetent hosts would allow initial escape from the immune system to 
achieve efficient viral replication (56). 
 
 
1.3 E1A 
 
E1A is the first gene to be expressed after viral internalisation, controlled 
by a constitutively active promoter (1). The Ad5 E1A gene starts at nucleotide 
499 and ends at nucleotide 1632; it contains two exons, the first at nucleotides 560 
to 1112 and the second located at nucleotides 1229 to 1542 (4). The second exon 
is followed by a stop codon and the poly-A coding region. The E1A gene codes 
for 5 different proteins (Fig. 4.B) generated from one transcript that is modified 
alternative splicing (Fig. 4.A) and not by post-translational proteolytic 
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degradation (63-65). The Ad5 E1A proteins were named based on their 
sedimentation coefficients (S) of their respective mRNAs: 13S, 12S, 11S, 10S and 
9S (63) and contain 289, 243, 217, 171 and 55 amino acids respectively, with 
molecular weights ranging from 58 to 28 kDa (3, 64). The mRNAs share a 
common 5’ and 3’ termini but differ in size of their excised introns; the different 
mRNA are derived from the larger 13S product by alternative splicing (4, 64). 
These proteins are encoded in the same reading frame, although because of the 
structure of the 9S splice junction, the second exon of 9S is read in a different 
frame (63, 64). Analysis of the residues of E1A proteins of several human 
serotypes has identified three conserved regions (CRs) (1, 3, 66). These conserved 
regions, along with arginine at position 2, the PXDLS motif and a short run of 
basic residues at the C-terminus are regions common in different serotypes (3). 
The PXDLS together with the basic residues in the C-terminus are highly 
conserved and some researchers have named that region the conserved region 4 
(CR4) (41). The sequence of the PXDLS pentapeptide only changes in one amino 
acid among different serotypes; in the case of Ad5, the amino acid sequence is 
PLDLS (41, 67). The other CRs are located within amino acids 40 and 80 (CR1), 
residues 121 to 140 (CR2) and 140 to 185 (CR3) (1, 4).  
 
The 13S protein is the only E1A product that contains the CR3 and these 
46 residues are the only missing in the 12S protein (1, 66). With the discovery of 
the 11S and 10S product, it was discovered that the CR3 was also present in the 
11S product (4, 64). The 11S product lacks the CR1, while the 10S protein lacks 
both CR1 and CR3. The 9S protein is the only product that lacks all CRs (4). The 
three-dimensional structure of E1A proteins has yet to be determined, despite 
numerous efforts by X-ray crystallography and nuclear magnetic resonance 
(NMR) (42, 68). They contain a high percentage of proline residues that probably 
limits the formation of secondary structures (42).  
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Fig. 4. Graphic rtepresentation of the E1A gene and the its products. A) Five E1A mRNA 
are generated by alternative splicing of the E1A gene. B) Translation of E1A mRNA 
produces 5 proteins. 13S and 12S are the main regulators of the entry into S-phase; these 
proteins only differ in the additional CR3 only present in 13S. Adapted from Mymryk, 
1998 (4). 
A 
B 
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In addition, E1A contains segments of linear sequence that mediate protein 
interactions and that are characterised by local structural plasticity, also called 
structural disorder (68). This led to the concept that E1A is formed by a series of 
small modular domains, as deletions of small fragments generally interfere with a 
small subset of functions without affecting E1A activity globally (68). Although 
the three-dimensional structure of the complete E1A protein is not known, NMR 
has been used to resolved the structure of the N-terminal portion of CR3, found to 
from an ?-helix, while CR4 has a series of ?-turns (3). Informatical predictions 
suggest that the N-terminus of E1A contains a ?-helix and three regions 
antiparallel strand (3, 68). 
 
The E1A proteins are acidic, localised in equal amounts in both the 
cytoplasm and the nucleus and are degraded rapidly, with a half life of 20 to 80 
minutes in infected cells (42) It was shown that the half life of 12S is 
approximately 80 minutes, while that of 13S is only 35 minutes, explaining why 
the concentration of the 12S protein is similar or greater than the concentration of 
13S, despite mRNA levels for 13S  being four times greater than for 12S (69).  
 
E1A products are also post-translationally modified. E1A 13S and 12S are 
phosphorylated at serine residues 89, 96, 132 and 219, while 13S is also 
phosphorylated at residues 185 and 188 (42). Current evidence indicates that these 
translational modifications are not essential for E1A activity, although they might 
modify function since mutations at these sites have modest effects on various E1A 
activities (4, 42). There is also evidence of E1A modulation by acetylation of a 
lysine residue; acetylation of Lys-239 in the 12S proteins (Lys-285 in 13S) by 
p300 and P/CAF decreased the binding affinity of E1A to the carboxy-terminal 
bindin protein (CtBP) (70). 
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The different E1A products are not expressed at the same time during 
infection; 9S mRNA is detected only late during infection, while 13S and 12S are 
produced both early and late (66). E1A products can be detected already one hour 
after infection and continue to be expressed at about 90% of its maximal rate 
through 9 hours after infection (65).   
 
 
1.3.1 Functions of E1A 
 
The main functions of E1A proteins are to activate transcription of viral 
early promoters for expression of viral proteins and to activate the host cell in 
order to enter S phase and prevent cell cycle arrest and death, so that the cellular 
transcriptional machinery is directed towards transcription and translation of viral 
genes only (1).  
 
 Fig. 5. Representation of E1A 13S, indicating the binding sites for the main E1A-interacting 
proteins. Adapted from Gallimore et al, 2001 (3). 
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1.3.1.1 Entry into S phase 
  
In order to activate the expression of early viral genes, E1A must first 
generate an optimum environment for transcription (3, 41, 71). E1A expression 
directs the cell to enter S phase so that the transcriptional machinery of the cell is 
available for viral transcription. It achieves this by interacting with multiple 
cellular proteins (Fig. 5) and modulating their function as E1A does not directly 
bind to DNA (72). The most important E1A interactions are binding to the pRb 
and the p300/CBP proteins (Fig. 6). 
 
The retinoblastoma protein (pRb) family members, also called pocket 
proteins, are proteins responsible for cell cycle regulation. In the absence of 
mitotic stimuli, hypophosphorylated pRb is bound to E2F. In response to growth 
factors, pRb is phosphorylated by cyclin-dependent kinases (cdk), causing the 
release of E2F and induction of S phase. E1A can also displace E2F by binding to 
hypophosphorylated pRb through a LXCXE motif present in the CR2, amino 
acids 122 to 126 (73).  The CR1 can also bind weakly to pRb, so this region was 
first thought to act as an auxiliary binding site (74, 75). However, the CR1 
sequence that binds to pRb is similar to the E2F sequence that contact pocket 
proteins; for this reason, it has been suggested that E2F is ultimately removed 
from pRb by competition with CR1, although little is known about this interaction 
(75-78).  
 
Binding to hypophosphorylated pRb by E1A overrides the 
phosphorylation-dependent regulation of pRb-E2F complexes. However, the 
transcriptional activity of pRb is not only regulated by the interactions with E2F. 
Rb not only represses E2F-dependent transcription, but also recruits histone 
deacetylases (HDACs), such as HDAC1, and methyltransferases such as HP-1 
and SUV39H1, to promoter complexes to inactivate gene expression. In addition, 
pRb can bind members of the SWI/SNF family of transcripitional regulators 
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hBRM and BRG1 to induce cell cycle arrest (78). E1A is also able to displace 
these members of the pRb-associated complex to modulate the transcription of 
target genes. Interestingly, E1A was reported to overcome transcriptional 
repression in response to a dominant negative E2F chimaera that was generated by 
fusing E2F DNA-binding domain to pRb (42). These data indicated that E1A 
could overcome transcriptional repression independently of E2F release. 
Consequently, displacement of other members of the repression complex, possibly 
hBRM and BRG1, is also important for transcriptional regulation.  
 
The interactions between pRb, E2F and E1A might be more complex than 
originally thought. There are eight E2F family proteins, although only E2F 1 to 5 
bind pRb, p130 and p107, with functions varying from transactivation to DNA 
repair (77). Two independent reports have shown that pRb-E2F1 complexes are 
not disrupted by E1A expression (77, 79). Rb-E2F2 to 4 complexes were absent in 
the presence of E1A and so were E2F2 to 4 bound to p107 or 130, even when the 
expression of E2Fs was increased (79). According to these findings, E1A cannot 
disrupt the interaction between pRb and E2F1 because of a second binding site in 
pRb that is specific for E2F1 and does not bind other E2F proteins or E1A. These 
findings were supported by the detection of pRb-E2F1-E1A complexes (77). Both 
reports suggested that the interactions between pRb and E2F1 contribute to cell 
viability in response to DNA damage or E1A, as disruption of pRb-E2F1 
complexes increased cellular sensitivity to DNA-damaging agents (77, 79).  
 
Disruption of pRb-E2F complexes by E1A induces cyclins E and A that 
are important to overcome the G1 checkpoint and enter S phase. These cyclins 
activate cdk2 that phosphorylates pRb to ensure efficient release of E2F to 
complete S phase induction and prevent cell cycle arrest (41). E1A binds cdk2 
indirectly via interactions with p107 and p130 to modulate their interactions with 
cyclins A and E, resulting in altered functions of the cyclins (80, 81). The 
interactions of E1A with the different pocket proteins could regulate different 
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functions. E1A CR2 binds similarly but not identically to pRb, p107 or 130 and 
even though the LXCXE residues are important for binding to all three proteins, 
mutations in adjacent residues resulted in changes in binding affinity to these 
proteins (73). In addition, the phosphorylation status of these proteins is 
differentially regulated by E1A. Transfection of U2OS cells with E1A 12S 
resulted in attenuated hyperphosphorylation of p130 and p107 without affecting 
the phosphorylation of pRb (82). These results suggested that E1A binds to pRb 
to induce E2F-dependent transcription while the interactions with other pocket 
proteins might prevent their hyperphosphorylation, consequently inhibiting cdks. 
However, E2F-dependent transcription is not only regulated by pRb. In cells 
lacking pRb a G1-arrest is maintined due to absence of E2F-induced transcription, 
suggesting that other pocket proteins and/or other cofactors can regulate E2F (76). 
In addition, E1A binding to pRb is a requirement for E1A-mediated 
transformation, while interactions with other pocket proteins, such as p130 and 
p107, are not essential (73, 82). 
 
In general, release of E2F activates E2F-dependent transcription. It has 
also been shown that E2F can induce apoptosis in growth arrested rodent cells, 
possibly by induction of the p19
ARF
 gene, repressing the functions of the p53-
antagonist MDM2 (HDM2 in humans) (42, 83). However, E1A-mediated 
apoptosis is not dependent on pRb sequestration, despite p53 stabilisation through 
E2F induction of p19
ARF
. E1A mutants lacking the pRb-binding region in CR2 are 
still able to induce apoptosis, showing that the CR2 is not required for E1A-
mediated apoptosis (84). Of note, this research did no take into consideration the 
interactions between pRb and CR1. Interactions of the CR1 and N-terminus of 
E1A with other cellular factors also induced p53-independent apoptosis. E1A also 
interacts with the p73 protein and induces apoptosis through p53-independent 
mechanisms (85). Other mechanisms involve interactions with p21, p400 or 
regulation of p300/CBP activity by E1A. 
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Accumulation of p53 after disruption of pRb-E2F complexes can induce 
members of the Cip/Kip family, like p21 and p27, and the cdk inhibitors from the 
INK4 family, p16, p15 and others (80, 86). These molecules repress the disruption 
of pRb-E2F complexes and induce senescence (41). The p21 protein represses 
cyclin E and ckd2 activities, preventing the disruption of pRb-E2F complexes 
(87). E1A abrogates activation of p21 by acetylating pRb in a process that 
involves the acetyltransferase activity of p300. Acetylated pRb forms a complex 
with MDM2 that binds to p53, inhibiting p53-dependent activation of p21. This 
process directs p53 towards the induction of apoptosis and might be important for 
the induction of DNA synthesis (78). Even though at first it is difficult to explain 
why E1A would induce an apoptotic process that could compromise viability, it is 
thought that this is a protective mechanism from p21-dependent senescence and 
G1 arrest, as other viral genes are able to inactive p53-dependent pro-apoptotic 
pathways (42). It has been reported that E1A directly interacts with p21 to 
abrogate its growth inhibitory functions and to overcome p21-mediated G1 arrest 
(88). Interestingly, the N-terminal region of E1A that binds p21 is essential for the 
induction of apoptosis in DNA-damaged cells after induction of p53 (89). 
 
In addition, p16-dependent senescence requires p16-pRb interactions; 
without this interaction, p16 induces apoptotic cell death (26). Additional studies 
in prostate epithelial cells showed that alterations in both p16 and pRb are 
required to bypass senescence (90). The relief of p16 and p27 induced G1 arrest 
by E1A requires other regions within CR2 that are independent of binding to pRb. 
Two motifs within CR2 were found to overcome p16 and p27 activities, a Gly-
Phe-Pro motif (GFP motif) and a SDDEDEE motif (80). These motifs are present 
at the N-terminus of CR2 in close proximity and could be considered as one 
GFPPSDDEDEE motif. The authors suggested that this region could recruit an 
additional repressor to target genes; this repressor could potentially be a HDAC, 
although HDACs bind pRb through a LXCXE motif (80).  
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The other main protein interacting with E1A is p300, usually in a complex 
with the CREB-binding protein (CBP), which are transcriptional regulators with 
histone acetyltransferase activities (HAT). The interactions occur at the N-
terminus and at a FPDSVML sequence within the CR1 of E1A (42, 91-94). 
However, new binding sites for p300/CBP that are required for the transactivating 
functions of E1A 13S have been found in the CR3 (95). These findings suggest 
that the regulation of the transcriptional activity of p300/CBP depends on the 
balance of 13S to 12S, as 12S represses CR3-mediated transcription by binding 
p300/CBP through the CR1 domain (96).  
 
While the main mechanisms for transcriptional regulation by p300/CBP is 
through HAT activity, this is not the only mechanism that has been described. 
There are reports demonstrating the role of p300/CBP in proteasomal degradation 
of transcriptional regulators located at promoter sites after E1A expression. The 
p300/CBP complex can bind to the APC/C complex, an ubiquitin E3 ligase. This 
would target proteins to degradation by the 26S proteasome (97). Interestingly, 
E1A can bind components of the proteasome such as the S4 and S8 subunits (98). 
It is possible that E1A interactions with both p300/CBP and the 26S proteasome 
favour the degradation of the targeted proteins.  
 
E1A can both inhibit p300/CBP HAT activity in some contexts and 
promote it in others; E1A probably redirects p300/CBP from cellular promoters, 
hence inactivating transcription, to inactive viral or cellular promoters, where it 
uses the HAT activity of p300/CBP (3). Activation of the viral E4 promoter 
requires the recruitment of p300/CBP by E1A 13S, showing that the CR3 region 
is needed for transcriptional activation, while the CR1 represses it (95). The 
p300/CBP complex activates transcription by acetylating histone tails or lysine 
residues of other transcription factors (42). The E1A N-terminus binds to the 
transcriptional adaptor motif (TRAM) of p300/CBP, thus inactivating HAT 
activity (99). The TRAM motif can also disrupt the p53-MDM2 complexes, 
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leading to stabilisation of p53. It is possible that E1A stabilises p53 by using CBP 
to disrupt this interaction. Other reports have shown that E1A must interact not 
only with pRb but also with p300 in order to stabilise p53 and induce p53-
dependent apoptosis (100). Disruption of pRb-E2F complexes are required for 
upregulation of p53, but additional interactions of E1A with p300/CBP are 
required to successfully stabilise p53 (101). However, E1A-mediated apoptosis 
and the E1A regions involved are more complex and also involve p53-
independent pathways. Apoptosis was detected in p53-null cells after expression 
of E1A; the mechanism was inhibited by co-expression of E1B or treatment with 
caspase inhibitors, indicating that the mitochondrial apoptotic pathways were 
implicated (102). Nevertheless, p53-independent apoptosis also required E1A 
binding to p300 and pRb, according to the results from the research. 
 
E1A can also bind and repress another HAT protein, the p300/CBP 
associated factor (P/CAF) indirectly in a complex with p300/CBP or by direct 
interaction with a sequence within the 60 N-terminal amino acids (42). When E1A 
binds to p300/CBP, it displaces PCAF and inhibits its intrinsic HAT activity (1). 
Interestingly, PCAF acts as a coactivator of p21 in response to DNA damage-
mediated p53 up-regulation and it is possible that the interactions of PCAF with 
E1A constitute an alternative method for p21 repression. Blockade of p21 
activation is not only important for the regulation of phosphorylation of pRb; 
down-regulation of p21 increases cyclin E and cdk2 activity to ensure the 
disruption of pRb-E2F complexes and entry to S phase. However, cyclins 
inactivate p300 through phosphorylation and probably constitutes another 
checkpoint for G1/S transition. In the presence of p21, cyclins are blocked and 
p300 can activate transcription. After E1A expression, low levels of p21 should 
contribute to p300 blockade, but E1A can inhibit cdk-dependent phosphorylation 
events in p300 and use its HAT activity to control transcription (103). However, 
other reports suggest that phosphorylation of p300/CBP increases its HAT 
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activity; E1A could form complexes with cyclin E and cdk2 to 
phosphorylate p300 and increase HAT activity (42, 103).  
 
Besides binding to p300/CBP, E1A interacts with the TATA-binding 
protein (TBP) to modulate transcription (92). Amino acids 2 to 6 and 20 within 
E1A are essential for E1A-mediated repression of transcription and binding to 
TBP and p300/CBP (92). TBP interacts with several transcription factors (TF), 
like TFIIA, IIB, IIF and RNA polymerase II that are also modified by p300/CBP 
 
Fig. 6. Diagram describing the interactions of E1A with cellular proteins and their downstream 
consequences. Thick arrows represent events upregulated after expression of E1A; thin arrows 
represent those events that are downregulated in the presence of E1A. E1A binds to the pRb 
family members, displacing E2F and inducing upregulation of cdk2, cyclin A/E and entry into 
S-phase. E2F will also stabilise p53; this can lead to apoptosis or p21/p16-dependent 
senescence. Senescence is abrogated by E1A binding to p300/CBP and acetylation of pRb, that 
then binds to MDM2 to inhibit p21 induction. E1A also bind to p400/TRRAP to downregulate 
p21. The E1B genes will inhibit apoptosis later on in the viral cycle. E1A binding to p300/CBP 
and p400 is also critical for S-phase induction; p400 allows myc expression and E1A binding to 
p300/CBP represses transcription of cellular genes involved in regulation of cell cycle 
checkpoints, hence allowing entry into S-phase.  
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dependent acetylation (99, 103). E1A binds to the same region of p300/CBP that 
interacts with TFIIB and components of the RNA polymerase II holoenzyme 
complex in order to repress transcription (103). It is likely that p300 serves as a 
scaffold for the repression of cellular promoters; p300 binds to transcription 
factors at an active promoter and modulate their function by acetylation, in 
addition to the acetylation of histones that allow transcription. E1A might prevent 
the recruitment of p300 to the promoter site by these transcription factors, as E1A 
interaction with p300 does not abrogate transcription controlled by transcription 
factors that do not interact with p300 (104).  
 
E1A has other mechanisms for the control of acetylation of histones. The 
CR4 can interact with CtBP, known to interact with HDACs (105). E1A can 
compete with HDACs for binding to CtBP and inhibit deacetylation of histones to 
allow transcription. In addition, absence of the CR4 favours E1A-mediated 
transformation and impairs the repression of HAT activity of p300/CBP bound to 
E1A (106). It was demonstrated that CtBP can interact with a protein called CtIP 
involved in the regulation of tumour suppressor genes like BRCA1 (3, 67). Other 
reports showed that interactions with CtBP can actually repress E1A 
transactivation; two different isoforms of CtBP, CtBP1 and CtBP2, were found to 
repress transcription when bound to E1A, with CtBP2 being the most efficient 
(107). However, E1A 12S was used in the study and not 13S, that is well known 
to have higher transactivating activity. Another group found that CtBP1 can bind 
to CR3 and reduce its transcriptional activity (108). However, the same study 
showed that E1A 13S but not 12S could activate a CtBP-repressed promoter. This 
was probably due to the ability of 13S to displace CtBP with the CR4 region 
while recruiting coactivators at CR3, showing that different E1A proteins 
modulate transcription differently using the same regulators. In addition, the 
interactions between E1A and CtBP can also be modulated by interactions of E1A 
with HAT complexes; E1A can be acetylated at lysine 239, what impairs binding 
to CtBP, a mechanism that could be involved in gene activation by E1A (70). 
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Transcriptional regulation by p300 can occur also at the matrix attachment 
regions, where chromatin binds to the nuclear matrix (109). E1A also interact 
with other chromatin remodelling factors to alter transcription of cellular genes. 
The transactivation/transformation domain protein (TRRAP) and p400 interact 
with E1A at the N-terminus (3, 41, 42). These proteins are known to remodel 
chromatin to facilitate transcription. TRRAP is a component of three distinct HAT 
complexes: TIP60, PCAF and GCN5 (110). One of the consequences of E1A-
TRRAP interactions is the repression of c-myc and E2F-dependent genes in a 
process that involves GCN5 HAT activity, although E1A 12S rather than 13S was 
used in those experiments (110). However, myc expression is essential for S 
phase induction. The p300/CBP complexes are known to repress myc and 
contribute to the G0/G1 checkpoint, in addition to p107-E2F complexes near the 
c-myc promoter site (42, 111). Sequestration of these proteins by E1A, should 
hence allow the expression of c-myc. The p400 protein also induces myc and it 
has been shown that E1A interactions with p400 are needed for transformation 
and repression of p21 (112). E1A promotes the association of p400 with myc that 
in turn reduces myc ubiquitination and recruits p400 to specific promoters (113). 
In fact induction of myc and S phase is reduced during the expression of an E1A 
mutant protein not binding p400 (111). Interestingly, p400 is also involved in 
E1A-mediated apoptosis, both p53-dependent and p53-independent pathways. 
The association of p400-TRRAP complexes with p53 has been reported (106); 
possibly this is another viral mechanism to stabilise p53. In addition, p53 and 
p400 colocalised at the p21 promoter to repress its expression, providing another 
viral mechanism to escape p21-mediated senescence (112). Apoptotic 
mechanisms independent of p53 also required E1A-p400 interactions and there is 
evidence that binding to p400 is necessary to downregulate the epidermal growth 
factor receptor (EGFR) to induce apoptosis in cancer cells (114). 
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1.3.1.2 Regulation of the 26S proteasome 
 
The 26S proteasome is the major non-lysosomal proteolytic machinery in 
eukaryotes, serving to degrade protein substrates targeted specifically by 
polyubiquitin modification in an ATP-dependent manner (115, 116). The 26S 
proteasome is formed by two large macromolecular subunits, the 20S proteasome 
and the 19S regulatory complex (19S RC). The 20S proteasome degrades non-
ubiquitylated proteins in an energy independent manner and contains four 
heptameric rings arranged into a cylinder with the proteolytic sites facing the 
inner chamber (115, 116). The 19S RC is formed by a base consisting of six 
homologous ATPases (S4, S6, S6’, S7, S8 and S10b) and three non-ATPases (S1, 
S2 and S5a), while the lid of the RC is made of eight additional non-ATPase 
subunits (116).   
 
E1A can regulate the proteasomal activity of the 26S proteasome both in 
the nucleus and the cytoplasm through binding of E1A to S8 (mammalian 
ortholog of Sug1) and S4 independently (98, 115). These interactions result in an 
inhibition of ATPase activity of S4 but not S8. The S8 subunit also has helicase 
activity that it is not affected by the interaction with E1A (115).  The interactions 
of E1A with the 19S RC inhibit p53 degradation after ubiquitination, while an 
E1A mutant unable to bind the ATPase complexes failed to do so (115). These 
data suggest that the N-terminal region of E1A can control the activity of the 26S 
proteasome by inhibiting ATPase activity of at least one subunit of the 19S RC. 
The same group also showed that the C-terminal region of E1A was able to bind 
the 26S proteasome and that the interaction regulated E1A degradation by the 26S 
proteasome. This process did not require ubiquitination of E1A but 
phosphorylation in regions rich in P, E, S, and T residues (PEST motifs) (115). 
The C-terminus of E1A contains five serine residues that can be phosphorylated at 
positions 227, 228, 231, 234 and 237 to modulate E1A stability. These residues 
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are phosphorylated by cyclin-dependent kinases, suggesting that E1A activation 
of cyclins could be a mechanism of self-controlling its own degradation (115).  
 
The interactions with 26S proteasome were later found to be important for 
the transcriptional activities of the E1A 13S protein. The CR3 can also bind to 
20S and S8, interactions that regulate E1A 13S-dependent transcriptional 
activation and elongation in vivo (116). Interestingly, the CR3 from different 
adenovirus groups binds S8 ans 20S, suggesting a conserved region with 
biological function. Previous work had already reported the involvement of S8 
and its homolog in yeast Sug1 in transcription and recruitment of transcription 
factors such as Gal4 or TBP (117). The interactions between E1A and 20S are 
independent of E1A-S8 interactions; in addtion E1A co-precipitated with other 
subunits of the 19S RC, S2 and S10b, indicating that E1A targets more the whole 
19S RC complex. The study of the regulation of the transcriptional activity of 
CR3 by S8 showed that low levels of S8 enhanced transactivation although 
binding was not essential. Expression of exogenous S8 at high levels repressed 
transcriptional activity, but this could also be a consequence of 26S-mediated 
proteasomal degradation (116). E1A, S8 and 20S were found associated with 
promoters of other early viral genes, indicating a role for the ATPases in viral 
transcription. In addition, the CR3 contains PEST motifs that could make E1A 
13S more prone to degradation by the 26S proteasome. This is in agreement with 
the observed half lives of the different E1A proteins, as 13S has a sorter half live 
than 12S, which lacks the CR3 (3, 116). The proteasome directly controls E1A 
13S transactivating activity by proteolytic degradation and indicates that E1A 
transcriptional activity is directly related to its stability (116). E1A can also 
modulate the degradation of proteins at the promoter by interactions with 
p300/CBP. These proteins bind to APC/C, a ubiquitin E3 ligase that targets 
proteins to the 26S proteaseome (97). Another mechanism involving 
transactivation activity and ubiquitination of E1A has been described. The BS69 
protein has been reported to interact with the CR3 and repress its translational 
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activity (118). In addition, this protein also bind smaller E1A products through the 
CR1 and the CR2 (118). Another group showed that interactions between E1A 
and BS69 inhibit ubiquitination of E1A and consequent ubiquitin-dependent 
proteosomal degradation through a mechanism that is independent of binding to 
CR3 (119). E1A can also interfere with the ubiquitin conjugation machinery (E2 
enzymes) through interactions of CR2 with UBC9 (3). UBC9 has also been 
implicated in SUMOylation of proteins and does not necessarily target proteins 
for degradation but could be involved in protein stability and localisation; the 
function of E1A-UBC9 interactions is yet unknown (3). 
 
 
1.3.1.3 Regulation of MHC class I presentation by E1A.  
 
E1A is also known to play a role in the evasion of the immune system, in 
particular the ability to evade CD8+ cytotoxic T lymphocytes (CTLs) immunity. 
This role is not shared by all adenovirus groups and it is a major determinant for 
adenovirus-mediated tumorigenicity. The tumorigenic potential of adenovirus 
refers to the ability to induce cellular transformation in vivo after infection, as it 
has been demonstrated that Ad5 E1A is also able to transform cells in vitro in 
cooperation with E1B or activated ras (46, 120). This feature will be discussed 
later on in this chapter.  
 
It was first thought that tumorigenic potential resided in the ability of 
certain adenoviruses to down-regulate MHC class I antigen presentation. Viruses 
like Ad12, known to be tumorigenic, contained a 20 amino acid spacer between 
CR2 and CR3 not present in non-tumorigenic adenoviruses like Ad5 (3). This 
region is highly conserved in the highly oncogenic simian Ad7 virus (121, 122). 
This region is thought to interact with the class I enhancer repression complex, 
hence decreasing the expression of MHC class I (123). Ad12 E1A may repress 
MHC class I expression by both inhibiting binding of the activator NF?B and 
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recruiting the transcription repressor COUP-TFII in a complex with HDACs 
(123). This was thought to be the reason behind the failure of cells transformed 
with Ad5 or Ad2 E1A to form tumour in immunocompetent animal models (122). 
In addition, oncogenic serotypes down-regulate two components of the 
immunoproteasome, LMP2 and LMP7, that results in a decrease of class I 
expression (3). This reduces and delays antigen presentation and could serve as an 
evasive mechanism used by different pathogens (124). However, there is no 
strong evidence that correlates reduced class I expression and tumorigenicity 
(121). Hence, tumorigenicity of E1A must involve other components of the 
immune system. The sensitivity of E1A transformed cells to natural killer cells 
(NK) mediated death is dependent on the E1A type used; cells transformed with 
Ad12S are resistant to NK-induced cell death. Contrary, transformation by Ad5 
E1A induces tumour rejection irrespective of the changes in MHC class I 
expression (125). The second factor that favours tumorigenicity of Ad12S but not 
of Ad5 E1A is the ability of Ad5 E1A to encode CTL-stimulating epitopes that 
have been found in context with MHC class I antigens (125). In addition, other 
reports have shown that even though Ad5 E1A does not down-regulate class I 
presentation on its own, it can cooperate with E3 proteins to enhance an E3-
dependent down-regulation of MHC class I antigen expression (61). The 
interaction of E1A with other transcriptional factors like p300 could also have a 
role in tumorigenicity and evasion of the immune system, not only in down-
regulation of class I presentation. E1A can induce cytolytic susceptibility and 
tumour rejection by affecting the transcription of genes involved in NK responses 
through interactions with p300 (126). It has also been shown that E1A can repress 
the expression of MHC class II by sequestering the transcriptional activator CBP 
(127). 
 
 The role of E1A in evasion of the immune system remains unclear; it can 
modulate promoters controlled by NF?B-dependent activation and it can 
modulate the expression of class I antigen alone or in collaboration with E3. 
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However, E3 also down-regulates translation rates of E1A mRNA during 
infection and E1A expression is also associated with sensitisation to TNF after 
NF?B transcriptional activation. Further investigation is needed to elucidate the 
implications of E1A in immunogenicity and immune response evasion.  
 
 
1.3.2 EMT and transformation 
 
Ad5 E1A first identified as one of the oncogenes present in the adenoviral 
genome; its expression is sufficient to induce partial transformation of rodent cells 
and full transformation if co-expressed with E1B or activated ras (42, 120, 128). 
The ability of E1A to cooperate with other genes to promote transformation has 
been a useful tool in the research of oncogenic potential of cellular genes. The 
GLI gene was found to also cooperate with E1A to transform cells, indicating the 
oncogenic potential of this gene, normally upregulated in gliomas (129). Similar 
studies were done for the v-src gene; in this case E1A 12S was also able to 
transform primary epithelial cells in cooperation with v-src although, in contrast 
to cooperation with ras, loss of the epithelial phenotype was reported (130). This 
could indicate that the achievement of transformation might involve different 
pathways that are dependent on the oncogenes used. This work also showed that 
deletions in E1A p300 binding site abolished transformation in cooperation with 
E1B or ras but not with v-src, supporting the idea that more than one region could 
modulate transformation in a cellular-dependent manner. 
 
Transformation of human cells by Ad5 E1A has not been reported, 
although Ad5 E1A can induce limited cell cycle progression (42). Ad12 E1A has 
been demonstrated to have the ability to transform human embryonic retinal cells 
(42). Despite successful immortalisation of rodent cells, Ad5 E1A-expressing 
failed to form tumours in immunocompetent animals models, as discussed above. 
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The differences in E1A transformation might not be species-specific as first 
thought, as later was discovered that expression of E1A suppressed tumorigenesis 
in a mouse melanoma cell line (131). In fact, E1A has shown anti-oncogenic 
activity in human cells and it has been used as cancer therapy in clinical trials 
through delivery of E1A-expressing plasmids in liposomes (132). E1A expression 
can also reverse the epithelial-mesenchymal transition (EMT) observed in the 
genesis of carcinomas, contributing to supression of oncogenesis (42). Expression 
of E1A can indeed induce epithelial characteristics; four human cancer cell lines 
of non-epithelial origin showed epithelial-like morphology, with epithelial-type 
adhesion molecules and intermediate filaments containing keratin after retroviral 
transduction of E1A (133). It is probable that E1A activates epithelial promoters 
to ensure efficient replication (133).  
 
Transformation of rodent cells is also dependent on the E1A protein used. 
The 12S protein was able to transform cells at higher efficiency than the 13S 
protein (134, 135), indicating that CR3 is not required for transformation. 
Nevertheless, transformation with 12S was sensitive to cold, with very slow 
transformation and proliferation at 32°C; possibly 13S modulates the transforming 
activity of 12S (135). Not all E1A proteins have transformation capacity; several 
reports indicate that E1A 9S is unable to transform cells in vitro, either by 
infection with a 9S-expressing virus or transfection (134, 135). Both CR1 and 
CR2 have been implicated in the transformation induced by E1A; deletions of 
amino acids in between these two regions had no effect on transformation, 
indicating that CR1 and CR2 binding proteins play a role in the immortalisation 
(120). In addition, mutations in the CR2 impaired the transformation ability of 
E1A, suggesting that interactions with pRb are needed for complete 
transformation. Immortalisation requires both control of cell growth through CR2 
and DNA synthesis through CR1; these functions are achieved by interactions of 
CR1 with cellular proteins, in particular p300/CBP (94, 97, 103). Deletions in the 
N-terminal region and CR1 inhibit DNA synthesis, while this is not observed in 
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CR2-mutated E1A proteins (71). Interactions between p300 and the APC/C are 
involved in transformation.  E1A targets APC/C-p300/CBP complexes during 
transformation and modulates the ubiquitin ligase activity of APC/C; E1A 
mutants unable to bind p300 are unable to fully transform primary rat embryo 
fibroblasts (97). Binding of E1A to this complex possibly inactivates p300 tumour 
suppressive abilities. Of note, the expression of E1A in the absence of E1B or ras 
does not transform but induces apoptosis by mechanisms related to p300/CBP and 
pRb. In addition, the CR4 also suppresses E1A/ras transformation but enhances 
E1A/E1B-mediated transformation (97). However, cooperation with v-src did not 
require p300/CBP but pRb binding but did not show epithelial phenotype (130); 
this suggests that the status of cellular oncogenes also plays a role in 
immortalisation and induce changes that are not dependent on E1A expression. 
 
 
 
1.3.3 E1A in cancer therapy: cancer specificity and sensitisation 
 
E1A is a promising tool for cancer treatment due to its apoptotic properties 
and have already been used in clinical trials for head and neck, ovarian and breast 
cancers (132, 136). In the context of viral therapy, E1A can be modified so that it 
only allows replication in cancer cells but not in healthy cells. Deletions in the N-
terminus or the CRs impair interactions with p300 and/or pRb, thus E1A cannot 
achieve a successful entry into S phase in normal cells. In cancer cells, these 
pathways are frequently altered, so E1A interactions with these proteins might not 
be necessary to achieve replication. In cancer cells with deregulated cycle 
checkpoints due to pRb pathway alterations, E1A does not need to interact with 
pRb and consequently the CR2 is dispensable (137, 138). This is the rationale for 
the design of viruses with deletions in the CR2, like the dl922-947 mutant, with a 
deletion of amino acids 122 to 129; this virus has shown selectivity for cancer 
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cells and a reduction of potency in normal cells (139). Other mutants with the 
same deletion, such as Ad?24, have shown similar results (140). However, 
deletions in CR2 might not always be specific. Other reports showed attenuation 
of viral potency in cancer cells when CR2 was deleted, in contrast with deletions 
of the p300 binding site, which retained potency (141). In this study, CR2-deleted 
viruses were still capable of inducing S phase in some normal cells but not in 
others. This was in contradiction with the original description of this E1A deletion 
that showed higher toxicity than Ad5 in cancer cells (139). More than one 
deletion can be introduced to improve selectivity; however, deletions of both CR1 
and CR2 should compromise viral potency, although there is a report that showed 
good potency with a double deleted E1A virus (142). However, other reports 
suggest that deletions in the p300 binding site attenuated potency in glioma cell 
lines (143). The data from the use of different mutations shows that in some cell 
lines CR1 deletions improve selectivity and toxicity more than CR2 deletions, but 
not in others. This suggests that the status of the cell must be taken into account 
before choosing the E1A fragment to delete. New strategies combine deletions in 
both E1A and E1B to avoid the attenuation of the E1A double deleted mutants 
while impairing the antiapoptotic properties of E1B (144, 145). 
 
E1A has another characteristic that makes it a promising gene for therapy; 
E1A expression can sensitise cancer cells to host immune responses, radiotherapy 
and chemotherapy. Sensitisation to immune responses is partially due to the 
interactions with the MHC class I described above. Several reports showed that 
E1A sensitises cancer cells to TNF-mediated apoptosis, NK cells and 
macrophages in vitro and in vivo by interacting with p300 or pRb (146, 147). 
Sensitisation to radiotherapy has also been reported (148). E1A interacts with 
pathways involved in the DNA damage response, so it was first thought that it 
could sensitise to DNA-damaging therapies like radiation or cytotoxic drugs that 
induce DNA damage. Good sensitisation has been observed to DNA-damaging 
drugs like gemcitabine or etoposide (145, 149, 150). However, other pathways 
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might be involved, as good synergistic effects have been reported between E1A 
and agents targeting the cytoskeleton, like taxol, cisplatin and related cytotoxic 
drugs (151-154). 
 
The mechanisms and the E1A regions involved remain unclear. There is 
evidence that down-regulation of Her-2/neu expression after paclitaxel treatment 
in combination with E1A is important for sensitisation in breast cancer (153). 
Other report showed that p21 inactivation by E1A was essential for sensitisation 
to DNA-damaging agents (89). Up-regulation of apoptotic mechanisms, caspase 
expression and/or downregulation of the PI3K/Akt pathway in response to 
cisplatin or paclitaxel due to PP2A up-regulation by E1A have also been 
described (155, 156). There is controversy about the E1A regions responsible for 
the sensitisation; some studies showed that sensitisation to radiotherapy and DNA 
damaging agents was dependent on p53, hence E1A must interact with pRb to 
induce it (157, 158). However, p53 induction was observed in E1A-mediated 
sensitisation of pRb deficient cells, indicating that in this context the sensitisation 
was dependent on p53 but not E1A interactions with pRb (138). Sensitisation 
must not be only dependent on p53, as E1A effectively sensitises cells with non-
functional, mutant p53 (138, 151). Possibly, all CRsin E1A play a role in 
sensitisation; absence of one might not affect E1A-mediated sensitisation 
depending on the status of the cellular pathways. Interactions with one of the CR 
could be sufficient to sensitise cancer cells if the pathways interacting with the 
absent region are deregulated in a way that favours E1A function. Deletion of the 
N-terminus and CR1 or CR2 totally impaired chemosensitisation to adriamycin in 
both human and murine fibroblasts, indicating that deletion of more than one 
domain abrogates sensitisation (138). Although more than one pathway may be 
involved in E1A-mediated sensitisation, the published evidence suggests that it 
requires both activation of proapoptotic factors and inactivation of antiapoptotic 
factors. 
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1.4 Adenoviruses in gene therapy 
 
Over 1340 gene therapy clinical trials had been completed, were ongoing 
or approved worldwide in 2007. In 1989, one month after the discovery of the 
cystic fibrosis gene, James Wilson already discuss the prospects of gene therapy 
to treat this disease by expressing the correct gene using a virus (159, 160). By 
1993 the first clinical trials were under way, although the patients did not respond 
to the treatment (159, 160). The first therapeutic human gene therapy clinical trial 
was approved in 1990 and involved two children suffering from a form of severe 
combined immunodeficiency (161), (162). The number of trials has increased 
every year; in 1996, 116 trials were approved worldwide. However, adverse 
effects observed in some trials in 1999 and 2002 forced regulatory bodies to 
critically examine the risk/benefit ratio and to restrict the number of trials while 
the adverse effects were investigated (161). The adverse effects observed were in 
some cases due to the vector used, but not always. These cases include 
development of leukaemia-like complications due to random insertion of 
retroviral vectors (163) or the death due to a fatal inflammatory resonse after 
adenovirus delivery in a patient with an ornithine transcarbamylase deficiency 
(164). 
 
Approximately 66% of clinical trials have addressed cancer, while 
cardiovascular and inherited monogenic diseases are the other diseases most 
commonly targeted in gene therapy clinical trials (161). Gene therapy is used in 
the clinic in different ways. Vectors can be used to deliver a therapeutic gene in 
vivo, either a gene correcting a genetic deficiency or, in the case of cancer, genes 
that regulate cell cycle and apoptotic pathways (161, 165, 166). Another approach 
is to use vector to express antigens in the target tissue that can be recognised by 
the immune system, called immunotherapy (1, 166). A different approach is to 
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design viruses that selectively destroy the target of interest, a therapy called 
oncolytic therapy in the case of cancer treatment (44, 166, 167).  
 
The vectors used in gene therapy can be classified as viral or non-viral 
vectors. Non-viral vectors are used as an alternative to viruses, due to a greater 
capacity to harbour therapeutic large DNAs and lower immunogenicity (161, 
165). The most commonly non-viral methods of gene delivery are cationic 
liposomes and “naked” DNA. The first involves a negative-charged lipid 
molecule transporting the therapeutic DNA; naked DNA means the use DNA 
directly injected into the target tissue (161, 165). E1A has actually been used as a 
therapeutic gene on a liposome-based delivery in a phase I clinical trials in breast, 
ovarian and head and neck cancer (132, 136). E1A therapy proved safe and 
promising, although efficacy was not reported in this trial. However, viruses are 
still the vectors of choice for most trials. Adenoviruses are the most commonly 
used virus in gene therapy, accounting for approximately 25% of all clinical trials 
to date (161). Retroviruses were the first vectors used in therapy but are currently 
only used in 22.8% of the trials, due to the adverse effects of viral genome 
integration in the host genome (161). Another virus is also becoming increasingly 
popular, the adeno-associated virus (AAV). These vectors are substituting 
adenoviruses as the vector of choice for the treatment of many diseases. AAVs are 
now being used in clinical trials for eye diseases in the United Kingdom (168). 
AAV are also used for the treatment of cystic fibrosis, muscular dystrophies and 
Parkinson’s disease (168). AAVs are also used for haemophilia and cancer 
treatment (169). Other viruses are also used, such as herpesvirus, vaccinia virus, 
reovirus, poliovirus, vesiscular stomatitis virus (VSV) and picornavirus (29, 161, 
165, 170).  
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1.4.1 Advantages and disadvantages of adenoviruses as vectors 
for gene therapy 
 
Adenoviruses are widely used in gene therapy for the advantages over the 
previously used retroviral vectors. Adenoviruses can infect both dividing and non-
dividing cells (1, 171) and do not integrate in the host genome, avoiding the 
adverse effects observed with retroviruses (161). The adenoviral replicative cycle 
is lytic, hence infected cells burst as soon as new viral particles are fully formed; 
an advantage especially promising for cancer treatment, enabling fast spread of 
virus at the tumour site. In addition, adenoviruses generate a high amplification of 
progeny, up to 10
5
 new viral particles per infected cell, enhancing the rapid spread 
of viral particles locally at the tumour site (1, 172, 173). Adenoviruses are also 
easy to design, manipulate and produce in large quantities and can accommodate 
relatively large segments of DNA, up to 7.5 kilobases (kb) (173).  
 
Although these advantages have made adenoviruses promising vectors for 
gene therapy, there are some disadvantages. Not all cell types can be infected, as 
their natural tropism are epithelial cell types (1). Adenoviruses are also highly 
immunogenic, inducing both humoral and cell-mediated immune responses (1, 
171). Despite adverse effects and the death of a patient in a clinical trial in 1999 
(173), data from the latest clinical trials has proven that adenoviruses are safe 
(167, 173). Most adult humans have already been exposed to Ad2 and Ad5, so the 
immune system can recognised viral proteins as antigens and the presence of 
neutralising antibodies is a challenge for multiple administration of adenoviral 
therapy (173). Another problem when using adenovirus in the clinic is the high 
viral uptake by the liver after intravenous administration. Viral particles enter the 
hepatocytes due to the interactions of the hexon with coagulation factors that 
allow infection in the liver (40).  
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1.4.2 Achievement of cancer specificity 
 
There is ongoing research to optimise safety and efficacy of adenovirus. 
They include a variety of mechanisms, from detargeting adenovirus fiber to the 
construction of gutless vectors, adenoviruses expressing a gene of interest but no 
viral genes that therefore need a helper virus that provides viral proteins for DNA 
synthesis (1, 171). Other strategies include the use of promoters controlled by 
irradiation or tissue-specific proteins like the AR for prostate cancer therapy (166, 
173) or cyclooxygenase-2 (COX2) dependent promoters for colorectal and 
pancreatic cancer (174). The main strategies to improve efficacy for cancer gene 
therapy are fiber and capsid modification, use of tissue-specific promoters and 
oncolytic viruses with deletions in viral genes that only allow replication in cancer 
cells. The design of the virus can also be optimised for particular therapies, as the 
different modifications available have different effects on potency and cancer 
selectivity (175). In addition, all these strategies can be combined in an attempt to 
maximise potency and specificity; one example is the Ad5/3cox2L?24 virus, with 
a COX2 promoter driving a CR2-deleted E1A gene and fiber knobs from Ad3 
(176). 
 
 
1.4.2.1 Fiber modifications 
 
Failure to reach the target tumour site is partially caused by uptake of virus 
in other tissues, specially the liver, and attachment of viral particles to erythrocyes 
(40, 177). This is due to interactions between the hexon and the fiber knob with 
coagulation factors that can hence influence the attachment of the virus by CAR-
independent mechanisms (177). Fiber knob modifications have been considered a 
promising approach to enhance successful target of the tumour and hexon 
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modifications as an approach to avoid liver blood factor X dependent transduction 
of hepatocytes in the liver. 
 
Modifications of the fiber can be classified in two categories; one 
approach is the replacement of Ad5 fiber by that of another serotype and a second 
approach is to modify the fiber so it binds receptors different from CAR. 
Replacement by another serotype fiber can be total or partial; there are reports of 
Ad5 fiber knob substitution by that of Ad3 (178). Ad5 modified viruses 
expressing the Ad35 fiber have also been constructed, targeting CD46 rather than 
CAR (179). These viruses have been further modified in order to optimise binding 
to their new receptor. These modifications included the molecular optimisation of 
the fiber to increase its affinity, like in the case of Ad5/35++ that expressed a 
Ad35 modified fiber (179), or the addition of the RGD motif to the fiber knob of 
Ad5/3 (180). The RGD motif (arginine-glycine-asapartic acid motif) binds to 
RGD-binding integrins, mainly ?v?3 (181).  Other domains have been inserted at 
the fiber knob; some strategies involved the used of proteins such as 
immunoglobulins (Igs) bridging between the knob and the cellular receptor. In 
this case, a protein binding Igs is attached to the fiber knob; then the viral capsid 
can bind an Ig targeting a specific receptor (182). 
 
 
1.4.2.2 Deletion of viral genes 
 
Oncolytic viruses have shown promising results in clinical trial, especially 
when they are combined with chemo or radiotherapy. This is due to the lack of 
cross-resistance between cytotoxic agents and viruses and the improvements in 
the cancer-specificy of these viruses. Specificy of these viruses is based on small 
deletions of viral genes that are essential to viral replication in normal cells, but 
dispensable in cancer cells as the interacting pathways are deregulated.  Even 
though new research is focused on deletions in the E1A gene as previously 
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described, other viral genes have also been altered to achieve cancer selectivity. 
Deletion in the E3 gene were suggested for therapy as these genes are not 
essential for viral replication and its absence would allow for insertion of 
transgenes of interest. However, those initial experiments did not consider the 
effect of these deletions in an immunocompetent model. It was soon demonstrated 
that E3 gene manipulations significantly attenuated the potency of oncolytic 
viruses in the context of a fully functional immune system (56).  
 
The other gene that was originally deleted was the E1B-55K; this 
generated the dl1520 mutant, also known as Onyx-015. It contains an 827 bp 
deletion and a point mutation that generates a premature stop codon preventing 
the expression of a truncated form of E1B-55K (183, 184). This virus was 
generated to selectively replicate in cancer cells with p53 deficiencies, as E1B-
55K inhibits p53-dependent apoptosis. Infection of healthy cells would induce 
p53-dependent apoptosis that could not be block by viral genes. Hence, an 
infected normal cell would induce a p53 response resulting in growth arrest or 
apoptosis without replication (183). However, further research showed that the 
lack of E1B-55K was not sufficient to abrogate replication in cells with 
dysfunctional p53 pathway (185). It has also been shown that dl1520 can override 
cell cycle checkpoints that are dependent on p53-interacting proteins and this 
induces mitotic catastrophy and endorreduplication in p53 expressing cells (185, 
186). The mechanisms for selective replication of dl1520 are not fully understood, 
but they are not dependent on p53 functional status. Some groups have proposed 
that the cause for selectivity might reside in the nature of the mutation within p53; 
the research showed that replication of dl1520 varied among cells expressing 
different p53 mutations, indicating that loss or gain of specific p53 functions 
might be important in the replication of Onyx-015 (187). E1B-55K is also 
involved in mRNA transport in collaboration with E4orf6, so this interaction 
could play a role in the selectivity. It could also explain the attenuation in potency 
of this virus compared to Ad5. Due to these disadvantages, other mutations in the 
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E1B will be tested in the clinic; deletions of E1B-19K have shown good cancer 
selectivity and sensitisation to chemotherapy without the attenuation of potency 
observed for dl1520 (145, 154). 
 
 Onyx-015 was the first adenovirus to undergo a clinical trial for cancer 
treatment (188). Since 1996, it has been used in a variety of clinical trials for 
different malignancies and it is now an approved therapy in China (161, 188). 
Phase I clinical trials have shown good safety data, with toxicity being well 
tolerated at the highest feasible doses (189, 190). This virus has been administered 
as single agent both intratumourally and intravenously; toxicity was well 
tolerated, with flu-like symptoms as the most common adverse effects (183, 189). 
However, efficacy was minimal in head and neck cancer clinical trials after 
multiple injections, with 14% of the patients showing partial regression of the 
tumours (183, 191). Data from these trials showed good correlation between viral 
replication and mutated status of p53 that also correlated with tumour regression 
(191). The outcome of these trial, however, was that the deletion of E1B-55K and 
the E3B region in this virus severely attenuated its potency and the modulation of 
the immune response that could explain the poor efficacy observed in addition to 
the variability of mutation in p53 (188, 191). However, new clinical trials have 
combined the Onyx-015 virus with chemo and radiotherapy; results were 
promising in patients with head and neck cancers after intratumoural 
administration and in colorectal liver metastases after hepatic arterial 
administration (188, 189). Onyx-015 was also used in a phase I clinical trial for 
solid tumours in combination with enbrel, a recombinant dimmer of the TNF-? 
receptor (192). This trial showed no significant adverse effect of the combination 
and higher detection of viral DNA when Onyx-015 was combined with enbrel 
treatment. In addition, a new phase I clinical trial started in 2008 combining 
Onyx-015 with systemic chemotherapy, doxorubicin and cisplatin, in patients 
with advanced sarcomas (193). The outcomes of the different trials have shown 
that adenoviruses can safely be combined with chemo- or radiotherapy, resulting 
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in a synergistic interaction of the two combined treatments. Combination 
therapies are now a more promising therapeutic strategy than the use of 
adenovirus as single treatment, due to the synergy observed in the mentioned 
trials. 
 
 
1.4.3 Gene therapy in prostate cancer 
 
Gene therapy is now a promising alternative to the lack of effective 
treatments for hormone-refractory prostate carcinomas. Gene therapy was first 
administered to a prostate cancer patient in 1994 and ten years later 61 clinical 
trials were registered on the Office of Biologic Activities Human Gene Transfer 
Protocol List (166). These clinical trials involved the use of viruses alone or in 
combination with chemotherapy or radiotherapy. The most commonly used viral 
vector used has been adenovirus, although vectors like retroviruses, adeno-
associated viruses and vaccinia virus have also been tested (166). The strategies 
used can be categorised into corrective or cytolytic therapy. Corrective therapy 
involved the use of viral vectors to expressed a tumour suppressor gene mutated 
in prostate cancer such as p53 or p16; it can also involve the use of silencing RNA 
to down-regulate the expression of oncogenes often overexpressed in prostate 
carcinomas such as Hdm-2, myc and Bcl-2 (166, 194, 195). Cytolytic therapy has 
been more widely used than corrective therapy; it involves the use of viral vectors 
that selectively destroy cancer cells. Three different approaches have been 
exploited to achieve tumour destruction by gene therapy: immunotherapy, 
prodrug converting enzyme delivery and oncolytic therapy. Immunotherapy aims 
to enhance the recognition of tumour cells by the immune system, increasing 
histocompatibility complex class I (MHC I) presentation or stimulation of 
lymphocytes to recognise cancer cells (166, 170). The major disadvantage of this 
approach is the cost and technical expertise required. As adenoviruses are easy to 
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manipulate and produce, they represent a good vector for delivery of prodrug-
converting enzymes. The virus would be administered in combination with a non-
toxic pro-drug that is converted to an active toxic drug in infected cells. The most 
commonly used enzymes for the treatment of prostate carcinoma are the herpes 
simplex virus thymidine kinase (TK) in combination with ganciclovir and the 
cytosine deaminase (CD) together with 5-fourocytosine (5-FC) (166, 167). These 
two enzymes have also been used in combination in the same virus, the Ad5-
CD/TKrep, used in 5 clinical trials for prostate cancer and osteosarcoma (166, 
167, 196). The expression of enzymes is controlled by the promoter of the 
cytomegalovirus (CMV) and it has proved to be clinically safe after a five-year 
follow-up of one clinical trial (197). PSA and PSMA specific enhancers and 
promoter are used to drive the expression of the TK gene in the AdIU1 adenovirus 
in order to achieve specific expression of the enzyme in prostate tissue (196). 
Efficiency of the pro-drug converting enzymes can also be modified and 
optimised; second generation adenoviruses expressing optimised enzymes are 
now in clinical trials, like the Ad5-yCD/mutTKsr39rep-ADP. This virus expresses 
optimised CD, TK and the adenovirus death protein (ADP) at high levels, 
improving efficiency of the virus and it is now in clinical trials (198). 
 
The last type of cytolytic therapy involves the use of oncolytic viruses. 
These are viruses with deletions in genes that are essential for viral replication in 
healthy cells, but that can be spared in cancer cells due to cellular aberrations in 
pathways controlling cell cycle. These viruses are often combined with 
chemotherapy or radiotherapy, as synergistic interactions between these 
treatments have been reported (199, 200). Cancer specificity can also be achieved 
by the use of tissue-specific promoters, like in the case of the AdIU1 virus 
described above. In fact, the same group also develop the Ad5-PSME-E1A virus, 
with E1A under the control of the same enhancer of prostate-specific PSMA 
expression (PSME), claiming better prostate cancer specificity than with the use 
of the PSA promoter (201). The CG7060, previously called CN706 and CV706 
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was one of the viruses using the PSA promoter-enhancer element to control E1A 
expression (202). Another virus evaluated in clinical trials is the CG7870 
adenovirus, previously called CV787 (202). This virus uses the rat probasin 
promoter to control E1A and the PSA promoter enhancer to control E1B 
expression. The use of this virus by intraprostatic delivery is now in phase II 
clinical trials and it is now in a phase I clinical trial for intravenous administration 
for treatment of metastatic tumours (202). The adverse effects reported in this trial 
showed mild to moderate flu-like symptoms; even though phase I trials are 
designed to test safety rather than efficacy, this trial showed a decrease in PSA 
levels of treated patients, being the first time that this is achieved after intravenous 
administration (202). There are reports that this virus can also synergise with 
drugs like docetaxel in vitro and in vivo (199).  
 
Even though gene therapy is already being tested for the treatment of 
prostate carcinomas, there is room for improvement of the vectors used. In the 
case of adenoviral vectors, it is known that the AR attenuates Ad5 replication 
(203). Research shows that AR and E1A are mutual inhibitors, and this interaction 
attenuates replication in AR-positive prostate cancer cells. Construction of viruses 
expressing a chimeric E1A-AR fusion protein has been proposed as an alternative 
to overcome this negative interaction of AR and E1A (203). Other factor that 
affects the success of adenoviral gene therapy is the expression of the receptor 
that viruses bind to. Expression of CAR is often reduced in carcinomas compared 
to healthy tissue and there are indications that CAR down-regulation correlates 
with the progression of the disease, even though the function of CAR remains 
unclear (204). 
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Aims of this thesis 
 
 
This thesis aimed to elucidate the regions within E1A that are essential for 
chemosensitisation of prostate cancer cells. Using a variety of adenoviruses, both 
replication-competent and deficient, with partial deletions in the E1A gene the 
aim was to find regions that are essential for sensitisation to cytotoxic drugs. Two 
different drugs currently used in prostate cancer treatment, mitoxantrone and 
docetaxel, would be combined with the viruses mentioned in order to investigate 
the efficiency of the combination treatments with drugs with different 
mechanisms of action. At a molecular level, this thesis aimed to find mechanisms 
involved in the E1A-mediated senstisation and the effects of the combination 
treatments in apoptosis induction, cell cycle and expression of proteins related to 
cell death, survival and cycle control. 
 
This work aimed to provide a better understanding of E1A-mediated 
senstisation that allow for the improvement of future oncolytic adenoviruses for 
the treatment of prostate cancer in combination with chemotherapy. 
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2Chapter 2 
  
  
Materials and methods 
  
 
  
  
2.1 Cell lines 
  
2.1.1 Human cell lines 
  
The human embryonic kidney cell line HEK293 was obtained from the 
Cancer Research UK Central Cell Service (Clare Hall, CRUK, Middlesex, UK). 
JH293 cells were obtained by clonal selection of HEK293 cells for optimisation 
of viral titration (Clare Hall). The human non-small cell ephitelial lung carcinoma 
cell line A549 was obtained from the American Type Tissue Culture Collection 
(ATCC). Three human prostate cancer cell lines were used: the DU145 cell line 
derived from brain metastasis, the PC3 cell line derived from bone metastasis and 
the 22Rv1 cell line derived from a human prostate carcinoma xenograft serially 
propagated in nude mice after castration. The three human prostate cancer cell 
lines were obtained fron the ATCC. All human cell lines were maintained at 37˚C 
and 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM; CRUK) 
supplemented with 10% foetal calf serum (FCS; Sigma-Aldrich, Chemie, 
Germany). A detailed description of the characteristics of the human prostate 
cancer cell lines used can be found in Table 2. 
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 PC3 DU145 22Rv1 
AR - - + 
Origin Bone metastasis Brain metastasis 
CWR22 
xenograft 
Morphology Epitheloid epitheloid epitheloid 
PSA RNA - - + 
PSA protein - - - 
p53 - mutated + 
pRb + mutated + 
Bcl-2 + - + 
p300 + + + 
CBP + + + 
E2F + + + 
p21 + + + 
p63 - - - 
HDM-2 + + + 
c-SRC + + + 
PTEN - + + 
p38 + + + 
p-p38 + + + 
Akt + + + 
p-Akt + - + 
Erk-1 + + + 
p-Erk-1 - + + 
Erk-2 + + + 
p-Erk-2 - + + 
JNK-1 + + + 
Chk-2 + + + 
Cyclin D1 + + + 
Cyclin E + + + 
Caspase 3 + + + 
PKA + + + 
PKC + + + 
Table 2. Alterations of cellular genes involved in cell cycle control found in the human prostate 
cancer cell lines used in this thesis. Status of these proteins was obtained from ref. (26, 205-208). 
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2.1.2 Murine cell lines 
  
The murine prostate carcinoma cell line RM-1 (209) was a kind gift from 
Dr. Thompson (Houston, TX, USA). RM-1 cells were maintained at 37˚C and 5% 
CO2 in DMEM supplemented with 10% FCS. The murine adenocarcinoma cell 
line TRAMPC was a kind gift from Dr. Vassaux (London, UK). TRAMPC cells 
(210) were maintained at 37˚C and 5% CO2 in DMEM supplemented with 20% 
FCS, 1 nM dihydrotestosterone (DHT) and 5 ?g/ml insulin (Sigma-Aldrich, 
Suffolk, UK). 
  
 
 
2.2 Viruses 
  
2.2.1 Replication-selective 
  
Replication-selective oncolytic adenoviruses with mutations in the CR1 
and CR2 regions of E1A were evaluated. In addition to the following deletions, all 
E1-mutant adenoviruses had the E3B gene deleted; dl1101 has a deletion of 
amino acids 4 to 25, dl1102 has a deletion of amino acids 26 to 35, dl1104 has a 
deletion in amino acids 48 to 60, dl1107 has a deletion of amino acids 111 to 123, 
dl1108 has a deletion of amino acids 124 to 127. dl922-947 has a deletion of 
amino acids 122 to 129 in CR2 region. Onyx-015 (dl1520, with a deletion in the 
E1B-55kDa gene) was also evaluated. Wild type Ad5 was used as a positive 
control whereas dl312 (E1-deleted virus) was used as negative control. 
Replication incompetent AdGFP, with GFP expression cassette under control of 
the CMV promoter replacing E1 and with intact E3 region, was also used as 
control. These viruses are described in more detail in Table 3 and Fig. 7. 
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Nucleotide 
deletion 
Amino acid 
deletion 
Comments 
Ad5 None None Wild type 
dl312 448-1349 1-289 No E1A protein 
dl1101 569-634 4-25 Does not bind p300 or p400 
dl1102 635-664 26-35 Does not bind p400 
dl1104 701-739 48-60 Does not bind p300 
dl1107 890-928 111-123 Does not bind pRb or p130 
dl1108 929-940 124-127 Does not bind pRb, p130 or p107 
dl922-947 923-946 122-129 Does not bind pRb, p130 or p107 
AdGFP 448-1349 1-289 
GFP gene under control of CMV protomer 
replacing E1A 
Table 3. Description of replication-selective adenoviruses used in this thesis, and the dl312 and 
AdGFP viruses used as controls for the assays. Detailed information of all E1A mutations can be 
found in Mymryk et al, 1998 (4). 
  
  Fig. 7. Diagram of E1A deletions of the replication selective adenoviruses used in this thesis. 
They all expressed E1A mutants based on the E1A-12S protein. 
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2.2.2 AdE1A-12S mutants 
  
2.2.2.1 Extraction E1A 
  
A549 cells were seeded in a 6-well plate at 1x10
4
 cells/well and Ad5 was 
added 24h later at a concentration of 100 particles per cell (ppc) in 2 ml of 2% 
FCS DMEM. Medium was removed 20h after infection and RNA was extracted 
from cells using 1ml of Trizol? Reagent (Invitrogen, Carlsbad, CA). RNA was 
purified using 0.2 ml of chloroform and centrifugation at 12000x g for 15 min at 
4˚C using an Eppendorf Centrifuge 5415R (Eppendorf, Cambridge, UK). The 
phase containing RNA collected and RNA precipitated with isopropanol and 
centrifuged for 10 min at 12000x g. The pellet was washed with 75% ethanol, 
centrifuged at 7500x g for 5 min and resuspended in RNAse-free distilled water. 
The RNA concentration was quantified using a Nanodrop
®
 ND-1000 
Spectrophotometer (Labtech International Ltd, East Sussex, UK), measuring the 
absorbance ratio 260 nm/280 nm.  
  
cDNA was synthesised from the mRNA using the TaqMan Reverse Transcription 
Reagents and oligo(dT) primers (Applied Biosystems, Foster City, CA) as 
described by the manufacturer. E1A cDNA was amplified by PCR, using the 
Advantage 2 PCR Kit (Clontech, Mountain View, CA). 30 cycles of PCR were 
performed; each cycle included 30 s at 94°C and 2 min at 68°C.  Primers 
purchased from Sigma-Aldrich were designed using DNA Strider 1.3f13 software 
(CEA, France); forward primer started with an inserted restriction site for BssH II 
and reverse primer with a site for Xho I. Primer sequences are shown in Table 4. 
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2.2.2.2 Cloning of E1A-12S cDNA 
  
PCR products were separated by agarose electrophoresis in a 2% agarose 
gel and E1A-12S cDNA was extracted from the gel using QIAquick Gel 
Extraction Kit (Qiagen, West Sussex, UK). Purified E1A cDNA was cloned into 
pCR2.1-TOPO vector (Invitrogen) to generate pCR2.1-TOPO-12S. TOP10 
chemically competent bacteria (Invitrogen) were transformed with pCR2.1-
TOPO-12S and cultured overnight at 37˚C in agar plates containing 50 ?g/ml of 
ampicilin (Sigma-Aldrich). Bacterial clones were selected and cultured overnight 
at 37˚C in brooth containing 50 ?g/ml of ampicilin. Qiagen Spin Miniprep Kit 
(Qiagen) was used to extract the pCR2.1-TOPO-12S plasmid. Sequencing was 
done and determined as 100% homology and correct orientation of E1A-12S 
cDNA in the vector. All sequence analysis was performed by the Genome Centre 
at the Institute of Cancer (London, UK). 
  
  
2.2.2.3 Construction of AdE1A-12S virus 
  
pCR2.1-TOPO-12S was digested with Kpn I and Xho I (New England 
Biolabs (NEB), UK) to extract E1A-12S and cloned into a pShuttle-CMV vector 
(Stratagene, TX, USA) previously linearised with the same restriction enzymes. 
Quick Ligation Kit from New England Biolabs was used for the ligation reaction, 
following manufacturer’s instructions. pShuttle-CMV-12S was transformed into 
TOP10 chemically competent bacteria cultured in brooth containing kanamycin 
(Sigma-Aldrich) at 50 ?g/ml  and amplified by maxiprep preparation. pShuttle-
CMV-12S was linearised with Pme I (NEB, UK) and recombined with pAdEasy-
1 plasmid (Stratagene) by transfection in BJ5183 electrocompetent bacteria 
(Stratagene). Electroporation was done with Biorad’s Gene Pulser II system 
(Biorad laboratories, Hercules, CA, USA), at 2.500V, 200 Ohms and 25 ?F. Cells 
were cultured over night in agar plates containing 25 ?g/ml of kanamacyin and 25 
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?g/ml of streptomycin. Selected colonies were collected and cultured in bacterial 
brooth containing 75 ?g/ml of kanamycin and 50 ?g/ml of streptomycin. 
pAdE1A-12S plasmid was extracted using Qiagen miniprep kit and TOP10 
electrocompetent bacteria (Invitrogen) were transformed as previously described. 
Transformed bacteria were seeded in agar plates containing kanamycin at 25 
?g/ml and culture overnight at 37˚C. Maxiprep of selected clones was done to 
extract the pAdE1A-12S plasmid. 
  
5 ?g of pAdE1A-12S was linearised with Pac I (NEB); 2 ?g of digested 
plasmid used to transfect JH293 cells with Fugene 6 Transfection Reagent 
(Roche; Basel, Switzerland), according to manufacturer’s instructions. 10 days 
after transfection, cells and medium were harvested and freeze-thawed three times 
in N2 (l). HEK293 cells in 20 ml of DMEM (10% FCS) at 70% confluency in a 
T75 flask were infected with 2ml of the supernatant of transfected JH293 cells. 
HEK293 cells and medium were collected 2 days after infection and freeze-
thawed three times to release virions from the cells. Supernatant was collected by 
centrifugation and stored at -80˚C; this represented the primary expansion of the 
virus.  
  
HEK293 cells grown in DMEM supplemented with 10% FCS were grown 
in a multiple-layer cell factory CF-10™ (Fisher Scientific, Leicestershire, UK). 
When 80% confluency was reached, 7 ml of primary expansion previously 
collected was used to infect HEK293 cells; infection was maintained in DMEM 
supplemented with 2% FCS for 72h. Infected HEK293 were collected when 
cytopathic effects of infection were seen as detachment of cells, then centrifuged 
for 10 min at 2000 rpm using a Sigma 6K15 centrifuge (Sigma, Germany) at 4˚C 
and resuspended in PBS. Pellets were collected again by centrifugation at 1000 
rpm for 10 min, resuspended in 10 mM Tris-HCl (pH 8.0) and freeze/thawed three 
times; the suspension was centrifuged for 10 min at 6000 rpm at 4˚C. The 
supernatants containing the viruses were layered onto caesium chloride (CsCl) for 
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purification. 10 ml of a 1.25 g/ml CsCl2 solution were placed in a 3.5” 
ultracentrifuge tube (Beckman, UK). Carefully, 7.6 ml of a 1.4 g/ml solution of 
CsCl was added at the bottom of the tube, avoiding mixing the two solutions of 
CsCl to create a density gradient. The virus-containing supernatants from the CF-
10
TM
 were carefully layered on top of the CsCl2 gradient in 4 tubes and 
centrifuged at 25000 rpm for 2h at 15˚C using a Beckman SW32Ti swing-out 
rotor in an Optima LE-80K ultracentrifuge. Three bands were visible after 
centrifugation: the top corresponding to cellular debris, the middle band 
corresponding to empty viral particles and the lowest band containing 
encapsulated infectious viral particles. Ultracentrifuge tubes were pierced with a 
19G needle fitted in a 10 ml syringe and the lowest band was aspirated. The band 
containing the virus was then layered onto 3 ml of a 1.35 g/ml solution of CsCl in 
a 2” ultracentrifuge tube (Beckman) and centrifuged at 40000 rpm at 15˚C for 15h 
using a combination of a Beckman SW55Ti swing out rotor in an Optima LE-80K 
ultracentrifuge. Virus was extracted from the ultracentrifuge tube using a 19G 
needle as described above and the volume was made up to 12 ml with TSG buffer 
(96 mM NaCl, 0.5 mM NaHPO4, 2.8 mM, KCl, 0.3 mM MgCl2, 0.5 mM CaCl2, 
and 30% (v/v) glycerol. The virus/TSG mixture was injected into a slide-a-lyzer 
(3-15ml, Pierce) using a 18G needle supplied. The slide-a-lyser was placed in the 
float provided and transferred to a 5 L beaker containing 2 L of dialysis solution 
(10 mM Tris-HCl pH 7.4, 1 mM MgCl2, 150 nM NaCl, 10% (v/v) glycerol  and 
distilled H2O). The beaker was placed on a magnetic stirrer at 4˚C for 24h. After 
dialysis, virus was removed using a syringe, aliquoted and stored at -80˚C. 
  
  
2.2.2.4 Generation AdE1A-12S deletion-mutants 
  
Generation of E1A-1102, E1A-1104 and E1A-1108 cDNA was done by 
gene splicing by overlapping extension PCR (SOEing PCR). This method consists 
on the amplification of two fragments of the gene of interest with primers that 
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overlap. These two fragments are then fused together, generating a deletion of the 
original gene. Primers were designed to generate the deletions corresponding to 
E1A-1102, E1A-1104 and E1A-1108 and are described in Table 4. For each 
mutant two independent PCR reactions were done, with primers corresponding to 
the 5’ of E1A and the 3’primer of the each mutation and the 5’primer of the 
mutation and the 3’ end of E1A. PCR reactions were done with a PTC-200 Peltier 
Thermal Cycler (MJ Research, BioRad). PCR products were separated by 
electrophoresis in a 2% agarose gel and purified using QIAquick Gel Extraction 
Kit (Qiagen). Fragments were quantified and mixed at equal molarity in a final 
concentration of 1ng/?l. A PCR cycle (96˚C for 6 min, 55˚C for 2 min, 72˚C for 3 
min) without primers was run with the mix to fuse the fragments, using 
Advantage 2 PCR Kit (Clontech, Mountain View, CA). Next E1A forward and 
reverse primers were added to the PCR reaction and PCR reaction was then 
completed (30 cycles). The generated E1A mutant cDNA was cloned into 
pCR2.1-TOPO vector and viruses were produced as described above. 
  
  
2.2.3 Viral DNA extraction 
  
DNA from each CsCl2-purified virus was extracted using the QIAmp 
DNA Blood Mini Kit (Qiagen). 20 ?l of proteinase K (Qiagen) was mixed with 
200 ?l of virus. 200 ?l of Buffer AL, supplied with the extraction kit, was then 
added, followed by incubation at 56˚C for 10 min in the heat block. 200 ?l of 
ethanol were added to the sample, mixed by pulse-vortexing for 15 s, and 
transferred to a QIAmp spin column in a 2 ml collection tube. After centrifugation 
for 1 min at 6000x g, the QIAmp spin column was transferred to a new collection 
tube. 500 ?l of Buffer AW1 (supplied) was added to and then sample was 
centrifuged at 6000x g for 1 min wash bound viral DNA. 500 ?l of Buffer AW2 
(supplied) was added and the column was centrifuged at 20000x g for 3 min. With  
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Table 4. Description of primers used in this thesis, indicating their respective sequence and the 
binding nucleotides in the Ad5 genome. Primer sets 1 to 8 were used for characterisation of viral 
E1A-mutants after production, while hexon and 18S primers were used for qPCR. 
  Sequence binding 
site in 
Ad5 
genome 
Forward GCGCGCACCATGAGACATATTATCTGCC 5’448 E1A 
Reverse CTCGAGTTATGGCCTGGGGCGTTTAC 3’1349 
Forward CCCGGTGAGTTCCTCAAGAGGCCAC 5’476 set 1 
Reverse CCGGACCCAAGGCTCTCTGCTCCGGCTGCTCGGGC 3’853 
Forward GTAATGTTGGCGGTGCAGGAAGGGATTG 5’767 set 2 
Reverse GGGTCCCCCGTATTCCTCCGGTGATAATGAC 3’1029 
Forward GTGTTCGCTTTGCTATATGAGGACCTGTGGC 5’1069 set 3 
Reverse CCTCGATACATTCCACAGCCTGGCGACGCCCACC 3’1453 
Forward CCTGTGATTGCGTGTGTGG 5’1554 set 4 
Reverse GACAACAGTAGCAGGCGATTC 3’2124 
Forward GCATCTGTGGAGAGCGGTTGTGAGACAC 5’2073 set 5 
Reverse GCGCCAGCAGATCAAGCTCATTAGCGC 3’2440 
Forward GCTTAATGACCAGACACCGTCCTGAGTG 5’2383 set 6 
Reverse GCACCAAGTGATCGGGCCTCAGCTCC 3’3434 
Forward CACCCTCACGCTCATCTGCAGCCTCATCACTGTGG 5’29915 set 7 
Reverse CTTCAGACGGTCTTGCGCGCTTCATCTGC 3’31038 
Forward CGCTGGGGTCGCCACCCAAGATGATTAGG 5’28715 set 8 
Reverse GAGTAGGGTACAGACCAAAGCGAGCACTG 3’29135 
Forward GGACAGGCCTACCCTGCTAAC 5’21564 Hexon 
Reverse TGCTGTCAACTGCGGTCTTG 3’21618 
Forward CAGCTGATCGAAAGCCATTTTGAACCACCTACCCTTCACG 5’664 1102 
Reverse TTCAAAATGGCTTTCGATCAGCTGGTCCAAAAGACTGG 3’635 
Forward CACGAACTGTATGCGGTTTCGCAGATTTTTCCCG 5’739 1104 
Reverse CTGCGAAACCGCATACAGTTCGTGAAGGGTAGGTGGTTC 3’701 
Forward ATCGATCTTACCGGCTTTCCACCCAGTGACGACG 5’940 1108 
Reverse GGGTGGAAAGCCGGTAAGATCGATCACCTCCGGT 3’929 
Forward CGCCGCTAGAGGTGAAATTC N/A 18S 
Reverse CATTCTTGGCAAATGCTTTCG N/A 
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the column placed in a sterile eppendorf tube, 70 ?l of distilled H2O were added 
and the column was centrifuged at 6000x g for 1 min. The collected filtrate 
contained purified viral DNA. 
  
  
2.2.4 Viral particle count determination 
  
2.2.4.1 Particle determination by optical density (OD) 
  
Dialysis buffer used for virus purification and lysis buffer (1% SDS, 0.04 
M Tris-HCl pH 7.4 in dH2O) were prepared; 300 ?l of each CsCl-purified virus 
was used for particle count determination by the optical density assay. Two 
samples were prepared for each virus: 
  
 Sample 1: 100 ?l of virus, 100 ?l of dialysis buffer, 200 ?l lysis buffer. 
 Sample 2: 200 ?l of virus, 200 ?l of lysis buffer. 
  
Samples were vortexed and incubated at 56˚C for 10 minutes in a heat 
block, vortexed 3 times and allowed to cool at room temperature for 10 minutes. 
600 ?l of distilled H2O was added to each sample and absorbance at 260 nm 
(OD260) was measured using a Beckman DU520 spectophotometer; OD260 of 
sample 1 should be below 0.02 and above 0.05 for sample 2, ensuring accuracy of 
the assay. The number of viral particles (vp/ml) was calculated using the 
following conversion factor: 
  
 vp/ml = OD260  x dilution factor x 1.12 x 10
12
 
  
Sample 1 had a dilution factor of 10; sample 2 had a dilution factor of 5. 
The coefficient factor 1.12x10
12
 was calculated based on virion total protein and 
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OD260, assuming that 87% of total dry weight of Ad5 is protein and that Ad5 
molecular mass of 2.3x10
7
 D (211). 
 
 
2.2.4.2 Particle determination by Pico Green Assay 
  
Pico Green particle determination was done using the Quanti-iT Pico 
Green dsDNA Assay Kit (Invitrogen) and the Tecan Infinite F200 plate reader 
(Tecan. Mannedorf, Switzerland). 1:10 and 1:100 dilutions of virus stock were 
prepared with TE buffer containing 0.5% SDS. Standard dilutions of Lambda 
DNA provided with the kit were also prepared, from 500 ng/ml to DNA-free 
standard sample in 5-fold serial dilutions. 100 ?l of each dilution was transferred 
to well of a 96-well plate. Each sample was analysed in triplicate. 100 ?l of a 
1:200 dilution of the Pico Green reagent was added to each sample and emission 
at 535 nm after excitation at 485 nm was measured using the Magellan V6.3 
software (Tecan). Using the fluorescence measurements from the Lambda DNA 
serial dilutions, a DNA concentration vs fluorescence graph was constructed with 
GraphPad Prism software and DNA concentration in virus samples were 
calculated according to the generated graph and to the dilution factor for each 
sample. Vp/ml were calculated on the basis that 1 ?g DNA was equivalent to 
2.7x10
10
 vp. 
  
  
2.2.5 Virus titration assay: TCID50 
  
The TCID50 assay (tissue culture inhibitory dose 50%) is a limiting 
dilution assay that enables the absolute quantification of any infectious particles in 
the test sample. The assay used in our lab was based on the original Karber-
Speaman equation modified as described by O’Reilley (212). 
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JH293 cells were seeded in 96-well plates at 1x10
4
 cells/well in 200 ?l of 
DMEM supplemented with 10% FCS. 24h after seeding, virus was diluted in FCS 
free DMEM to 1x10
-7
 of the stock and 20 ?l was used to infect each well of the 
first row on the 96-well plate. Serial dilutions within the same plate from each 
well of the first row to the second row and so until the seventh row (row G), as 
last row (row H) was left uninfected as a control of the assay. Cytopathic effect 
(CPE) 11 days post-infection was scored and the number of wells with CPE in 
each row were counted and used in the following equation to calculate the TCID50 
value: 
  
 Log TCID50 =  A - D (S – 0.5)  
  
 A = Log of the highest dilution showing CPE in more than 50% of the wells 
 D = Log of the dilution factor. 
 S = summation of the proportion of positive wells in each row. 
  
Quantification of infectious particles was expressed as plaque forming 
units per ml (pfu/ml). This was calculated by adjusting the Log TCID50 to the 
volume used to infect the wells to obtain Log TCID50/ml and multiply this value 
by the coefficient factor 0.69. According to the Poisson distribution, the 
proportion (p) of wells not receiving infectious units at a given dose is e
-?
, where 
? is the concentration of infectious viral particles at that dose. As, TCID50 is the 
dose at which 50% of the wells are infected (p =0.5), meaning that 0.5=e
-?
, 
therefore ?=0.69. A more detailed explanation of the mathematics behind these 
equations can be found in ref. (212). 
  
Viral particles/plaque forming units (vp/pfu) ratio was determined for each 
purified virus. All viruses used in these thesis had a vp/pfu ratio lower than 50. 
  
  
 82 
2.3 Cell viability 
  
2.3.1 Dose-response to drug 
  
Docetaxel (Taxotere?, Aventis, Dagenham, UK) is a drug in the taxoid 
class that binds to microtubules, promoting their assembly and hence preventing 
cells from dividing, resulting in ultimate cell death. Mitoxantrone (Onkotrene?, 
Baxter, Norfolk, UK) is a synthetic anthacenedione that suppresses tumour 
growth by intercalation into cellular DNA and inhibition of topoisomerase II.  
  
1x10
4
 cells for the DU145 and PC3 cell lines or 2x10
4
 cells for 22Rv1 
were seeded in each well of 96-well plates. Cells were exposed 24h later to serial 
dilutions of docetaxel or mitoxantrone, starting at 200 ?M and diluting 1:5 down 
to 0.1 nM. Media alone and untreated cells were used as control. MTS assay kit 
Cell Titre 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega, WI, 
USA) was used to determine cell viability 6 days after treatment.  
  
The MTS assay is a colorimetric method for determining cell viability, by 
using the tetrazolium compound (3-(4,5-dymethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)2H-tetrazolium; MTS) combined 
with phenazine methosulphate (PMS), an electron coupling reagent. 
Mitochondrial enzymatic activity of viable cells reduces MTS to formazan, that is 
water-soluble. The number of living cells is directly proportional to the 
concentration of formazan in the sample, determined by the absorbance at 490nm. 
MTS, PMS and DMEM were mixed before addition to the wells (80 ?l DMEM, 
20 ?l MTS, 1 ?l PMS per well) and media in the wells was decanted and replaced 
by the MTS-reagent mixture. Absorbance at 490 nm was measured after 3h of 
incubation at 37˚C and 5% CO2, using a OpsysMR plate reader (Dynex 
Technologies Inc, Chantilly, US). Absorbance values for wells with media alone 
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were subtracted from cell wells (background value of MTS mixture in the absence 
of cells) and values were expressed as percentages of the absorbance of untreated 
cells (100% viable cells) according to the following formula: 
  
  
  
  
Dose-response curves were constructed using GraphPad Prism version 
4.0a for Macintosh (GraphPad Software, San Diego CA, USA). The EC50 values, 
efficient concentration killing 50% of the cells, was calculated from the equations 
of the sigmoidal curves generated by GraphPad Prism software. 
  
 
 
2.3.2 Dose-response to viruses 
  
1x10
4
 cells for the DU145 and PC3 cell lines or 2x10
4
 cells for 22Rv1 per 
well in 96-well plates. Cells were exposed 24h later to 5-fold serial dilutions of 
each virus, starting at a concentration of 1x10
5
 particles per cell (ppc), down to 
0.05 ppc. Cell viability was determined by the MTS assay 6 days after infection, 
as described above. 
 
 
 
 
 
 Abssample - 
% cell death = 100 - x 100
 Absuntreated - Absmedia 
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2.4 Infectability 
  
2.4.1 Infectability of prostate cancer cell lines 
  
2x10
5
 cells (DU145 and PC3 cell lines) or 4x10
5
 cells (22Rv1 cell line) 
were seeded per well in 6-well plates. Cells were infected with the non-replicating 
AdGFP at 0, 10, 100 or 1000 ppc in 1ml of FCS free DMEM 24h after seeding. 
Medium was replaced after 2h with DMEM supplemented with 2% FCS. Cells 
were collected by trypsinisation 24, 48, 72 and 96h post-infection and washed 
with DMEM supplemented with 10% FCS to remove the remaining trypsin. Cells 
were recovered by centrifugation and resuspended in PBS supplemented with 2% 
FCS. GFP-positive cells were quantified using a benchtop argon laser flow 
cytometer (FACSCalibur; Becton Dickinson, Cowley, UK) with Cell Quest Pro 
Software (Becton Dickinson). Green fluorescence was detected at 525 nm using 
the fluorescence channel 1 (FL-1), with 1x10
4
 cells adquired in total. 
  
  
2.4.2 Infectability in combination with drugs 
  
2x10
5
 cells (DU145 and PC3 cell lines) or 4x10
5
 cells (22Rv1 cell line) 
were seeded per well in 6-well plates. 24h later, cells were infected with AdGFP 
at 2.5, 10 or 100 ppc respectively in 2 ml of DMEM, supplemented with 2% FCS 
or in 2 ml of DMEM with 2% FCS and mitoxantrone at 50 nM. A second set of 
samples for each cell line were infected with AdGFP at 100 ppc in 1 ml serum-
free DMEM. 2h later medium was removed and replaced by 2 ml of 2% FCS 
DMEM or with 2ml of 2% FCS DMEM containing mitoxantrone at 50 nM. The 
number of GFP-expressing cells was quantified by flow cytometry 48h after 
treatment and expressed as a percentage of total cell number, as described above. 
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2.5 Replication 
  
2x10
5
 cells/well of the prostate cancer cell lines were seeded in 6-well 
plates in 2 ml of DMEM supplemented with 10% FCS. Medium was decanted 
24h later and cells were infected with each virus at 100 ppc in 1 ml of serum-free 
DMEM. Medium was replaced by 2 ml of DMEM supplemented with 2% FCS. 
Cells were harvested with a sterile plastic scrapper at 24, 48 and 96h and collected 
together with the respective media from each well. Samples were freeze/thawed 3 
times in N2 (l) and the supernatant was collected after centrifugation at 1000 rpm 
for 5 min. Replicating viral particles in each sample was determined by the 
limiting dilution TCID50 assay. Replication of Ad5 was also measured in the 
presence of mitoxantrone; cells were infected for 2h and media was replaced with 
DMEM (2% FCS) containing mitoxantrone at 10 or 50 nM. 
  
 
 
2.5.1 Hexon quantification 
  
The hexon gene was used to quantify viral DNA amplification by qPCR as 
an indirect method to assess viral replication of Ad5, dl1102, AdE1A-1102, 
dl1104, AdE1A-1104, dl1108 and AdE1A-1108. Cells were infected with these 
viruses at 100 ppc for 2h, as described above. DNA was extracted 3, 24,48 and 
72h after infection. 
 
 
 
 
2.5.1.1 DNA extraction 
 86 
DNA was extracted from infected prostate cancer cell lines at the time 
points mentioned above. Media was removed from the wells and cells were 
washed with PBS and harvested by scraping with a sterile plastic scrapper in 200 
?l of PBS. The Qiagen DNA Blood Extraction Kit (Qiagen) was used for 
extraction of DNA, as described in section 2.2.3. DNA was quantified using 
nanodrop and concentration for each sample was adjusted to 5 ng/?l using sterile 
distilled H2O. 
 
  
2.5.1.2 qPCR 
  
Hexon copy number was quantified by qPCR, using a 7500 Real Time 
PCR System and Power SYBR
®
 Green PCR Master Mix (Applied Biosystems). 2 
?l of each sample was used in the qPCR reaction in a total volume of 20 ?l 
containing the SYBR green solution and primers at a concentration of 10 ?M. The 
forward and reverse primers for hexon amplification are shown in Table 4. 
Purified Ad5 DNA was used to generate standard dilutions of known 
concentrations of viral particles for a standard curve. Ad5 DNA was diluted to a 
concentration of 9847 pg/?l, equivalent to 5x108 viral particles, assuming that 
mass of 1 particle is approximately 3.9x10
-5
 pg. DNA was then serially diluted 
1:10 down to 9.8x10
-5
 pg/?l, equivalent to 5 viral particles. 2 ?l was used in each 
reaction to generate a standard curve. 
  
The hexon copy number at 3h post-infection was used as a reference for 
viral particles that had entered the cells prior to viral replication and genome 
amplification. Hexon copy number at later time points was expressed as the ratio 
of the 3h value for each virus in each cell line, showing an increase in viral 
genomes over time. 
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2.6 Transfections 
  
E1A-12S cDNA was cloned into pcDNA3.1(+) (Invitrogen) by digestion 
of pCR2.1-TOPO-12S and pcDNA3.1(+) with Kpn I and Xho I (NEB). Fragments 
were separated by agarose electrophoresis and ligated as previously described to 
generate pcDNA-12S. Plasmid was amplified by transformation of TOP10 
chemically competent bacteria under ampicilin selection and maxiprep 
preparation.  
  
The pcDNA-GFP plasmid was used for optimisation of the transfection 
protocol for each one of the reagents used. GFP expression in transfected prostate 
cancer cell lines was analysed by flow cytometry as described in section 2.4.1; 
this was done for all transfection reagents and the different conditions used for 
each one in order to determine the most efficient reagent to transfect prostate 
cancer cell lines. 
  
Human and murine prostate cancer cells were seeded in 6-well plates at 
2x10
5
 cells/well and 24h later were transfected with pcDNA-12S or pcDNA-GFP 
with different transfection reagents. Cells were trypsinised and collected in PBS 
48h after transfection to be analysed for GFP expression by flow cytometry. 
  
  
2.6.1 Genejuice 
  
2 ?g of plasmid were mixed with 6 ?l of GeneJuice Reagent (Novagen; 
Darmstadt, Germany) in 100 ?l of serum-free DMEM. The mix was incubated at 
room temperature for 15 min and then added to the cells. 
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2.6.2 Jetpei-RGD 
  
Three different conditions were used for transfection with JetPEI-RGD 
(Poly-Plus, Illkirch, France). 2 ?g of plasmid were diluted in 100 ?l of NaCl at 
150 mM. 4, 6 or 8 ?l of JetPEI-RGD solution were diluted in 100 ?l of NaCl in a 
separate tube. JetPEI-RGD mix was added to the DNA dilution, resulting in 
DNA:JetPEI-RGD ratios of 1:2, 1:3 or 1:4. The mixtures were incubated at room 
temperature for 15 and 30 min for all ratios tested, followed by addition to the 
cells. Transfection at DNA:JetPEI-RGD ratio of 1:2 with 15 minutes of 
incubation showed best transfection efficiency, based on GFP-expressing cells 
48h after transfection with pcDNA-GFP. 
  
Prostate cancer cell lines were also transfected with this reagent in 96-well 
plates. Cells were seeded at 1x10
4
 cells/well in 200 ?l of DMEM, 10% FCS. 24h 
later, cells were transfected with pcDNA-12S or pcDNA-GFP, using 0.125 ?g 
diluted in 10 ?l of NaCl and 0.25 ?l of JetPEI-RGD in10 ?l of NaCl per well. The 
order of addition of the reagents and the incubation times were the same as for 
transfection in 6-well plates. 
  
  
2.6.3 Fugene 6 
  
Fugene 6 Transfection Reagent (Roche, Basel, Switzerland) was used at 2 
different DNA to Fugene 6 ratios, 1:3 and 1:6. 2 ?g of plasmid was mixed with 6 
or 12 ?l of Fugene 6 reagent in 100 ?l of DMEM, free of FCS and antibiotics. 
The mixtures were incubated at room temperature for 15 min and added to cells 
maintained in DMEM supplemented with 2% FCS. A ratio of 1:3 (DNA:Fugene 
6) showed the best transfection efficiency. 
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2.6.4 TransIT 
  
Mirus TransIT Prostate Transfection Reagent (Cambridge Bioscience, 
Cambridge, UK) was the only transfection reagent specifically designed to 
transfect prostate cells. It contained two different reagents, TransIT-Prostate 
Reagent and Boost Reagent, that were combined at different ratios with 2 or 3 ?g 
of plasmid DNA to achieve optimal transfection efficiency. The conditions used 
are described in the following table (Table 5): 
  
 TransIT-
Prostate 
Reagent (?l) 
Boost 
Reagent (?l) 
Ratio 1 4 0 
Ratio 2 4 4 
Ratio 3 4 8 
Ratio 4 6 4 
  
TransIT-Prostate Reagent was added directly into 200 ?l of DMEM (FCS 
free). After 15 minutes incubation at room temperature, 2 or 3 ?g of plasmid 
DNA was added to the diluted transfection reagent and the mix was incubated for 
15 minutes at room temperature. Then Prostate Boost reagent was added to the 
mix and after 15 minutes of incubation at room temperature the mix was 
transferred to the cells. Best transfection efficiency was obtained with 2 ?g of 
DNA, 6 ?l of TransIT-Prostate Reagent and 4 ?l of Boost Reagent. 
Table 5. Different combinations of TransIT-Prostate Reagent and Boost Reagent 
used together with 2 and 3 ?g of plasmid DNA for transfection of pcDNA-12S 
and pcDNA-GFP using the Mirus TransIT-prostate transfection reagent 
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2.6.5 Effectene 
  
0.4 ?g of plamid was diluted in 100 ?l of buffer EC, provided with the 
Effectene transfection kit (Qiagen). 3.2 ?l of enhancer solution (provided with the 
kit) was added and mixture was incubated for 5 minutes at room temperature. 
After incubation, 10 ?l of Effectene transfection reagent was added to the 
samples, followed by incubation at room temperature for 10 minutes. DMEM 
supplemented with 10% FCS was added to each sample and then transferred to 
the cells, maintained in 1 ml of DMEM supplemented with 10% FCS.  
  
 
 
 
2.6.6 Clone selection after JetPEI-RGD transfections. 
  
Human prostate cancer cells were transfected with JetPEI-RGD as 
described above. 48h after transfection, media was replaced by DMEM (10% 
FCS) containing geneticin G418 (Sigma-Aldrich) at 800 ?g/ml. Cells were 
maintained under these conditions for a week until successful selection was 
achieved. Stably transfected cells were maintained in DMEM supplemented with 
10% FCS and G418 at 400 ?g/ml. 
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2.7 Retroviruses 
  
2.7.1 Construction plasmids 
  
Amphotropic phoenix cells (ATCC) were used for retrovirus production. 
Cells were grown in DMEM, supplemented with 10% FCS, containing 
hygromycin (Sigma-Aldrich) at 300 ?g/ml and diphtheria toxin (Sigma-Aldrich) 
at 1 ?g/ml for a week to ensure the selection of cells able to package retroviral 
particles.  
  
Phoenix cells were seeded in 10 cm dishes at 70% confluency were 
transfected with pLPC-12S or pLPC-GFP (kind gifts by Dr. Pilar Martin-Duque, 
Zaragoza, Spain) using FUGENE 6 kit (Roche, Basel, Switzerland). The pLPC-
12S plasmid contained the retroviral packaging signal, the adenovirus E1A-12S 
cDNA under the control of the CMV promoter and a puromycin-resistance gene. 
The pLPC-GFP was used for the construction of a control retrovirus expressing 
GFP. Media was changed to 6 ml of DMEM supplemented with 10% FCS 24h 
after transfection. Again 24 h later, medium was collected and replaced by 6 ml of 
fresh DMEM supplemented with 10% FCS. 24h later, medium was collected and 
dish discarded. The collected medium containing each retrovirus was filtered with 
a 0.45 ?M filter and diluted 1:2 in 10% FCS DMEM and 12 ?l of polybrene 
(Sigma-Aldrich) at 8 mg/ml was added to a final concentration of 10 ?g/ml before 
storage at -80ºC. 
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2.7.2 Retroviral transduction of prostate cancer cells and clone 
selection 
  
Human and murine prostate cancer cell lines were seeded at 2x10
5
 
cells/well in 6-well plates in DMEM supplemented with 10% FCS. 24h later, 
media was replaced by a 1:2 dilution of retrovirus stock in DMEM (10% FCS). 
48h post-infection, media was replaced by DMEM (10% FCS) containing 2 ?g/ml 
of puromycin (Sigma-Aldrich). Cells were treated under these conditions for a 
week to ensure total selection of infected cells. In addition, percentage of cells 
infected with the GFP-expressing retrovirus was analysed by flow cytometry as 
described for infectability assays with AdGFP. Infectability was analysed before 
and after selection with puromycin. 
  
  
  
2.8 Combination treatments 
  
2.8.1 Synergy  
  
1x10
4
 cells of each prostate cancer cell line were seeded in 96-well plates 
and treated after 24 h with different combinations of virus and drug at constant 
ratios of 62.5, 12.5, 2.5 or 0.5 ppc/nM.  One row of the plate was used for each 
combination; single agent treatment with drug or virus was also performed on 
each plate and each experiment was set up in triplicate. Untreated cells and wells 
containing medium alone were used as controls. MTS reagent was added to wells 
6 days after treatment and absorbance was used to quantify cell death as described 
in section 2.3.1. Dose-response curves of each treatment (single or combinations) 
were constructed with GraphPad Prism to generate EC50 values. Isobolograms 
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were constructed to determine synergistic interactions and combination indexes 
(CI) using Microsoft Excel as described by the mathematical formula: 
  
  
Where vEC50 is the EC50 of virus alone, dEC50 is the EC50 of drug alone, 
vcEC50 is the EC50 of the virus in combination with the drug and dcEC50 is the 
EC50 of the drug in combination with virus. 
  
  
  
2.8.2 Fixed concentrations of virus and drugs 
  
Prostate cancer cell lines were treated with a combination of fixed 
concentrations of mitoxantrone and replication-selective adenoviruses. 
Mitoxantrone at 10 nM, was the concentration chosen based on dose-response 
studies in each cell line, as it induced no more than 10% cell death in 22Rv1, PC3 
and TRAMPC cell lines. Mitoxantrone was combined with two viral doses 
inducing less than 25% or 50% cell death. These viral doses were selected for 
each cell line based on the dose-response studies to each virus. Concentrations of 
mitoxantrone and viruses selected are shown in  
Table 6. 
 
vcEC50 dcEC50 
dEC50 vEC50 
 +      CI = 
CI<0.8 = synergistic interaction 
 
0.8<CI<1.2 = additive interaction 
 
1.2<CI = antagonistic interaction 
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Table 6. Viral particles used to infect PC3, 22Rv1 and TRAMPC cells in combination with 
mitoxantrone at 10 nM. 
 
 
The PC3 and TRAMPC cells were seeded in 96-well plates at 1x10
4
 
cells/well and the 22Rv1 cells at 2x10
4
 cells/well in 200 ?l of DMEM 
supplemented with 10% FCS. 24h later media was decanted from the plates and 
replaced by DMEM with 2% FCS. Viruses and mitoxantrone were diluted in 
DMEM (2% FCS) to a concentration 10x of that selected for treatment and then 
10 ?l were added to the cells. Cells were treated with mitoxantrone at 10 nM, 
viruses at the chosen doses or a combination of both in a total volume of 100 ?l of 
 Dose 
PC3        
(ppc used) 
22Rv1       
(ppc used) 
TRAMPC   
(ppc used) 
1 83.1 1.01 1500 
Ad5 
2 193.8 2.2 4250 
1 83.1 1.01 1500 
dl312 
2 193.8 2.2 4250 
1 690 2.85 2100 
dl1101 
2 1683 6.4 14027 
1 281 0.64 2870 
dl1102 
2 659.7 1.6 7798 
1 846 27 2720 
dl1104 
2 2589 31.5 13187 
1 42.5 0.85 1350 
dl1107 
2 260.8 1.7 4233 
1 13.7 0.53 2130 
dl1108 
2 111.9 0.88 4365 
1 112 0.42 1140 
dl922-947 
2 365.5 0.74 3336 
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DMEM supplemented with 2% FCS. Cell viability was analysed by MTS assay 6 
days after treatment as previously described. 
 
 
 
2.8.3 Sensitisation: dose-response to drugs in the presence of 
fixed concentrations of virus 
  
The third type of combination of drugs and viruses consisted of the 
addition of a fixed dose of virus to cells treated with serial dilutions of 
mitoxantrone or docetaxel, in order to study changes in sensitivity to these drugs 
during combination with viruses. 
 
 
2.8.3.1 Sensitisation by replication selective viral mutants  
  
The 22Rv1, PC3 and TRAMPC cells were seeded in 96-well plates as 
previously described. Cells were exposed 24h later to serial dilutions of 
mitoxantrone, starting at 8 ?M and diluting 1:5 down to 4x10-3 nM, alone or in 
combination with fixed doses of each replication-selective adenovirus in a total 
volume of 100 ?l of DMEM supplemented with 2% FCS. The viral doses used are 
described in  
Table 6. Cell viability was analysed by MTS assay 6 days after treatment. 
Virus alone was used as control and cell viability was adjusted to subtract the 
effects of virus alone. EC50 value for each treatment was calculated using 
GraphPad Prism 4.0 and expressed as a percentage of the EC50 value of 
mitoxantrone as single treatment. 
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2.8.3.2 AdE1A-mutants 
  
22Rv1, PC3 and DU145 cells were seeded in 96-well plates as previously 
described. 24h later, cells were exposed to 1:5 serial dilutions of mitoxantrone or 
docetaxel, starting at 8 ?M and finishing at 4x10-3 nM in the presence or absence 
of different concentrations each AdE1A-mutant, in 100 ?l of DMEM 
supplemented with 2% FCS. Viral concentration inducing no cell death or 
inducing less than 30% cell death were individually chosen for each cell line 
based on the dose-response studies to the AdE1A-12S mutant. DU145 cells were 
treated with drugs in combination with 2 doses of viruses, 10 and 100 ppc. Three 
viral concentrations were used in PC3 cells: 10, 50 and 100 ppc. For 22Rv1 cells, 
1, 2.5 and 10 ppc were used in combination with the drugs. Cells were also treated 
with drugs or viruses alone. Cell viability was analysed 6 days after treatment by 
MTS assay; EC50 value for each treatment was calculated using GraphPad Prism 
4.0 and expressed as a percentage of the EC50 value of each drug as single 
treatment. 
  
  
2.8.4 E1A RT-qPCR 
  
2.8.4.1 Replication selective viruses 
  
PC3 cells were seeded in 6-well plates at 2x10
5
 cells/well in 10% FCS 
DMEM. 24 later, media was replaced by 1 ml DMEM (2% FCS) with Ad5 at a 
concentration of 100 ppc. Infection was allowed for 2h and then virus was 
replaced by 2ml of DMEM (2% FCS) or DMEM (2% FCS) containing 
mitoxantrone at 10 or 50 nM or docetaxel at 0.1 or 1nM. RNA was extracted from 
the sample 24 and 48h post-infection using Trizol (Invitrogen) and cDNA was 
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generated from the RNA of each sample as previously described in section 2.2.2.1 
for the generation of E1A-12S cDNA. 2 ?l of cDNA sample was used to 
quantified E1A in each sample by qPCR and each reaction was carried out in a 
total volume of 20 ?l with Power SYBR® Green PCR Master Mix and primers for 
E1A at a concentration of 10 ?M. Cellular 18S RNA was also quantified as 
control for the reaction. Samples were diluted 1:1000 in distilled H2O and 2 ?l 
was used for the quantification of 18S. Primers for E1A and 18S are described in 
Table 4. E1A mRNA quantity in each sample was normalised to 18S RNA. 
 
 
 
2.8.4.2 AdE1A-mutants 
  
DU145, PC3 and 22Rv1 cells were seeded in 6-well plates at 2x10
5
 
cells/well for DU145 and PC3 or 4x10
5
 cells/well for 22Rv1 cells in 10% FCS 
DMEM. Two conditions were tested 24h after seeding: in one condition, cells 
were infected with AdE1A-12S virus at 100 ppc for 2h in 1 ml of serum-free 
DMEM, and then virus was removed and DMEM (2% FCS) or DMEM (2% FCS) 
containing mitoxantrone at 50 nM was added to the cells. In the second condition 
tested cells were were infected with 2.5 (22Rv1), 10 (DU145) or 100 ppc (PC3) in 
the presence or absence of mitoxantrone at 50 nM; virus was not removed during 
the length the assay. mRNA was extracted from each sample and cDNA 
constructed as previously described. E1A and 18S were quantified by qPCR as 
described above; E1A expression was normalised to 18S expression.  
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2.9 Western blotting 
  
2.9.1 Whole cell extract preparation 
  
Prostate cancer cells were seeded in 6-well plates as previously described. 
For detection of viral proteins, cells were infected with virus at 100 ppc for 24h. 
For detection of E1A after transfection, cells were transfected and whole cell 
lysates recovered 24, 48, 72h or 7 days after transfection. For protein detection in 
combination assays with Ad5, cells were infected for 2h with virus at 100 ppc and 
then mitoxantrone at 10 nM or docetaxel at 0.1 nM was added to the cells, in 2% 
FCS DMEM. Whole cell lysates were harvested 24 and 48h after infection. For 
the detection of proteins during combination of mitoxantrone with AdE1A-
mutants, prostate cancer cells were treated with mitoxantrone at 50 nM, each 
AdE1A-mutant at 2.5 ppc (22Rv1), 10 ppc (DU145) or 100 ppc (PC3), or a 
combination of both in 2% FCS DMEM. Whole cell lysates were recovered at 24, 
48 and 72h. 
  
For harvesting of cell lysates, medium was removed from the wells and 
cells were washed with PBS. PBS was removed and 100 ?l of lysis buffer (25 
mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40 (v/v), 1% sodium deoxycholate 
(w/v), 0.1% SDS (w/v) and protease inhibitor) were added to each well. Cells 
were then scraped, recovered and incubated on ice for 30 min. Cells were 
centrifuged at 14000 rpm for 10 min using an Eppendorf Centrifuge 5415R, 
lysates were collected and stored at -80˚C. 
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2.9.2 Protein quantification 
  
Protein concentrations in the whole cell extracts were quantified using the 
Bradford Protein Assay (BioRad). Protein was quantified by diluting 5 ?l of 
whole cell extract in 1 ml of BioRad reagent diluted 1:5 in distilled H2O. In 
addition, 1, 2, 5, 10 and 15 ?l of bovine serum albumin (BSA; Sigma-Aldrich) at 
1?g/?l were diluted in 1 ml of diluted BioRad reagent. Absorbance of samples at 
595 nm was measured using a Beckman DU520 spectophotometer. A stantard 
curve of absorbance vs concentration was constructed for the different 
concentrations of BSA and the protein concentration in each sample was 
calculated using this graph. 
  
Whole cell lysates were diluted to a concentration of 1 ?g/?l with distilled 
H2O and 5x loading buffer (5% SDS, 250 mM Tris-HCl pH7.5, 5mM EDTA, 
glycerol (50%by volume) and Bromophenol Blue); samples were stored at -80˚C 
prior to use and heated to 100°C for 5 min before separation by electrophoresis.  
  
  
2.9.3 SDS polyacrylamide gel electrophoresis and protein 
detection 
  
20 ?l of each sample was loaded onto 10%, 12% or 15% polyacrylamide 
gels prepared with a Hoefer SE-400 western blot system (Amersham Biosciences, 
Bucks, UK). PageRuler Prestained protein ladder (Fermentas UK, York, UK) was 
also loaded on the gels. Separation of proteins by electrophoresis took place at 
120V for 90 min in Tris-Glycine SDS PAGE buffer. Proteins were then 
transferred onto nitrocellulose membranes provided with the iBlot system  
(Invitrogen) following manufacturer’s protocol.  
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Membranes were blocked with 5% (w/v) non-fat milk and 0.01% Tween-
20 in PBS for 2h at room temperature. Membranes were washed for 10 min in 
TBS-Tween buffer and primary antibody was added to the membranes as 
described in  
 
Table 7. Primary antibody was incubated with the membrane overnight at 
4˚C, removed and the membrane was washed with TBS-Tween for 10 min at 
room temperature. Secondary antibody was added to the membrane and incubated 
for 30 min. Membrane was then washed 3 times with TBS-tween for 10 min. 
  
Detection of protein was done by chemoluminescent detection of 
horseradish peroxidase-conjugated secondary antibody using the ECL Western 
Blotting Detection Reagent (Amersham Biosciences, UK). Signal was visualised 
with Super RX Fuji Medical X-Ray Film (Fujifilm; Düsseldorf, Germany) 
developed in a Curix 60 Developer (Agfa, Middlesex, UK). 
  
  
  
2.10 Cell cycle analysis 
  
2x10
5
 cells (DU145 and PC3 cell lines) or 4x10
5
 cells (22Rv1 cell line) 
per well were seeded in 6-well plates in DMEM supplemented with 10% FCS. 
24h later, cells were treated with mitoxantrone at 50 nM, each AdE1A-mutant at 
2.5 ppc (22Rv1), 10 ppc (DU145) or 100 ppc (PC3), or a combination of both in 
DMEM supplemented with 2% FCS. Attached cells were recovered by 
trypsinisation after 24, 48 or 72h of treatment. Cells were washed with PBS and 
recovered by centrifugation at 1700 rpm for 3 min and fixed in 1 ml of 70% 
ethanol. 24h later, cells were centrifuged and ethanol was decanted. Pellets were 
washed with PBS and recovered by centrifugation, then diluted in 50 ?l of RNAse 
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A at 100 ?g/ml and finally 200 ?l of propidium iodine (PI) at 50 ?g/ml was 
added. 
  
  
  
  
Antibody Type Species Conditions Supplier 
E1A Primary Rabbit 
1:1000 in 1.5% BSA 
TBS-tween, 4˚C, O/N 
Santa 
Cruz 
Hexon Primary Rabbit 
1:500 in 1.5% BSA 
TBS-tween, 4˚C, O/N 
Ab 
Frontier 
Bcl-2 Primary Rabbit 
1:500 in 1.5% BSA 
TBS-tween, 4˚C, O/N 
Santa 
Cruz 
Caspase 3 Primary Mouse 
1:500 in 1.5% BSA 
TBS-tween, 4˚C, O/N 
AbCam 
p21 Primary Mouse 
1:500 in 1.5% BSA 
TBS-tween, 4˚C, O/N 
Cell 
Signalling 
p53 Primary Mouse 
1:500 in 1.5% BSA 
TBS-tween, 4˚C, O/N 
Santa 
Cruz 
Androgen 
receptor 
Primary Rabbit 
1:500 in 1.5% BSA 
TBS-tween, 4˚C, O/N 
Santa 
Cruz 
Tubulin Primary Mouse 
1:20000 in 1.5% BSA 
TBS-tween, 4˚C, O/N 
 
Sigma 
Anti-rabbit-
HRP 
Secondary Goat 
1:2000 in TBS-tween, 
30 minutes, RT 
Dako 
Anti-mouse-
HRP 
Secondary Goat 
1:1000 in TBS-tween, 
30 minutes, RT 
Dako 
 
 
Table 7. Antibodies used for protein detection in this thesis. RT = room 
temperature; O/N = overnight. Antibodies providers are Santa Cruz 
Biotechnology (CA, USA), Ab Frontier (Seoul, Korea), AbCam (Cambridge, 
UK), Cell Signalling
®
 Technology (MA, USA), Sigma (MO, USA), Dako 
(Cambridge, UK). 
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Samples were analysed by flow cytometry using the Benchtop argon laser 
flow cytometer (FACSCalibur; Becton Dickinson, Cowley, UK) with Cell Quest 
Pro Software (Becton Dickinson, Cowley, UK). Gates for sub-G1, G1, S and 
G2/M phase were set based on the cell cycle profile of untreated cells. Percentage 
of cells in each cell cycle phase was determined for each sample and histograms 
were constructed using GraphPad Prism 4.0 sfotware. 
  
  
  
2.11 Caspase inhibitors 
  
2.11.1  Inhibition of sensitisation 
  
22Rv1, DU145 and PC3 cells were seeded in 96-well plates, 1x10
4
 
cells/well for DU145 and PC3 and 2x10
4
 cells/well for 22Rv1 cells in 200 ?l of 
10% FCS DMEM. 24h later, cells were treated with serial dilutions of 
mitoxantrone as single treatment or in combination with 2.5 ppc (22Rv1), 10 ppc 
(DU145) or 100 ppc (PC3) of each AdE1A-mutant in 2% FCS DMEM, as 
previously described for sensitisation assays with these viruses in section 2.8.3.2. 
In addition, cells were also treated with serial dilutions of AdE1A-12S, AdE1A-
1102, AdE1A-1104 or AdE1A-1108 viruses in 100 ?l of DMEM (2% FCS) or 
DMEM (2% FCS) containing mitoxantrone at 50 nM. This treatment was done in 
the presence or absence of the pan-caspase inhibitor z-VAD-FMK (Calbiochem, 
La Jolla, CA, USA) at a final concentration of 25 ?M. Medium was decanted 
from the plates 3 days after treatment and cell viability was measured by the MTS 
assay as described in section 2.3.1. EC50 values for the drug or each virus in each 
condition were calculated using GraphPad Prism 4.0 software and expressed as 
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the ratio of the EC50 for the combination treatment compared to mitoxantrone 
alone.  
  
2.12 Analysis of mitochondrial depolarisation 
  
22Rv1, DU145 and PC3 cells were seeded in 6-well plates and 24h later 
treated with mitoxantrone at 50 nM, AdE1A-mutant viruses or a combination of 
both as described for the cell cycle analysis. Medium and cells were recovered at 
24, 48, 72 and 96h for analysis of mitochondrial depolarisation (??) with 
tetramethylrhodamine ethyl ester (TMRE) as a measure of apoptotic death. TMRE 
enters the mitochondria of healthy non-apoptotic cells and is trapped inside, being 
released when mitochondrial depolarisation occurs. 
  
 Cells were recovered by centrifugation at 1700 rpm for 3 minutes, washed 
with PBS and recovered again by centrifugation. Pellets were diluted in 500 ?l of 
PBS and 40 ?l of TMRE (Invitrogen) at 1 ?M were added followed by incubation 
at 37ºC for 20 minutes. Cells were then recovered by centrifugation, washed with 
PBS and recovered again. Pellets were diluted in 500 ?l of PBS and 50 ?l of 4',6-
diamidino-2-phenylindole (DAPI; Molecular Probes, Eugene, Oregon, USA) 
solution at 1?g/ml was added to each sample. Samples were analysed by flow 
cytometry using the FSR flow cytometer (Becton Dickinson). Fluorescence 
channel 2 FL-2) was used to measure TMRE intake by cells and FL-4 to measure 
DAPI. Cells were gated using Cell Quest Software (Becton Dickinson) and 
separated into live cells, proapoptotic cells and dead cells based on the intake of 
TMRE and DAPI. Percentage of live proapoptotic cells was determined and data 
was presented using the GraphPad Prism software. 
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2.13 Statistical analysis 
 
Sample data were statistically analysed by t-test for parametric samples when only 
two data sets were compared. For comparison of more than two data sets, 
ANOVA was performed and each sample was indidually compared to the control 
sample using the t test with the Bonferroni’s correction. The Bonferroni’s 
correction addresses the problem of multiple comparisons to avoid familywise 
error rate. The correction consists on multiplying the p-values obtained in each 
comparison by the number of comparison made with all the data sets.  
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3Chapter 3 
  
  
  
Effects of E1A-mutated replication 
selective adenoviruses and cytotoxic drugs 
in prostate cancer cell lines. 
  
  
  
  
3.1 Effects of adenovirus mutants in prostate cancer cell 
lines. 
  
3.1.1 Deletion of p300 binding region of E1A attenuated viral 
toxicity in prostate cancer cell lines. 
  
In order to evaluate the potential of replication-selective adenoviruses in 
the treatment of prostate cancer, we examined the toxicity of these viruses as 
single agents. The human prostate cancer cell lines DU145, 22Rv1 and PC3 and 
the murine prostate cancer cell lines TRAMPC and RM1 were infected with serial 
dilutions of different Ad5 replicating E1A-deletion mutants, starting at a 
concentration causing 100% cell death down to concentrations that had no toxic 
effects on the cells. Dose-response curves were generated and the effective 
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concentrations inducing 50% cell death (EC50 values), expressed as number of 
particles per cell (ppc), were calculated to determine viral potency in each cell line 
for each virus (Fig. 8). The murine cell lines were significantly more resistant to 
Ad5-induced death than the human cell lines. TRAMPC and RM1 cells had EC50 
values 1000-fold higher than those of 22Rv1 or DU145 and 10 fold higher than 
that of PC3 cells. 
  
PC3 cells were more resistant to viral toxicity than the other human cell 
lines tested, with an EC50 value of 104.1 ppc for Ad5. DU145 cells had an EC50 
value of 6.9 ppc for the wild-type virus, while the 22Rv1 cells were the most 
sensitive, with an EC50 value of 1.4 ppc. A similar trend was observed when E1A-
mutant viruses were tested; cell lines resistant to Ad5 toxicity were also more 
resistant to the mutant viruses tested. Sensitivity to each mutant was different 
while the order of potency was similar in all human cell lines. Toxicity was 
attenuated in viruses expressing mutant E1A proteins unable to bind p300 (dl1101 
and dl1104), with significantly higher EC50 values compared to Ad5 in each cell 
line. 
  
The other E1A-mutant viruses tested were as efficient as Ad5 in inducing 
cell death in all human cell lines.  Similar results were obtained in the murine cell 
lines RM1 and TRAMPC; cell death induced by dl1101 and dl1104 mutants was 
attenuated as compared to Ad5, with significantly increased EC50 values. The 
E1A-mutant dl1107 also showed statistically significant attenuation of toxicity in 
RM1 cells. 
  
Additionally, potency of the E1A-deletion mutants was compared to the 
well-established attenuated efficacy of the E1B55K-deleted replication-selective 
mutant dl1520. As expected, the toxicity of this virus was significantly attenuated 
in all prostate cancer cells except in the murine cells TRAMPC and RM1. 
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            To confirm that the differences observed in EC50 values were not due to a 
low number of active viral particles in our virus stocks, the ratios of viral 
particle/plaque forming unit (vp/pfu) were calculated for each virus tested (Table 
8). Only viruses with a vp/pfu ratio below 50 were used in these studies. All ratios 
were within standard range (3 to 30 vp/pfu), with little variation that did not 
explain the observed differences in potency; therefore, differences in EC50 values 
were likely the result of the mutation in each virus and the corresponding gene 
alterations in the cancer cell lines.  
 
 
  
Table 8. Viral titres, particles/ml (vp/ml) and plaque forming units/ml (pfu/ml), and 
ratios (vp/pfu) for Ad5 and the corresponding E1-deletion mutants used in this and 
future studies. 
vp/ml pfu/ml vp/pfu ratio
Ad5 6.16E+11 3.10E+10 19.9
dl1101 1.00E+12 1.19E+11 8.4
dl1102 1.59E+12 1.19E+11 13.4
dl1104 3.90E+12 4.30E+11 9.1
dl1107 9.00E+11 5.80E+10 15.5
dl1108 2.50E+12 6.80E+11 3.7
dl922-947 3.62E+12 6.80E+11 5.3
dl1520 1.05E+12 7.59E+10 13.8
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3.1.2 Resistance to viral toxicity correlated with poor 
infectability. 
  
To determine whether the different sensitivity to virus-induced cell death 
of each cell line was caused by differences in infectivity, cells were infected with 
10, 100 or 1000 ppc of a non-replicating GFP-expressing Ad5 virus (AdGFP). 
GFP-expressing cells were quantified by flow cytometry 48h after infection (Fig. 
9).  
  
All cell lines expressed GFP in a dose-dependent manner, suggesting that 
cellular uptake of virus was directly proportional to the AdGFP dose. The human 
cell line 22Rv1 showed the highest percentage of GFP expression at all viral 
concentrations tested, with more than 30% of cells infected at 100 ppc and nearly 
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Fig. 9. Percentage of GFP-expressing cells 48h post-infection with 10, 100 or 1000 ppc of a 
non-replicating AdGFP. The murine cell lines TRAMPC and RM1 and the human cell line PC3 
were less infectable than 22Rv1 and DU145 cells. Data presented as percentage of total cells 
expressing GFP with standard deviation (n=3). 
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80% of cells expressing GFP at 1000 ppc. AdGFP virus successfully infected 
DU145 cells, with approximately 70% of cells expressing GFP at 1000 ppc. The 
PC3 cell line was the only human cell line tested that showed poor infectability; 
only 30% of cells were expressing GFP at 1000 ppc.  
  
Both murine cell lines were poorly infectable, with approximately 20% of 
cells infected at 1000 ppc. Murine cells were infected to levels similar to those of 
PC3 cells, thus poor infectability was not the cause of resistance to viral toxicity 
in murine cells, as PC3 cells were more sensitive to virus-induced cell death 
despite their poor infectability (Fig. 9). 
 
 
 
3.1.3 Ad5 efficiently replicated in human but not in murine 
prostate cancer cell lines. 
  
To determine if differences in viral toxicity correlated with replication 
efficiency, the level of replication of Ad5 was assessed in each cell line at 24, 48, 
72h and 96h post-infection (Fig. 10).  Wild type adenovirus failed to replicate in 
the murine cell lines TRAMPC and RM1, explaining the resistance to viral 
toxicity in these cells. Replication was observed in all human cell lines with the 
amount of virus produced significantly increased 48h after infection and 
continued to increase up to 96h after infection. Ad5 replication was more efficient 
in DU145 cells, producing approximately 7500 pfu/cell after 96h. 22Rv1 cells 
were also able to support high levels of replication, with approximately 1500 
pfu/cell 96h post-infection. PC3 was the only human cell line that supported viral 
replication poorly, being significantly lower than in DU145 or 22Rv1 cells. 
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3.2 The PC3 cell line showed higher resistance to 
cytotoxic drugs currently used for prostate cancer 
treatment. 
 
 To investigate whether prostate cancer cell lines were sensitive to the 
cytotoxic drugs commonly used in the clinic, cells were treated with serial 
dilutions of mitoxantrone or docetaxel, dose-response curves were generated and 
EC50 values for the drugs were determined in each cell line (Fig. 11). 
  
PC3 DU145 22Rv1 TRAMP RM1
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96h
Fig. 10. Replication of Ad5 in prostate cancer cell lines over time. Cells were infected with 100 
ppc for 2h and production of virus (pfu/cell) was determined by the TCID50 assay at the indicated 
time points. Amplification of virus was seen after 48h of infection and peaked at 96h in human 
prostate cancer cell lines; no amplification of virus was observed in the murine cell lines, 
indicating that Ad5 did not replicate in these cells. Average and standard deviation of 2 
independent experiments. 
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All cell lines were more sensitive to docetaxel than to mitoxantrone. Sensitivity to 
mitoxantrone was similar for all tested cell lines except for the PC3 cells that were 
significantly more resistant to this drug (Fig. 11). The EC50 value for 
mitoxantrone in PC3 cells was 160.5±23 nM, while the values in other cell lines 
varied from 50 to 70 nM. Similar trends were seen with docetaxel with the PC3 
cells being more resistant than other tested prostate cancer cell lines. The 22Rv1 
cells were the most sensitive cells to docetaxel, with an EC50 value of 3.6±1.9 nM. 
  
DU145 PC3 22Rv1 TRAMPC RM1
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
***
DU145 PC3 22Rv1 TRAMPC RM1
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0
10.5
*
 
 
Fig. 11. Toxicity of mitoxantrone (A) and docetaxel (B) in prostate cancer cell lines expressed as 
the EC50 value for each drug (nM). Data was analysed by ANOVA and t test with Bonferroni’s 
correction were used to compare data from each cell line with those of the other cell lines. The 
human prostate cancer cell line PC3 was significantly more resistant to mitoxantrone than the other 
cell lines used, p<0.001 (***).  PC3 cells were also significantly more resistant to docetaxel than 
22Rv1 cells, p<0.05 (*). Bars represent an average of 5 to 9 independent experiments with standard 
deviation. 
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3.3 Enhancement of cancer cell killing by combining 
treatments of chemotherapy and replication-selective 
adenoviruses. 
  
 To explore whether combination of viruses and drugs could sensitise 
prostate cancer cell lines to the cytotoxic effects of mitoxantrone, different 
combination studies were designed to investigate interactions between the E1A-
mutant adenoviruses and mitoxantrone. By testing different combinations, these 
studies would enable us to elucidate what deletions in the E1A-gene might affect 
chemo-sensitisation. 
  
  
3.3.1 The magnitude of the synergistic effects with mitoxantrone 
and adenoviruses in prostate cancer cells was cell line dependent. 
  
 The first combination tested was designed to elucidate the possible 
synergistic interaction between viruses and cytotoxic agents. This assay enabled 
us to determine whether virus and drug acted in synergy, greater than the additive 
effect of each treatment used independently, or antagonistic, less than the additive 
effect of each agent alone. The human PC3, 22Rv1 and murine TRAMPC cell 
lines were treated with serial dilutions of mitoxantrone and replicating Ad5 or 
E1A-mutant adenoviruses combined at four constant ratios of 0.5, 2.5, 12.5 and 
62.5 ppc/nM. EC50 values and combination indexes (CI) were calculated to 
determine synergistic (CI?0.8), additive (0.8<CI<1.2) or antagonistic interactions 
(CI?1.2) (Table 9). An example of how CIs were calculated is shown in Fig. 12 
and Fig. 13. 
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Treatment 
EC50 value for virus 
(ppc) 
EC50 value for mitoxantrone 
(nM) 
Ad5 193.8 N/A 
Mitoxantrone N/A 443.9 
Ad5 + mitox (0.5 ppc/nM) 58.1 116.1 
Ad5 + mitox (2.5 ppc/nM) 124.0 48.6 
Ad5 + mitox (12.5 ppc/nM) 284.4 14.7 
Ad5 + mitox (62.5 ppc/nM) 237.6 3.7 
PC3
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Ad5 + mitox (12.5 ppc/nM)
Ad5 + mitox (62.5 ppc/nM)
 
A 
B 
Fig. 12. Example of isobologram construction: determination of EC50 values for virus and 
drug at every combination ratio. PC3 cells were treated with Ad5 and mitoxantrone as 
described in materials and methods and dose-response curves were constructed 
independently for the virus and the drug at different concentrations (A). EC50 values were 
calculated from the dose-response curves for virus and mitoxantrone at every combination 
ratio using Prism Software (B). 
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Treatment Combination index (CI) 
Ad5 + mitox (0.5 ppc/nM) 0.56 
Ad5 + mitox (2.5 ppc/nM) 0.75 
Ad5 + mitox (12.5 ppc/nM) 0.98 
Ad5 + mitox (62.5 ppc/nM) 1.23 
 
A 
B 
Fig. 13.  Example of isobologram construction: determination of combination indexes. 
EC50 values obtained from Fig. 12 were used to construct an isobologram of the 
combination (A). The X-axis indicates EC50 values for Ad5 for each combination ratio; 
the Y-axis representes the EC50 values for mitoxantrone. Both values for each ratio 
intersect in a blue point that represents that particular combination ratio. The red points 
indicate the EC50 value for virus or drug as single agents. Data points below the line 
linking these values indicate a synergistic interaction between virus and drug; points 
above the line indicate antagonism. Using the mathematical formula described in the 
materials and methods section, combination indexes (CI) were obtained for quantitative 
measure of the interactions. The calculation of the CI for the first ratio tested is given as 
example, using the EC50 values calculated in Fig. 12 (B): synergisctic (CI?0.8), additive 
(0.8<CI<1.2) or antagonistic (CI?1.2). 
CI (0.5ppc/nM) = 
58.1 
193.8 
116.1 
443.9 
+  = 0.56 
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             In PC3 cells, combinations with mitoxantrone resulted in clear synergy in 
at least two out four ratios for all mutants except for dl1108 that, similar to Ad5, 
showed synergy only at the lowest virus to drug ratio. CI values for all other E1A-
mutants were lower than for Ad5. The dl1108 and the dl1107 mutants were the 
only viruses that interacted antagonistically with mitoxantrone, with CI values 
higher than 1.2 in one to two of the ratios tested. Synergy in PC3 for all ratios was 
only achieved in combinations with the dl1102 or dl1104 mutants; the dl1104 
mutant showed the best synergistic interactions with mitoxantrone, with CI values 
of 0.09 and 0.18 for the 2.5 and 12.5 ppc/nM ratios respectively. The dl1107 
mutant also showed very low CI values for three of the combinations, while at a 
ratio of 62.5 ppc/nM antagonistic effects were observed (Table 9). The E1A-
deleted virus dl312 was also used, but CI values could not be determined as the 
dose-response curve could not be constructed due to the severe potency 
attenuation of this mutant. The dl1520 mutant, with an intact E1A gene but 
lacking E1B-55K, showed better synergistic interactions than Ad5, indicating than 
deletions in the E1B gene could improve the synergistic interactions between 
viruses and mitoxantrone. 
  
 No synergy was observed for mitoxantrone and the E1A-mutants in the 
22Rv1 cell line, except with the dl922-947 mutant at the lowest ratio (0.5 
ppc/nM). Synergy between Ad5 and drug was only obtained at one of the four 
ratios tested; treatment at other ratios only resulted in additive effects (2.5 and 
62.5 ppc/nM) and antagonism at the lowest ratio (Table 9). Interactions with the 
drug did not improve in combination with the dl1520 mutant compared to Ad5, as 
observed in PC3 cells, possibly indicating that functional status of different 
cellular pathways might have an important role in chemosensitisation. 
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 The effects of combination of mitoxantrone and E1A-mutant adenoviruses 
in the murine TRAMPC cells resulted in additive effects at most combination 
ratios. Ad5 and the dl1101 and dl1102 mutants showed CI values close to 0.8 at 
all ratios tested, indicating additive effects with a trend towards synergy. As 
observed in PC3 cells, the dl1520 mutant had better CIs than Ad5, even though 
both viruses express wild type E1A proteins. Synergistic interactions were 
observed with the other mutants at one or two of the ratios used. The mutant 
1 2 3 4
Ratio (ppc/nM) 0.5 2.5 12.5 62.5
Ad5 0.68 ± 0.16 0.92 ± 0.24 0.93 ± 0.07 1.01 ± 0.31 n=3
dl1101 0.49 ± 0.13 0.62 ± 0.28 0.99 ± 0.20 1.09 ± 0.21 n=3
dl1102 0.69 ± 0.07 0.7 ± 0.21 0.88 ± 0.05 0.81 ± 0.02 n=3
dl1104 0.64 0.09 0.18 0.57 n=1
dl1107 0.25 0.31 0.63 1.51 n=1
dl1108 0.78 1.36 1.12 1.83 n=1
dl922-947 0.91 0.36 0.43 1.2 n=1
dl1520 1.27 0.16 0.21 0.52 n=1
1 2 3 4
Ratio (ppc/nM) 0.5 2.5 12.5 62.5
Ad5 0.89 ± 0.13 0.75 ± 0.09 0.86 ± 0.10 0.77 ± 0.25 n=3
dl1101 0.99 ± 0.19 0.96 ± 0.25 0.98 ± 0.32 0.74 n=3
dl1102 0.8 ± 0.45 0.79 ± 0.19 0.74 ± 0.33 N/A n=3
dl1104 0.99 1.17 1.42 0.66 n=1
dl1107 1.02 0.6 0.51 1.12 n=1
dl1108 1.11 1.36 1.03 N/A n=1
dl922-947 0.61 0.76 1.13 1.07 n=1
dl1520 0.56 0.53 1.22 0.9 n=1
1 2 3 4
Ratio (ppc/nM) 0.5 2.5 12.5 62.5
Ad5 1.58 1.22 0.76 1 n=1
dl1101 1.22 1.39 1.39 1.33 n=1
dl1102 1.13 1.46 1.24 1.18 n=1
dl1104 1.36 1.25 1.17 1.32 n=1
dl1107 1.49 1.15 1.63 1.89 n=1
dl1108 1.15 1.57 1.68 1.43 n=1
dl922-947 0.59 0.95 1.22 1.34 n=1
dl1520 0.99 0.97 1.35 0.89 n=1
PC3: combination index: viral mutants and mitoxantrone
TRAMP-C: combination index: viral mutants and mitoxantrone
22Rv1: combination index: viral mutants and mitoxantrone
Table 9. Combination indexes (CI) of the different combinations of mutant 
adenoviruses or Ad5 with mitoxantrone in PC3, TRAMPC and 22Rv1 cells. Values 
below 0.8 represent clear synergy: values between 0.8 and 1.2 indicate additive effect. 
Values over 1.2 indicate antagonistic effect of the combination. Number of times the 
experiment was repeated is indicated (n). 
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dl922-947 showed low CI values at the two lowest ratios used, while the dl1107 
mutant showed better interactions at 2.5 and 12.5 ppc/nM ratios. The dl1104 
mutant showed synergy with mitoxantrone at the higher ratio tested, although it 
acted antagonistically with the drug at one of the ratios (Table 9). 
  
 These data indicated that synergistic interactions between viruses and 
mitoxantrone were not only dependent on the specific deletions within E1A in 
each mutant but also on E1B-deletions (dl1520 mutant) and the gene expression 
profile of each cell line, possibly due to the functional status of pathways 
controlling cell survival and/or apoptosis. Combinations of viruses and drug in 
PC3 cells resulted in good synergistic interactions with almost all the mutants 
tested, while these interactions were mostly antagonistic in 22Rv1 cells. The 
dl1108 mutant was the only virus that did not show synergistic interactions in any 
of the cell lines tested although other mutant viruses with smaller deletions in the 
same pRb-binding region, dl1107 and dl922-947, were able to act in synergy with 
mitoxantrone.  
 
  
3.3.2 Combination of mitoxantrone and viruses at fixed 
concentrations showed that sensitisation was dependent on both 
the respective cell line and the concentration of mitoxantrone or 
viruses.  
  
 Based on the synergy studies a more simplified experimental set up was 
used to further evaluate the response to viral mutants in combination with 
mitoxantrone. The 22Rv1, PC3 and TRAMPC cell lines were treated with fixed 
concentrations of drug and virus. Concentrations of mitoxantrone that induced 
less than 10% cell death were combined with two viral doses that killed less than 
25% or 50% of the cells (Fig. 14); these doses were determined for each cell line 
 119 
from dose response curves obtained during the analysis of viral toxicity. 
Observations of supra-additive effects (synergistic effects) on cell death in 
response to the combination treatments suggested that cell killing efficacy was 
improved. The murine TRAMPC cells showed higher supra-additive effects than 
the human cell lines 22Rv1 and PC3, despite the poor replication and infectivity 
previously observed with adenoviruses in this cell line (Fig. 9 and Fig. 10). There 
was an increase in cell death for all combinations tested with mitoxantrone and 
low levels of Ad5, E1A-deletion mutants and the E1B55K-deleted virus in 
TRAMPC cells. This increase was higher with the dl922-947 and dl1520 mutants 
than with Ad5. At the higher concentrations of virus, only the dl1107 mutant 
failed to induce supra-additive effects in combination with the drug. These results 
were slightly different from the findings reported in the previous section, with 
improved cell killing using the fixed concentrations conditions. No supra-additive 
effect was observed with the E1A-deleted mutant dl312, indicating that E1A 
expression is required for chemosensitisation.  
  
 In the human cell lines the combination treatments did not result in 
significant supra-additive effects; no increase in cell death was observed with any 
adenovirus in 22Rv1 and PC3 cells when mitoxantrone was combined with the 
lower viral concentrations. Higher concentrations of viruses resulted in small 
supra-additive effects in 22Rv1 cells; all E1A-mutant adenoviruses with the 
exception of the dl1108 mutant, were able to induce a small increase in cell death 
compared to the theoretical additive effect. However, 22Rv1 cells were very 
sensitive to virus-induced cell death and the viral concentrations tested induced a 
higher percentage of cell death than expected, that could have affected the results, 
as seen for the dl1108 and dl922-947 mutants. The use of fixed concentrations of 
viruses and mitoxantrone showed similar results as the synergy studies, 
suggesting that 22Rv1 cells were more resistant to chemosensitisation by 
adenovirus E1A than other prostate cancer cell lines. 
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Fig. 14. Effects on cell viability by mitoxantrone, E1A-mutant adenoviruses or combination of 
both at a low dose (A) or a high dose (B) of the respective viruses. Viral doses used can be found 
in Fig. 15.B. Bars in black indicate the percentage of cell death caused by each agent as a single 
treatment; red bars indicate the theoretical additive cell death when combined and the green bars 
represent the observed cell death induced by the combination of mitoxantrone with each virus. 
Statistical analysis consisted on t-test comparing the percentage of cell death of the combination 
with the theoretical additive value for each virus; p<0.05 (*), p<0.01 (**), p<0.001 (***). Data is 
an average of 3 independent experiments with standard deviation.
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            The effects of combination treatments in the PC3 cells at the higher viral 
dose showed no significant increase in cell death, with the exception of the dl1520 
mutant that increased cell death by 10% (p<0.05). The dl1107 and dl1108 mutants 
also showed an increase in cell death in combination with mitoxantrone but was 
less than 5% compared to the theoretical additive value of drug and virus alone 
and was not significant difference. At the lower viral dose no additional increase 
in cell death in response to the combination treatment was detected, rather 
additive or less than additive effects were observed. The data from the PC3 cells 
in this study was in contrast to the findings in the previous section demonstrating 
clear synergy at specific ratios with several mutants (Table 9). It is likely that the 
sensitising interactions required doses of drug and virus different from the 
selected concentrations as we previously observed in the synergy studies that not 
all combination ratios resulted in synergistic interactions. This hypothesis is 
supported by the differences in the level of sensitisation observed in TRAMPC; a 
low dose of virus was more effective at killing cells in combination with 
mitoxantrone than the highest dose used. 
 
 
3.3.3 Sensitisation to mitoxantrone by replication-selective E1A-
mutant adenoviruses varied among cell lines. 
  
 To resolve whether combination treatments with the various mutants and 
mitoxantrone could induce supra-additive (synergistic) increases in cell death, 
further studies and improvements of test conditions were necessary.  To optimise 
the possibility of identifying supra-additive effects on cell death, prostate cancer 
cell lines were treated with mitoxantrone to generate dose-response curves with 
and without the addition of viruses at fixed concentrations inducing less than 25% 
or 50% cell death alone. EC50 values for mitoxantrone were calculated for each 
cell line under all conditions and results were expressed as percentages of the 
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EC50 value for mitoxantrone alone (Fig. 15). This assay enabled the combinations 
of numerous drug concentrations with the viruses, hence optimising the possible 
determination of cell death mechanisms.  
  
 Sensitisation by E1A-mutant adenoviruses was more effective in the 
human cell lines 22Rv1 and PC3 than in the murine cell line TRAMPC; the 
majority of E1A-mutants caused a significant reduction in the EC50 value for 
mitoxantrone in both human and murine cell lines. Ad5 reduced the EC50 values 
for mitoxantrone to a level that was statistically significant compared to drug 
alone in all cell lines, while dl312, lacking the E1A gene, failed to induce 
sensitisation to mitoxantrone in any cell line.  
  
As previously observed during the study of synergistic interactions 
between viruses and mitoxantrone, adenovirus infection showed good ability to 
sensitise PC3 cells to this drug. All replication-selective mutants tested induced 
sensitisation to chemotherapy, although with the dl922-947 and dl1107 mutants 
the reduction in EC50 value was not statistically significant with any of the doses 
tested. These mutants showed a greater reduction in EC50 values for mitoxantrone 
at the lower doses. The dl1104 mutant showed similar sensitisation effects with 
both concentrations. Only the dl1102 mutant was able to induce a reduction 
greater than 50% of the EC50 value at the highest dose tested. However, in the 
22Rv1 cells the dl1102 mutant was the only mutant that failed to reduce the EC50 
values for mitoxantrone.  The mutants dl1108 and dl922-947, unable to bind to 
different members of the pRb family, showed similar sensitising effects, with 
reductions of EC50 value of approximately 30% compared to value of drug alone. 
The dl1101 and dl1104 mutants showed better sensitisation in this cell line than 
dl1108 or dl922-947. Interestingly, the dl1107 mutant failed to sensitise these 
cells to mitoxantrone at the lower dose used, but it showed the best reduction of 
EC50 value at the highest dose, with a reduction in EC50 value of 80% with respect 
to drug alone.  
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PC3 Dose Viral particles 
(ppc)
% cell death
1 83.1 25.13
2 193.8 49.37
1 83.1 -11.1
2 193.8 -10.68
1 690 35.45
2 1683 53.41
1 281 18.56
2 659.7 35.78
1 846 22.13
2 2589 45.42
1 42.5 15.44
2 260.8 32.89
1 13.7 10.97
2 111.9 25.05
1 112 35.46
2 365.5 50.55
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22Rv1 Dose Viral particles 
(ppc)
% cell death
1 1.01 28.45
2 2.2 63
1 1.01 -13.02
2 2.2 -15.2
1 2.85 10.9
2 6.4 49.13
1 0.64 3.82
2 1.6 25.05
1 27 59.55
2 31.5 73.29
1 0.85 49.83
2 1.7 57.07
1 0.53 8.49
2 0.88 26.76
1 0.42 56.15
2 0.74 79.28
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1 1500 2.53
2 4250 51.26
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2 4250 0.678
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2 14027 38.47
1 2870 8.78
2 7798 11.25
1 2720 9.13
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Fig. 15. Sensitisation to mitoxantrone by replication-selective E1A-mutant adenoviruses. A) 
Histograms representing decreases in EC50 values for mitoxantrone in combination with a low dose 
of virus (red bars) or high dose (green bars) compared to mitoxantrone alone (black bar). Data is an 
average of 3 independent experiments with standard deviation; ANOVA and t test with 
Bonferroni’s correction were used to statistically analyse the data, statistically significant results 
are shown as P<0.05 (*), P<0.01 (**) and P<0.001 (***). B) Table showing number of viral 
particles chosen as described in materials and methods for each E1A-mutant adenovirus for 
combination studies with mitoxantrone; cell death induced by viruses alone is shown as percentrage 
of untreated cells for low dose (dose 1) or high dose (dose 2) as used for combination studies. 
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This was the only experimental setting that showed sensitisation to 
mitoxantrone in 22Rv1 cells; however, good sensitisation correlated with high cell 
death due to viral infection. Even though virus-mediated cell death was taken into 
account for the calculation of the EC50 values in combination treatments, the high 
percentage of cell death made these data unreliable and subjected to high 
variability due to the small number of surviving cells. 
  
 In the TRAMPC cells the E1A-mutant adenoviruses did not induce 
significant reductions in EC50. Only the dl1101 mutant induced a great reduction 
in EC50 value at the lower viral concentration tested; at the highest dose tested, 
this virus induced a reduction of 30% in EC50 value, similar to the sensitisation 
effect observed with Ad5 at the two doses tested and with the dl1108 mutant at 
the highest concentration tested. The dl922-947 mutant also induced a small 
reduction in EC50 value, while the other mutants tested did not decrease the EC50 
value for mitoxantrone. 
  
 This experimental design was likely to be the most useful to study 
sensitisation by E1A-mutant viruses, as it allowed to combine viruses with 
decreasing concentrations of drug. The studies resulted in a more reproducible 
decrease of EC50 values that could not be observed when fixed concentration of 
virus and drug were used. In addition, it is a simplified design compared to the 
laborious synergy studies and even though it did not provide information about 
the interactions, such as CI values, it allowed to determine what E1A-mutant 
viruses could chemosensitise prostate cancer cell lines to mitoxantrone. 
Sensitisation was cell-dependent, with the 22Rv1 cells being more difficult to 
sensitise than the other cell lines tested; even though we reported in a previous 
section that viruses unable to bind p300 were attenuated in potency, they were 
still able to sensitise prostate cancer cell lines to cytotoxic drugs. It is also 
possible that the high percentage in cell death observed after viral infection might 
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have had an effect in the sensitisation to drugs or in the outcome of the assays, as 
the observed cell death by virus alone, in particular in 22Rv1 cells, was higher 
than expected.  
  
  
3.4 Changes in viral protein expression and replication 
when viral mutants were combined with cytotoxic drugs. 
  
 The following results were generated to determine if the presence of 
cytotoxic drugs had effects on viral gene expression, replication and infectivity. 
Combination treatments resulted in sensitisation of the prostate cancer cell lines 
and in order to better understand the interactions between virus and drug, we 
analysed the effects that the presence of drug had on adenovirus infection.  As 
mitoxantrone and virus were added at the same time, it is possible that changes in 
viral protein expression were due to an increase in infectivity, and increase in viral 
transcription or a combination of both.  
 
  
3.4.1 Effects on viral protein expression in response to cytotoxic 
drugs. 
  
 To determine if the enhanced cell death in response to combination 
treatments of virus and cytotoxic drugs was caused by increased viral gene 
expression, early and late viral proteins, E1A and hexon respectively, were 
analysed by western blotting. DU145 and PC3 cells were infected with Ad5 and 
treated with mitoxantrone at 10 nM or docetaxel at 0.1 nM (both <<EC50 value) 
and proteins were extracted 24 and 48h post-infection (Fig. 16). These cell lines 
were chosen as they showed best sensitisation after adenovirus infection than 
22Rv1 cells or murine prostate cancer cell lines. 
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 The level of E1A after Ad5 infection was higher in DU145 than in PC3 
cells as expected from the infectivity and replication data. E1A expression 
remained unchanged in DU145 cells infected with Ad5 in combination with 
mitoxantrone or docetaxel. However, hexon expression was observed already at 
24h post-infection at very low levels in these cells when Ad5 was combined with 
docetaxel but not with mitoxantrone or when given alone. Hexon expression was 
increased with all treatments at 48h after infection.  
  
 In the PC3 cells E1A expression was increased after 24h in combination 
with both mitoxantrone and docetaxel.  Hexon expression was detected already 
after 24h in the presence both drugs but not with virus alone. Levels of hexon 
were similar with all treatments at 48h, while combination of Ad5 with 
mitoxantrone showed a small increase in E1A at this time point. This data 
 
Fig. 16. Hexon and E1A expression in PC3 and DU145 was analysed by western blotting. 
Earlier expression of hexon was observed in both cell lines when Ad5 was combined with 
mitoxantrone at 10 nM or docetaxel at 0.1nM. Increased E1A expression was observed in 
PC3 cells in response to both drugs. Representative data of 2 independent experiments. 
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suggested that the enhanced killing effect observed in combination treatments 
could be due to an increased rate in viral replication or to the pro-apoptotic 
properties of E1A, further enhanced by an increase in expression.  
 
 
3.4.2 Levels of viral mRNA increased in the presence of 
mitoxantrone. 
  
 To assess whether the changes in viral protein expression were paralleled 
by similar changes in mRNA levels, E1A transcripts were quantitated by qPCR at 
24 and 48h post-infection with and without mitoxantrone and docetaxel 
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 Fig. 17. PC3 cells were infected for 2h with Ad5 at 100 ppc, followed by addition of 
medium only or containing mitoxantrone at 10 and 50 nM or docetaxel at 0.1 and 1 nM. 
Determination of E1A mRNA expression levels by qPCR showed an increase in E1A 
mRNA levels over time with all conditions; E1A mRNA levels increased significantly 
at 48h in the presence of mitoxantrone at 50 nM compared to infected cells in the 
absence of drugs (t-test, P<0.05). Data represents average and standard deviation of 3 
independent experiments, presented as E1A-copy numbers normalised to 18S cDNA for 
each sample 
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combinations (Fig. 17). PC3 cells were infected with Ad5 for 2h and then treated 
with two different concentration of mitoxantrone or docetaxel. E1A mRNA levels 
did not change significantly at 24h post-infection in the presence of drugs; 
however, there was a significant increase in E1A expression at 48h when cells 
were treated with mitoxantrone at 50 nM. Small increases in E1A were also 
observed with a lower dose of mitoxantrone and with docetaxel at the highest 
dose tested. These data together with the western blot results indicated that E1A 
expression increased in the presence of cytotoxic agents; the small increase 
observed by western blot correlated with small increases in mRNA when 
mitoxantrone was used at a concentration of 10 nM. We also observed that 
treatment with a higher dose of mitoxantrone significantly increased the levels of 
E1A mRNA. Therefore we decided to use mitoxantrone at 50 nM for further 
studies, as it allowed for significant changes in viral gene expression. 
  
  
3.4.3 Mitoxantrone affected infectability of prostate cancer cell 
lines. 
  
 The increase in viral protein expression could be caused by an increase in 
transcription rate or by increased virus uptake in the presence of the 
chemotherapeutic drugs. To determine whether virus uptake was enhanced in the 
presence of drugs, 22Rv1, DU145 and PC3 cells were transduced with a 
replication defective GFP-expressing adenovirus in the presence of mitoxantrone 
at 50 nM. The virus was not removed from the medium to mimic the conditions of 
the sensitisation assays to mitoxantrone (Fig. 14 and Fig. 15). In addition, a lower 
number of viral particles were used; 22Rv1 cells were infected with 2 ppc, while 
DU145 and PC3 cells were transduced with 10 and 100 ppc respectively. The use 
of 100 ppc, as in the replication studies, would have resulted in 100% infection 
after 48h when virus was not removed. Number of transduced cells was 
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determined by quantification of GFP-expressing cells after 48h by flow 
cytometry. The percentage of transduced cells in 22Rv1 and PC3 cells only 
showed a small increase, approximately 3%, which was not enough to be 
considered statistically significant. Interestingly, the percentage of GFP-
expressing cells almost doubled in DU145 cells (Fig. 18.A). 
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Fig. 18. Analysis of effects of mitoxantrone treatment on adenoviral transduction of 
human prostate cancer cells. Cells were treated with AdGFP in the presence or absence 
of mitoxantrone at 50 nM during 48h (A, B) or transduction was only allowed for 2h, 
followed by replacement of virus with media with or without mitoxantrone (C, D). 
Combination of mitoxantrone and AdGFP virus resulted in an increase in the percentage 
of transduced cells in DU145 cells with 10 ppc, but the increase was not significant in 
PC3 cells infected with 100 ppc and 22Rv1 cells infected with 2.5 ppc (A). Under these 
conditions, presence of mitoxantrone increased the GFP intensity/cell in 22Rv1 and 
DU145 cells (B). When these cell lines were transduced with 100 ppc for 2h and virus 
was replaced by medium only or medium containing mitoxantrone at 50 nM, no 
increase in the percentage of transduced cells was detected in any cell line (C) although 
GFP intensity/cell increased (D). The data represents the average and standard deviation 
of 3 independent experiments, statistically significant results are indicated with their 
corresponding P-value, obtained by t-test analysis within each cell line. 
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            Brightness intensity, measured by the geometric median of GFP 
expression in each cell line, was also analysed as an indication of GFP expression 
in individual cells; in the absence of mitoxantrone, 22Rv1 cells showed a higher 
GFP intensity per cell than other prostate cell lines. In the presence of 
mitoxantrone, GFP expression per cell increased significantly in 22Rv1 and 
DU145 cells, but not in PC3 cells (Fig. 18.B).  
  
 These cell lines were also transduced with 100 ppc of AdGFP for 2h in the 
presence or absence of mitoxantrone, followed by removal of virus and incubation 
in medium containing mitoxantrone at 50 nM. No significant changes in the 
number of transduced cells were observed after 48h with or without mitoxantrone 
(Fig. 18.C). However, an increase in GFP intensity per cell was observed for 
22Rv1 and DU145 cells (Fig. 18.D). Overall, this data suggests that mitoxantrone 
increased viral infection when virus was not removed after 2h; it is possible that 
mitoxantrone treatment increased the number of CAR receptors and integrins over 
time, thus allowing a higher percentage of transduction. In addition, the brightness 
per cell increased in both experimental conditions, indicating that more GFP 
protein was produced in transduced cells when mitoxantrone was present and 
suggesting that CMV-GFP transcription might be upregulated in combination 
treatments. 
  
  
3.4.4 Viral replication decreased in the presence of 
mitoxantrone. 
  
 We next assessed whether viral replication was affected by the presence of 
mitoxantrone. Since we observed an increase in viral proteins at earlier time 
points, it was possible that viral replication was also affected. DU145 and PC3 
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cells were infected with Ad5 at 100 ppc for 2 hours as described in the Materials 
and Methods section.  
  
 Viral replication was decreased over time after infection with Ad5 in 
combination with mitoxantrone at 10 or 50 nM; this was observed in both DU145 
and PC3 cells (Fig. 19.A). The extent of the decrease also correlated with the 
concentration of drug, with a greater decrease with mitoxantrone at 50 nM. 
Differences between Ad5 alone or in combination with the drug at both doses 
were highly significant at 72h (P<0.001). This decrease in replication could have 
been caused by cell death induced by the presence of the chemotherapeutic agent; 
a decrease in the number of cells due to the toxic action of mitoxantrone would 
result in a reduction on the number of cells that could be infected by new virions 
over time.  
  
 To elucidate this, we measured the percentage of cell death occurring 
under the conditions of the replication assays (Fig. 19.B). Cell death was 
measured at 24, 48 and 72h after treatment with virus in the presence or absence 
of mitoxantrone. Cell death induced by viral replication in DU145 reached 15% of 
cells after 72 hours, similar percentages were observed after treatment with 
mitoxantrone at 10 nM. This percentage was significantly higher in combination 
with Ad5. Cell death observed with the higher concentration of mitoxantrone 
reached 60% and increased in the presence of Ad5. The effects of mitoxantrone 
were similar in PC3 cells, with an observed cell death of 16% and 23% at 10 and 
50 nM respectively; however, the combination of mitoxantrone and Ad5 resulted 
in increased cell death at 24 and 48h, but no differences were observed at 72h 
between the combination and mitoxantrone alone. We concluded that the resulting 
decrease in viral replication in the combination treatments was likely due to the 
toxic effect of the drug, reducing the number of cells that the virus could infect. 
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Fig. 19. Assesment of replication of Ad5 in DU145 and PC3 in the presence of two 
concentrations of mitoxantrone. Viral replication was monitored over time by the TCID50 
method. Production of new virions was reduced in the presence of mitoxantrone in both 
human prostate cancer cell lines (A). The decrease in replication correlated with the cell 
death associated with the cytotoxic effects of the drug (B). Data expressed as average with 
standard deviation of 3 independent experiments. 
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 The data is this chapter indicated that deletions of the p300/CBP binding 
site in E1A (dl1101 and dl1104 mutants) attenuated viral potency compared to 
Ad5 and other E1A-deletion mutants. All mutants showed sensitising abilities in 
prostate cancer cell lines; the efficiency of sensitisation was dependent on cell line 
and the doses of viruses and drugs used, suggesting that cellular alterations might 
determine or influence the efficiency of E1A-mediated chemosensitisation, in 
addition to the mode of administration, as we observed that sensitisation was not 
achieved under all conditions tested with these viruses. We concluded that E1A 
expression is essential for sensitisation, as the dl312 mutant that lacks E1A did 
not have an effect in chemosensitisation. However, other viral genes might also 
play a role. Interestingly, we observed higher infectability of prostate cancer cells 
treated with mitoxantrone that resulted in higher expression of E1A. 
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4Chapter 4 
  
  
  
  
  
  
  
  
Expression of E1A proteins using plasmids 
and retroviral vectors. 
  
  
  
 In addition to E1A, both E1B and E3 viral genes are expressed early 
during infection with the replication-selective E1A-mutant adenoviruses used in 
the previous chapter. Proteins coded by these genes are involved in cell cycle 
regulation and virus-induced cell death mechanisms. To assess the role of E1A 
and the different E1A mutations in the absence of other viral proteins and viral 
replication, the E1A gene was isolated and cloned into non-replicating vectors. 
  
  
4.1 Cloning of E1A gene 
  
 Lung carcinoma A549 cells were infected with Ad5 in order to synthesise 
E1A cDNA. First RNA was extracted from the cells 20h post-infection and cDNA 
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generated from mRNA using TaqMan® Reverse Transciption Reagent as 
described in materials and methods. E1A cDNA was amplified using primers 
targeting the beginning and end of the complete gene. Several bands were 
obtained by PCR with specific primers, as shown in Fig. 20. These bands 
corresponded to cDNA derived from mRNA coding for the different E1A proteins 
reported to be produced during infection: 13S, 12S, 11S, 10S and 9S. 
  
 To avoid potential transcriptional activation by the E1A CR3 region 
present in the E1A-13S protein, we selected the E1A-12S cDNA for further 
studies. Hence, the band corresponding to the E1A-cDNA was extracted and 
purified from the agarose gel as described in material and methods. This cDNA 
was cloned into a TOPO-CR4 vector for cloning and sequencing. Data regarding 
sequencing of E1A cDNA used during this thesis can be found in the appendix 
section (chapter 9). The verified E1A-12S cDNA was cloned into a pcDNA-
3.1(+) plasmid.   
  
 
Fig. 20. E1A cDNA obtained from RNA extracts of Ad5 infected A549 cells after separation 
in 2% agarose gel. Bands correspond to the expected cDNAs representing the different E1A 
proteins expressed during infection. The E1A-12S band was extracted and purified to be 
cloned into pcDNA-3.1(+) plasmid. 
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4.2 Assessment of transfectability of prostate cancer cell 
lines. 
  
 Prostate cancer cell lines are known to be difficult to transfect. Five 
commercially available reagents were used to optimise transfection conditions in 
the prostate cancer cell lines used in this thesis. Fugene 6, Gene Juice and 
Effectene are reagents widely used for transfection of cell lines of different 
origins. The Prostate TransIT transfection kit from Mirus Bio Corporation had 
been demonstrated to have improved efficacy in different prostate cancer cell 
lines. JetPEI-RGD was indicated for the transfection of cell lines of epithelial 
origin that were poorly transfectable. 
  
 The pEGFP-C2 (described in Materials and Methods) plasmid was used to 
determine efficacy of each reagent in five prostate cancer cell lines. The 
percentage of GFP-expressing cells was determined by flow cytometry 48h after 
transfection (Fig. 21).  
  
 Effectene was the only reagent tested that failed to transfect any of the cell 
lines. GeneJuice and Fugene 6 reagents showed transfection efficiencies of up to 
50% and 40% for 22Rv1 cells respectively. Different transfection conditions were 
tested with Fugene 6 in order to optimise the transfection efficiency; the results 
shown in Fig. 21 correspond to the optimised protocol for transfection with this 
reagent, consisting of DNA:reagent ratio of 3:1 for 48h without replacing the 
medium in the wells. These conditions showed an efficiency similar to that 
obtained with the prostate-specific reagent Prostate TransIT from Mirus. 
Transfections with this kit were also optimised to improve efficiency, using 3 μl 
of IT reagent and 2μl BR reagent with 2 μg of DNA for 48h to obtain the best 
results, shown in Fig. 21. 
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  Highest transfection efficacies were achieved with JetPEI-RGD.  Despite 
being designed to transfect prostate cancer cell lines, the TransIT Mirus reagent 
was less effective than JetPEI-RGD in all cell lines used. JetPEI-RGD was the 
only commercial kit that succesfully transfected more than 40% of cells of the 
human cell lines; this reagent also showed the best transfection efficiencies for the 
murine cell lines RM1 and TRAMPC. RM1 cells were not transfected at 
satisfactory levels with any reagent used, although JetPEI-RGD was the only 
reagent that resulted in more than 15% of transfected cells. However, this reagent 
showed very good transfection of TRAMPC cells. Jet-PEI-RGD showed the best 
Fig. 21. Percentage of GFP-expressing cells 48h after transfection of pEGFP-C2 using 
different commercially available transfection reagents. Date presented as averages of 2 
experiments with standard errors. 
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efficacy of the reagents tested and was therefore chosen for further  transfection 
experiments.  
4.2.1 Effects of E1A in drug toxicity using a plasmid as 
expression vector. 
  
 The human prostate cancer cell lines 22Rv1, PC3 and DU145 were 
transiently transfected with pcDNA-12S or pcDNA-GFP, then seeded in 96-well 
plates and treated with serial dilutions of mitoxantrone or docetaxel to generate 
dose-response curves (Fig. 22). No significant sensitisation to the drugs was 
observed in 22Rv1 cells. Decreases in EC50 values for both mitoxantrone and 
docetaxel were observed in DU145 and PC3 cells. However, sensitisation caused 
by transfection with pcDNA-GFP in both cell lines and by mock-transfection in 
PC3 cells was also observed. These results could be explained by the high cell 
death and slow growth rate observed in transfected cells after seeding in 96-well 
plates. Next, to minimise cell death due to handling of transfected cells, 
transfections with pcDNA-12S or pcDNA-GFP were performed directly in the 96-
well plates before treatment with mitoxantrone or docetaxel. The high percentages 
of cell death induced by the transfection protocol, almost 70% in 22Rv1 cells 
(Fig. 23) made data of dose-response studies to drugs difficult to reproduce, 
highly variable, and not comparable with data from untransfected cells. 
  
 In addition, transient transfection did not achieve a constant expression of 
E1A during the length of the dose-response assays. As shown in Fig. 24 
expression of E1A in 22Rv1 cells was detectable at 72h post-transfection but not 
after 7 days. In the sensitisation studies cells were treated with mitoxantrone or 
docetaxel for 4 to 6 days, and consequently sensitising effects induced by E1A 
might not have been detectable in cells transfected with E1A-expressing plasmids 
in contrast to cells infected with virus, where E1A expression was maintained 
over time. 
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Fig. 22. Dose response curves to mitoxantrone and docetaxel of DU145, PC3 and 22Rv1 cells 
transfected with pcDNA-12S, pcDNA-GFP, mock transfected or untransfected. Toxicity to drugs 
increased with expression of E1A in DU145 and PC3 cells. Mock transfection and GFP expression 
also induced sensitisation to drugs, although cell death induced by transfection protocol could 
influence these results. 
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            Based on the described results, transient transfection was considered a not 
reliable and reproducible method to achieve E1A expression in prostate cancer 
cell lines. We considered the selection of stably transfected clones as an 
alternative to transient transfection. Transfected cells were selected with geneticin 
as described in Material and Methods in order to obtain E1A-expressing clones. 
Same selection was done in cells transfected with a plasmid expressing GFP as 
control. Resistant clones showed a very slow growth ratio compared to parental 
cell lines, both in E1A and GFP transfected clones. In addition, E1A expression 
was lost after one passage in culture while geneticin resistance was maintained 
(Fig. 24).  
  
 Taken together, these data indicated that transfection was not suitable to 
study E1A effects on drug toxicity in prostate cancer cell lines; transient 
transfection showed high cell death induced by the transfection protocol. The 
attempts to select E1A-expressing clones showed a reduced growth rate that made 
this cells difficult to compare to their parental cell lines. 
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Fig. 23. Histogram showing percentages of cell death (yellow) induced by the transfection 
protocol and the percentage of transfection achieved, expressed as percentage of GFP-expressing 
cells 48h after transfection (blue). Averages of 3 independent experiments with standard 
deviations. 
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4.3 Use of retroviruses to generate E1A-expresssing 
prostate cancer cell lines. 
  
 Transient transfection and selection of clones was not a successful method 
to express E1A in prostate cancer cell lines. In order to generate cells that stably 
expressed E1A rather than transient expression resulting in poor E1A expression 
in the above studies, retroviral transduction was evaluated as an alternative. 
Amphotropic retroviruses with the E1A gene were generated using Phoenix cells, 
as these cells produced viruses capable of transducing human and murine cell 
lines.                            
Fig. 24. Changes in E1A expression levels over time after transfection. A) 22Rv1 cells were 
transfected with pcDNA-12S and E1A expression was monitored over time by western blot. E1A 
was detected up to 72h post-transfection, but not after 7 days. 22Rv1 cells infected for 48h with 
Ad5 were used as positive control for E1A detection. B) Decrease in percentage of GFP-
expressing cells one passage after transfection of 22Rv1 cells selected by G418; averages and 
standard deviation of 3 experiments. C) Expression of E1A was lost one passage after 
transfection of 22Rv1 cells determined by western blotting. 
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E1A-12S cDNA was inserted in the pLPC plasmid to construct retroviruses 
expressing E1A and control viruses expressing GFP.  
  
 Prostate cancer cell lines were very resistant to retrovirus transduction 
(Table 10). Succesfully transduced cells were selected with puromycin as 
described in materials and methods. Good level of selection resulting in 
enrichment of GFP expressing cells was achieved as shown by infection with GFP 
expressing retroviruses and analysis by flow cytometry (Table 10). 
  
  
4.3.1 Expression of E1A with retroviral vectors and its effects on 
sensitisation to cytotoxic drugs. 
  
 Cell viability was not affected by the E1A expression and were similar to 
the parental cell lines (Fig. 25). Expression of E1A-12S was determined by 
western blotting in cells transduced with retrovirus and selected with puromycin 
(Fig. 26). DU145 and TRAMPC cells expressing E1A-12S were exposed to serial 
 before puromycin selection after puromycin selection 
 % GFP-expressing cells SD % GFP-expressing cells SD 
PC3 2.64 0.23 65.65 0.81 
22Rv1 6.25 3.00 52.49 1.74 
DU145 2.50 3.29 76.82 4.18 
RM1 5.28 0.29 41.95 1.04 
TRAMP-C 4.54 1.88 42.21 0.35 
 
Table 10. Percentages of GFP expressing cells after retrovirus transduction. Expression of GFP 
was very low after infection with GFP-retrovirus in all prostate cancer cell lines. Selection of 
infected cells with puromycin for 3 days significantly increased the percentage of GFP-
expressing cells (n=3). 
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dilutions of mitoxantrone or docetaxel to determine whether expression of E1A 
would decrease the EC50 value for the drugs compared to parental cell lines (Fig. 
26). E1A expression sensitised these cells to both chemotherapeutic drugs; 
mitoxantrone at 28.2 nM killed 50% of DU145 parental cells, while the 
concentration required to obtain the same effect in E1A-expressing DU145 cells 
was 10.2 nM. A similar sensitisation effect was observed with docetaxel, with 
EC50 values of 1.3 nM in the parental DU145 cells and 0.37 nM in the E1A-
expressing cells. This effect was also observed in the murine TRAMPC cells; 
E1A expression reduced the EC50 value for mitoxantrone from 135.1 nM to 80.8 
nM and the value for docetaxel decreased from 11.25 nM to 4.4 nM. 
  
 This study was repeated after further passaging of the E1A expresing cells 
to determine reproducibility of the sensitisation. However, E1A expression was 
lost in the retrovirus-transduced prostate cancer cells even though puromycin 
resistance was maintained (Fig. 27). After one passage of the cells E1A 
expression was not detectable by western blot, whereas cells grew at a normal rate 
in puromycin-containing medium. E1A expression was monitored after each 
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Fig. 25. Cell viability was similar to untreated cells in DU145 cells infected with a E1A-
expressing retrovirus and selected with puromycin. Transduced cells showed a similar growth 
rate to parental cells both in the presence (dotted blue) and the absence (blue) of puromycin, 
while untreated cells were killed by the selection agent (dotted red). Data represent the average 
and standard deviation of 3 independent experiments. 
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passage, showing great decreases in expression levels from one passage to the 
next, compromising the reproducibility of the data. Consequently, retroviral 
infection as an alternative to transfection was not feasible, resulting in similar 
difficulties and loss of E1A expression observed with transfection protocols. 
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Fig. 26. Dose-response studies comparing E1A or GFP expressing DU145 and TRAMPC cells 
with their respective parental cell lines. A shift of the curve to the left when E1A was expressed 
indicated a sensitisation effect to the drugs, observed for mitoxantrone and docetaxel in both cell 
lines. E1A expression was confirmed by western blotting. 
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Fig. 27. Sensitisation was not observed after one passage of the retrovirus infected cells. E1A-
expression was lost, even though puromycin resistance was maintained, resulting in lack of 
sensitisation. 
DU145
0.001 0.01 0.1 1 10 100 1000 10000 100000
-10
0
10
20
30
40
50
60
70
80
90
100
110
docetaxel (parental cell lines)
docetaxel (E1A-expressing cells)
docetaxel (GFP-expressing cells)
Chemodrug (nM)
 
TRAMPC
0.0001 0.001 0.01 0.1 1 10 100 1000 10000 100000
-10
0
10
20
30
40
50
60
70
80
90
100
110
mitoxantrone (parental cell lines)
mitoxantrone (E1A-expressing cells)
mitoxantrone (GFP-expressing cells)
Chemodrug (nM)
 
 
docetaxel (GFP-expressing cells)mitoxantrone (GFP-expressing cells)
docetaxel (parental cells)mitoxantrone (parental cells)
docetaxel (E1A-expressing cells)mitoxantrone (E1A-expressing cells)
 147 
5Chapter 5 
  
  
  
  
  
  
  
Use of replication-deficient E1A-mutant 
adenoviruses for expression of the E1A 
gene in prostate cancer cell lines. 
  
  
  
  
  
  
 Since transfection and retroviral transduction failed to successfully 
maintain E1A expression in the prostate cancer cell lines in a reproducible 
manner, a different approach was necessary. One idea was to use replication-
defective adenoviruses as gene-transfer vectors, expressing the various E1A gene 
deletions but lacking the E1B and E3 genes. This would allow to study the role of 
E1A expression in the absence of other viral proteins involved in cell killing or 
cycle regulation, hence minimizing viral replication. The pAdEasy-1 vector 
enabled the construction of adenovirus vectors that lacked E1B and E3 genes and 
expressed the gene of interest under control of the CMV promoter. 
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5.1 Construction and characterisation of a replication 
deficient adenovirus expressing E1A-12S protein. 
  
 First, the E1A-12S cDNA, described in the previous chapter, was cloned 
into a pShuttle-CMV plasmid and then recombined with the pAd-Easy-1 plasmid 
as described in Materials and Methods, section 2.2.2.3. This generated pAdE1A-
12S plasmids that were linearised and transfected into JH293 cells in order to 
produce the recombined AdE1A-12S virus. The virus was further expanded to 
larger quantities using the HEK293 cells as the producer and packaging cells. 
  
 Viral DNA was extracted to check the correct insertion of E1A and the 
absence of E1B and E3 by PCR (Fig. 28). E1A was sequenced to ensure that no 
recombination had occurred during the production of the virus with the cellular 
genome. The sequence data showed perfect homology with the E1A-12S cDNA 
sequence previously described in the literature. Details of the sequencing data can 
be found in the Appendix (Chapter 9). Amplification was observed with the E3 
primers in the pAdE1A-12S plasmid. The bigger band was extracted and 
sequenced. A BLAST search showed 100% homology with the sequence of the 
pAdEasy-1 plasmid. The other bands were considered non-specific amplification. 
Fig. 28. PCR of E1A, E1B and E3 viral genes. The AdE1A-12S virus did not have E1B 
and E3 as expected and the  E1A was smaller in size than in the Ad5 wild type virus since 
Ad5 carries the complete gene, coding for the additional E1A-13S protein. The bigger 
band observed in pAdE1A-12S with the E3 primers correspond to a sequence present in 
the pAdEasy-1 plasmid used to genereate pAdE1A-12S. the other bands are non-specific 
amplification. 
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5.1.1 Expression of E1A in AdE1A-12S infected cells was 
confirmed by western blotting. 
  
 In order to use AdE1A-12S as a vector to express E1A in prostate cancer 
cell lines, the level and timing of expression should be similar to that of the intact 
Ad5 and was subsequently evaluated. 
  
 22Rv1, PC3 and DU145 cells were infected with Ad5 or AdE1A-12S at 
10, 100 and 1000 ppc and proteins were harvested after 24h. Expression of E1A-
12S in AdE1A-12S infected cells was confirmed by western blotting (Fig. 29). 
Levels of the E1A protein were similar in Ad5 and AdE1A-12S infected cells 
after 24h of infection. 
  
  
 
  
Fig. 29. Expression levels of E1A in DU145 cells by AdE1A-12S virus were similar to that 
of Ad5. Cells were infected with 10, 100 or 1000 ppc and proteins were harvested 24h post-
infection. Same results were observed in PC3 and 22Rv1 cells (not shown). 
 Ad5 
 E1A 
 Tubulin 
 AdE1A-12S 
 55Kd 
  
  
 43Kd 
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5.1.2 Cytotoxicity of the AdE1A-12S virus was attenuated 
compared to Ad5. 
  
 Toxicity of the AdE1A-12S virus was compared to that of Ad5 to evaluate 
the effect that the absence of E1B and E3 had on viral toxicity. Dose-response 
studies with the AdE1A-12S mutant and Ad5 were performed in the human 
prostate cancer cell lines 22Rv1, DU145 and PC3. EC50 values were determined 6 
days after infection (Fig. 30). Lack of E1A-13S, E1B and E3 genes in AdE1A-
12S significantly attenuated the potency of the 12S-mutant compared to intact 
Ad5 in the three cell lines tested. Infection of PC3 cells with AdE1A-12S resulted 
in an EC50 value of 17000 ppc, while the value for Ad5 was 110 ppc. A similar 
attenuation was observed in DU145 cells, with EC50 values of 1600 and 2 ppc for 
AdE1A-12S and Ad5 respectively (Fig. 30.B).  The attenuation in viral toxicity 
was not as great in 22Rv1 cells as in the other cell lines. EC50 value for Ad5 was 1 
ppc, while the value for AdE1A-12S was 30 ppc. However, these cells were also 
more sensitive to infection with the dl312 mutant, with an EC50 value for this 
virus of 1220 ppc while EC50 value in DU145 and PC3 was higher than 1x10
5
 
ppc. It is possible that 22Rv1 cells were very sensitive to viral infection and that 
viral entry into the cell triggered a cell death mechanism, in addition to E1A 
expression and/or viral replication.  
  
 We observed an attenuation of toxicity when E1B and E3 genes were not 
expressed. Nevertheless, the AdE1A-12S virus was more potent than the E1A-
deleted mutant dl312 in all cell lines; this indicated that cell death was induced by 
E1A expression. We next analysed replication of AdE1A-12S to elucidate if the 
observed toxicity was due only to E1A expression or to potential replication of the 
virus. 
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EC50 values (ppc) 
 Ad5 AdE1A-12S dl312 
22Rv1 1 30 1220 
DU145 2 1600 8500 
PC3 110 17000 >100000 
22Rv1
10-2 10-1 100 101 102 103 104 105 106
-50
-25
0
25
50
75
100
125
150
Virus (ppc)
 
DU145
10-2 10-1 100 101 102 103 104 105 106
-50
-25
0
25
50
75
100
125
150
Virus (ppc)
 
PC3
10-2 10-1 100 101 102 103 104 105 106
-50
-25
0
25
50
75
100
125
150
ad5 AdE1A-12S dl312
Virus (ppc)
 
 
Fig. 30. Representative dose-response assays in 3 human prostate cancer cell lines treated 
with serial dilutions of AdE1A-12S (blue), Ad5 (black) or dl312 (green) (A) with EC50 
values calculated (B). AdE1A-12S virus showed less toxicity than Ad5 in the cell lines 
tested, but it was more cytotoxic than the dl312 mutant. Representative dose-response curves 
from 3 independent experiments. 
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5.1.3 The AdE1A-12S virus failed to replicate in human prostate 
cancer cell lines. 
  
 One explanation for the observed attenuation of cytotoxicity in the tested 
cell lines could be poor replication of the AdE1A-12S virus. Therefore, 
replication of this virus was investigated in the human cell lines used above. 
Replication was not detected after 48h of infection in 22Rv1, DU145 or PC3 cells 
(Fig. 31). It was therefore concluded that expression of E1A-12S protein was not 
sufficient to support replication of the E1B and E3 deleted AdE1A-12S mutant 
and consequently replication was not a cause of the observed cytotoxicity. 
  
 
Fig. 31. The AdE1A-12S virus failed to replicate in the three human prostate cancer cell 
lines. Cells were infected with 100 ppc of Ad5 or AdE1A-12S for 2h. Media and cells 
were collected 48h post-infection and TCID50 assays were done to determine viral 
replication. Data represent the averages of 3 independent experiments with standard 
deviation. 
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5.1.4 Greater synergistic interactions were achieved with 
AdE1A-12S than with Ad5 in combination with cytotoxic drugs. 
  
5.1.4.1 Further enhancement of synergistic interactions with AdE1A-12S 
and mitoxantrone, a DNA-damaging agent. 
  
 PC3 and DU145 cells were treated with different combination ratios of 
mitoxantrone with AdE1A-12S, Ad5 or dl1520 in synergy assays as described in 
Chapter 3. EC50 values for virus, mitoxantrone and the combinations were 
calculated and isobolograms were constructed to quantify the level of synergy 
through determination of combination indexes (CI).   
  
 Synergistic interactions were higher in combinations of mitoxantrone with 
AdE1A-12S than with Ad5 or the E1B-55kd deleted dl1520 in DU145 cells. With 
Ad5 only the combination ratios at low ppc/nM resulted in two CI values lower 
than 0.8 (Fig. 32). Values were close to 0.8 for all combinations with Ad5, 
showing a trend towards synergy in these cells. The dl1520 mutant showed better 
synergy than Ad5 with two combinations resulting in clear synergistic interactions 
with mitoxantrone, although the combination at the lowest ratio was antagonistic. 
However, infection with the AdE1A-12S virus resulted in synergistic cell death in 
combination with mitoxantrone at three of the four ratios tested, with CI values 
below 0.7. At the highest ratio tested, an additive interaction was observed, with a 
CI value of 0.84. 
  
 In PC3 cells, the dl1520 virus showed synergistic interactions with 
mitoxantrone at all four test ratios also resulting in the lowest CI values (Fig. 33). 
The AdE1A-12S virus showed synergistic interactions at three of the ratios with 
an additive effect observed at the lowest ratio tested, CI value of 0.81.  
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ratio (ppc/nM) Combination index
0.50 0.73
2.50 0.72
12.50 0.86
62.50 1.10
 
 
ratio (ppc/nM) Combination index
0.50 1.31
2.50 0.95
12.50 0.63
62.50 0.31
ratio (ppc/nM) Combination index
0.50 0.59
2.50 0.51
12.50 0.67
62.50 0.84
Fig. 32. DU145 cells were treated with mitoxantrone in combination with Ad5, dl1520 or AdE1A-
12S viruses at four different constant ratios as described in materials and methods. Isobolograms 
were constructed and combination indexes (CI) calculated for each ratio are shown in tables next to 
each isobologram. The AdE1A-12S virus showed better synergistic interactions with mitoxantrone 
than the dl1520 mutant. Ad5 showed weak synergistic interactions with the drug, resulting in CI 
values close to 0.8.  Representative data of 2 independent experiments. 
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ratio (ppc/nM) CI
0.50 0.55
2.50 0.38
12.50 0.89
62.50 1.12
ratio (ppc/nM) CI
0.50 0.32
2.50 0.27
12.50 0.33
62.50 0.49
ratio (ppc/nM) CI
0.50 0.81
2.50 0.59
12.50 0.50
62.50 0.55
 
 
 
Fig. 33. Analysis of synergistic interactions between mitoxantrone and Ad5, dl1520 or 
AdE1A-12S at four different ratios in PC3 cells. Isobologram analysis of the 
combinations is shown for each virus and their respective CI values shown in adjacent 
tables. The dl1520 mutants showed best interactions with the drug, resulting in lower CI 
values. The AdE1A-12S virus also showed better synergistic interactions than Ad5. 
Data is representative of 2 independent experiments.  
 156 
            The CI values for the other ratios varied between 0.49, at 12.5 ppc/nM, 
and 0.59 at 62.5 ppc/nM. Similar to the observations in DU145 cells, in PC3 cells 
Ad5 also showed less synergistic effects than the other two mutants. For Ad5 the 
interactions with mitoxantrone were additive at the two highest ratios tested and 
synergistic at the lowest ratios. Good synergy resulted from combination of Ad5 
and mitoxantrone at a ratio of 2.5 ppc/nM, with a CI value of 0.38. 
  
 More efficient synergistic interactions were observed with the AdE1A-12S 
virus than with the dl1520 mutant and Ad5; the AdE1A-12S was the only virus 
that showed synergistic interactions at the four ratios tested in DU145 cells; in 
PC3 cells, this virus showed an effect similar to the dl1520 mutant and always 
better than Ad5. The absence of replication did not seem to influence an efficient 
synergistic interaction between AdE1A-12S and mitoxantrone.  
  
  
5.1.4.2 Synergistic interactions with docetaxel, a microtubule stabilising 
chemotherapeutic drug, were observed with AdE1A-12S but not with Ad5. 
  
 DU145 and PC3 cells were also treated with combinations of docetaxel 
and AdE1A-12S, dl1520 or Ad5. The aim was to determine if synergy was 
observed with viruses in combination with a drug that acts through mechanisms 
that do not involve direct DNA damage as opposed to mitoxantrone. 
  
 Ad5 failed to act synergistically with docetaxel in DU145 in three out of 
the four ratios tested (Fig. 34). Minor synergistic interactions were observed at the 
lowest ratio (0.5 ppc/nM), resulting in a CI value of 0.76. Synergy was higher 
with docetaxel and the dl1520 mutant with one of the ratios resulting in a CI value 
of 0.6, indicating a synergistic interaction. Two of the other three ratios tested 
showed CI values just below 0.8, while at the highest ratio (62.5 ppc/nM) the 
combination of drug and virus only resulted in additive effects. However, all four 
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combination ratios of docetaxel and AdE1A-12S virus resulted in CI values lower 
than 0.8, indicating that docetaxel and this virus acted in synergy at all 
combination ratios tested.  
  
 Results in PC3 were similar to those in DU145 cells; Ad5 only showed a 
weak synergistic interaction at a ratio of 0.5ppc/nM, with a CI of 0.71 (Fig. 35). 
The interactions between Ad5 and the drug were additive at the other ratios tested. 
The results for the combination of the dl1520 mutant with docetaxel were similar 
to those with Ad5; the interactions observed were only additive, although the CI 
value for the ratio 12.5 ppc/nM was 0.74 and could be considered an indication of 
a weak synergistic interaction. Combination of docetaxel with AdE1A-12S 
resulted in improved synergistic interactions compared to the other two viruses 
tested; with additive interactions at the lowest ratio, 0.5 and synergy at the higher 
ratios.  
  
This data indicated that synergistic interactions with mitoxantrone and 
docetaxel were stronger with AdE1A-12S than with Ad5 and the dl1520 mutant. 
The value of the CIs also indicated that viral infection resulted in better synergy in 
combination with mitoxantrone, a DNA-damaging agent, than with docetaxel, a 
microtubule-stabilising agent. The higher synergy with the AdE1A-12S virus 
could have been due to the increase of supra-additive interactions between the 
drug and E1A, constantly expressed in infected cells due to CMV promoter 
regulation. Expression of E1A in Ad5 infected cells varies during the viral cycle; 
the different E1A proteins are differentially expressed during the cycle and 
consequently might have influenced the synergistic interaction between E1A and 
the drugs. 
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ratio (ppc/nM) Combination index
0.50 0.76
2.50 1.03
12.50 0.94
62.50 0.91
ratio (ppc/nM) Combination index
0.50 0.75
2.50 0.65
12.50 0.66
62.50 0.70
ratio (ppc/nM) Combination index
0.50 0.73
2.50 0.60
12.50 0.78
62.50 1.21
Fig. 34. DU145 cells were treated with docetaxel in combination with Ad5, dl1520 or AdE1A-
12S at four different ratios. Isobolograms of the combinations were constructed and CI values 
for each ratio are shown in adjacent tables. Weak synergistic interactions were observed with 
AdE1A-12S at all ratios; the dl1520 mutant showed synergistic interactions, but not with all 
combination ratios tested. Combination of Ad5 and docetaxel resulted in additive effects at all 
ratios tested. Data representative of 2 independent experiments. 
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ratio (ppc/nM) CI
0.50 0.71
2.50 0.83
12.50 0.92
62.50 1.07
ratio (ppc/nM) CI
0.50 0.91
2.50 0.77
12.50 0.69
62.50 0.55
ratio (ppc/nM) CI
0.50 0.90
2.50 0.86
12.50 0.74
62.50 0.85
 
 
Fig. 35. Isobolographic analysis of interaction between docetaxel and Ad5, dl1520 or AdE1A-12S at 
four different ratios in PC3 cells. CI values for each combination are shown in tables next to the 
isobolograms. Better synergistic interactions were observed with docetaxel in combination with 
AdE1A-12S virus than with dl1520 and Ad5 that showed weak synergy only at one of the combination 
ratios tested. Data is representative of 2 independent experiments. 
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5.2 Construction of new replication-defective AdE1A12S-
deletion mutants. 
  
 The AdE1A-12S virus proved to be an efficient vector to express E1A and 
study its interactions with chemotherapy in prostate cancer cell lines, in the 
absence of other viral proteins. Because of the promising results with the AdE1A-
12S mutant new viruses were generated; we selected E1A mutants with deletions 
in the N-terminus (E1A-1102), the CR1 domain (E1A-1104) and the CR2 domain 
(E1A-1108) in order to identify regions that were critical for sensitisation. These 
deletions were identical to those in the replication competent viruses tested in 
chapter 3. These mutants were chosen as each one has a deletion in highly 
conserved regions of known function for E1A; the E1A-1102 mutant is deleted in 
the N-terminus, so it does not bind to p400 but can interact with p300. The E1A-
1104 mutant is deleted in the p300-binding region of E1A; the E1A-1108 mutant 
was chosen as it is the mutant with the bigger deletion in the CR2 region (as 
compared to E1A-922-947 or other mutants). Hence, each mutant lacks the 
binding site for one major cellular pathway (p400, p300 or pRb) but not the 
others. Gene splicing by overlapping extension PCR (SOEing PCR) was used to 
generate the selected E1A-mutants as described in materials and methods section 
2.2.2.4, and new viruses were constructed as described for the AdE1A-12S virus 
in this chapter.  
  
  
5.2.1 Expression of E1A proteins by the newly constructed 
AdE1A12S-deletion mutants. 
  
 Expression of E1A proteins by the newly generated replication defective 
adenoviruses was confirmed by western blotting. DU145 cells were infected with 
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100 ppc of each virus and proteins were harvested 24h post-infection. E1A 
proteins expressed by the different mutants were similar in size to E1A-12S, with 
the exception of the E1A expressed by AdE1A-1104 infection that was smaller 
than the other E1A-mutant proteins (Fig. 36).  
  
5.2.2 The AdE1A-1104 mutant showed attenuated cytotoxicity.  
  
 Prostate cancer cell lines were treated with increasing doses of each virus 
to determine differences in E1A12S-induced toxicity for the newly constructed 
mutants. We observed no replication with the AdE1A-12S mutant virus, hence 
toxicity was due to the effects of E1A on the cells. Therefore, differences among 
the newly constructed viruses would be indicative of the efficiency of each E1A-
12S mutant to induce cell death. 
  
 22Rv1, DU145 and PC3 cells were treated with serial dilutions of each 
virus followed by calculation of EC50 values 6 days post-infection, as described in 
Materials and Methods (Fig. 37). Differently from the data in Fig. 30 the EC50 
 
Fig. 36. Expression of E1A-12S by the newly generated AdE1A-12S-deletion mutant adenoviruses 
in DU145 was confirmed by western blotting. Cells were infected with 10 ppc and proteins were 
harvested 24h later; all E1A proteins expressed by the different mutants were similar in size, with 
the exception of E1A-1104. 
55 Kd 
  
43 Kd 
  
  
35 Kd 
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values for the AdE1A-12S virus were significantly lower. The reason for this 
difference was the change in assays for viral particle determination. For the 
viruses used in Fig. 30, viral content was determined by the traditional optical 
density assay (described in Materials and Methods) since Ad5 and dl312 viruses 
were previously quantified by this method after production. However, in this and 
all future studies, virus was quantified by the more sensitive pico-green 
technology that consistently resulted in lower particle values (vp/ml) and hence a 
lower EC50 value in dose-response assays. 
Fig. 37. Cytotoxicity of the new E1A-expressing replication-defective adenoviral vectors was 
assessed in human prostate cancer cell lines. Dose-response curves were constructed and EC50 
values calculated 6 days after infection. As observed previously for the AdE1A-12S virus, 
potency of the new viruses was attenuated compared to Ad5. The AdE1A-1104 virus showed 
the highest EC50 values in the 3 cell lines tested. The vp/pfu ratio, shown in table, varied 
between 19.9 for Ad5 to 39.2 for AdE1A-1102; these differences were not sufficient to 
account for the attenuation in toxicity. Data represent averages of 3 independent experiments 
with standard deviations. T-test statistical analysis showed that cytotoxicity for all AdE1A-
mutant viruses was significantly attenuated compared to Ad5 (p<0.001 in PC3 and DU145; 
p<0.01 in 22Rv1)  
22Rv1
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
p<0.05p<0.05
p<0.05
p<0.01
 
DU145
0
10
20
25
125
225
325
425
p<0.01
p<0.05 p<0.05 p<0.05
p<0.001
 
PC3
0
250
500
500
1500
2500
3500
4500
5500
6500
p<0.01 p<0.001
p<0.001
 
  VP/PFU ratio 
Ad5 19.9 
AdE1A-12S 34.5 
AdE1A-1102 39.2 
AdE1A-1104 18.9 
AdE1A-1108 26.5 
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 PC3 cells were the most resistant to viral toxicity, as previously observed 
with replication selective viruses. The AdE1A-1102 and AdE1A-1108 mutants 
were more potent than AdE1A-12S, while potency for the AdE1A-1104 mutant 
was attenuated compared to AdE1A-12S (Fig. 37). All replication defective 
viruses were at least 100 fold less toxic than Ad5. A similar trend was observed in 
DU145 cells with AdE1A-1102 and AdE1A-1108 showing a lower EC50 value 
than AdE1A-12S. AdE1A-1104 had a similar potency to the E1A-12S expressing 
adenovirus. As observed in PC3 cells, all newly generated viruses were at least 50 
times less potent than the replicating Ad5. These differences between Ad5 and 
replication-defective viruses were not as pronounced in the 22Rv1 cells (Fig. 37) 
in which AdE1A-12S, with an EC50 value of 5 ppc, was the most potent of the 
newly constructed viruses, while the value for Ad5 was 1.4 ppc. The AdE1A-
1102 and AdE1A-1108 viruses had similar potency to AdE1A-12S, while the 
AdE1A-1104 mutant was attenuated, with an EC50 value of 13 ppc. 
  
 These data suggest that the deleted region in the E1A-1104 mutation was 
involved in E1A-induced cell death in prostate cancer cell lines. In addition, the 
mutations in E1A-1102 and E1A-1108 appeared to still maintain potency at a 
level similar to that of wild type E1A or even increased the potency as observed in 
the PC3 cells. 
  
  
5.2.3 Significantly attenuated replication of the new E1A-12S-
deletion mutants. 
  
 Human prostate cancer cell lines were infected for 2 hours with 100 ppc of 
the replication-selective viruses previously used in chapter 3 (dl1102, dl1104, 
dl1108) and the replication-defective mutants (see above) expressing the 
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corresponding E1A deletions in the 12S-protein. Replication of adenoviruses was 
determined 48 hours post-infection. The replication-selective adenoviruses 
replicated as efficiently as Ad5 in PC3 and DU145 cells (Fig. 38). However, in 
the 22Rv1 cells the dl1102 and dl1104 mutants were less efficient at replicating 
compared to Ad5 and the dl1108 mutant viruses. Infection with Ad5 resulted in 
1070 ± 88 pfu/cell after 48 hours, while the dl1102 and dl1104 viruses only 
produced 745 ± 34 and 624 ± 85 pfu/cell respectively, statistically significant 
compared to Ad5 (p<0.05). 
  
 Absence of E1B and E3 in the newly generated mutant viruses resulted in 
low replication as observed previously for the AdE1A-12S virus (Fig. 31). 
Replication was not detectable  (<1pfu/cell) with the AdE1A-12S and AdE1A-
1104 viruses in any of the tested cell lines (Fig. 38). The AdE1A-1102 and 
AdE1A-1108 mutants showed poor replication that resulted in low levels of 
particle production, approximately 50 pfu/cell in PC3 and 22Rv1 cells and 100 
pfu/cell in DU145 cells.  Nevertheless, the poor replication observed for these two 
mutants was significantly reduced to that of Ad5, with p<0.01 in all the three cell 
lines (Fig. 38).  
  
 Viral genome amplification was also determined as an indirect measure of 
viral replication by qPCR. RNA was extracted from prostate cancer cell lines 3, 
24, 48 and 72 hours after infection, as described in materials and methods (section 
2.5.1). Hexon DNA copy number was quantified and expressed as a ratio of 
hexon copy number 3h post-infection (as a measure of viral infection in each 
sample) (Fig. 39).  
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Fig. 38. Replication of the new AdE1A12S-deletion mutants and the corresponding replicating 
viruses. The TCID50 assay was used to assess replication in human prostate cancer cell lines 
48h post-infection. Replication could not be detected for the AdE1A-12S and the AdE1A-1104 
viruses while the AdE1A-1102 and AdE1A-1108 mutants showed low levels of replication in 
PC3 cells although, at lower levels than the replicating equivalents dl1102 and dl1108. 
Replication-selective mutants replicated as efficiently as Ad5 in DU145 and PC3 cells; 
replication of dl1102 and dl1104 viruses in 22Rv1 cells was less efficient than that of Ad5. 
Data represent averages with standard errors of 3 independent experiments. All AdE1A-
mutants were significantly deficient in replication compared to their respective replicating 
viruses, p<0.001, t-test (*) 
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            Similar to the results from TCID50 assays, the increase in hexon DNA 
copies over time was higher in DU145 and 22Rv1 than in PC3 cells after Ad5 
infection (Fig. 39). The newly generated viruses AdE1A-mutants showed 
defective replication in the three prostate cancer cell lines tested; the weak 
replication observed for the AdE1A-1102 and AdE1A-1108 mutants by TCID50 
correlated with a small increase in hexon copy number observed by qPCR, while 
no increase in hexon was observed for AdE1A-12S and AdE1A-1104 viruses. 
However, the small increases were never comparable with the increase in hexon 
copy number observed with the replicating mutants dl1102 and dl1108 (Fig. 39). 
The replicating viruses showed an attenuated replication in 22Rv1 but not in 
DU145 cells, in agreement with the previous observations by TCID50. The dl1104 
and dl1102 mutants showed attenuated replication in PC3 cells at 48h, although 
hexon DNA in dl1102 infected cells was increased at 72h to levels similar to Ad5 
and the dl1108 mutant (Fig. 39). Hexon expression was also detected at the 
protein level in prostate cancer cells infected with the AdE1A-1102 and AdE1A-
1108 mutants (Fig. 43).  
 
 Taken together, we concluded from the TCID50 assay and qPCR data that 
AdE1A-mutants were replication defective and that cell death induced by these 
viruses was caused by the expression of their respective E1A proteins. Detection 
of hexon by western blotting (Fig. 43) and the small amount of replication 
observed for AdE1A-1102 and AdE1A-1108 mutants could be due to impurity of 
the viruses due to recombination with cellular DNA from the packaging cell line 
HEK293, resulting in intact E1A and/or E1B that were below the detection limit 
for both PCR and sequencing. Despite showing traces of hexon protein and 
attenuated replication, toxicity of the AdE1A-12S mutant viruses was greatly 
attenuated compared to Ad5 and very similar to the potency of the AdE1A-12S 
virus. This suggests that the recombination that might have occur during the 
production process was low and that the replication observed is not enough to 
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induce changes in the potency of these viruses. Further plaque-purification is 
necessary to isolate viruses free from recombination.  
   
  
 
Fig. 39. Viral DNA, determined as hexon DNA copies, increased over time after infection with 
replication-selective E1A-mutant viruses but not with their newly generated replication 
deficient equivalents. Hexon DNA was quantified by qPCR at 24, 48 and 72h and standardised 
to hexon copy number 3h post-infection for each sample. As observed by TCID50, AdE1A-
mutants showed defective replication in prostate cell lines compared to their equivalent dl-
mutants. Weak increase in hexon copy number was observed with AdE1A-1102 and AdE1A-
1108 mutants, but never to levels similar to dl1102 or dl1108. Data represent averages and 
standard errors of 2 independent experiments. 
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6Chapter 6 
 
 
Combination of cytotoxic drugs and 
replication deficient E1A-expressing 
adenovirus mutants in prostate cancer cell 
lines. 
 
 
 
 
 
6.1 Binding to p300 is necessary for chemosensitisation of 
prostate cancer cell lines by E1A. 
 
We determined in the previous chapter that the replication deficient 
AdE1A-12S mutants were good vectors for the expression of E1A proteins in 
prostate cancer cell lines. We also observed that synergistic interactions with the 
cytotoxic agents were more efficient with AdE1A-12S than with Ad5. Next we 
tested if any of the deletions in E1A expressed by these viruses had attenuated 
sensitising effects in combination with mitoxantrone or docetaxel. 
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 Human prostate cancer cell lines were treated with increasing 
concentrations of mitoxantrone or docetaxel in the presence or absence of a fixed 
dose of viral particles; EC50 values for each drug were calculated. Different doses 
of virus were chosen to determine whether the amount of virus used could have 
different effects in combination with the cytotoxic drugs. EC50 values for each 
drug were calculated 6 days after infection and drug addition as described in 
materials and methods. 
 
 DU145 cells were treated with drugs in combination with 10 or 100 ppc of 
each replication-defective E1A12S-mutant adenovirus. The non-replicating 
AdGFP virus used as a control did not sensitise DU145 cells to either 
mitoxantrone or docetaxel, indicating that E1A expression was causing the drug 
sensitisation (Fig. 40.A). Sensitisation by the AdE1A-mutants was observed at 
both viral concentrations although cell death induced by 100 ppc was significantly 
higher than for 10 ppc (Fig. 40.B). Infection with 100 ppc induced a high 
percentage of cell death except with the AdE1A-1104 mutant. AdE1A-1108 
mutant at 100 ppc induced a 70% cell death as single treatment, while AdE1A-
1102 induced a 55% and AdE1A-12S virus almost 40% (Fig. 40.B). It is possible 
that such high percentage of cell death could have affected EC50 value 
calculations of the combination with drugs. Even though values were corrected 
for virus-induced cell death, high cell death implied that few cells remained viable 
and calculations could be affected. At 10 ppc, the AdE1A-1108 mutant induced 
less than 20% cell death, while AdE1A-1102 only caused 4%. The other viruses 
tested did not induce cell death.   
  
 Sensitisation was more efficient with mitoxantrone than with docetaxel, 
suggesting that the degree of sensitisation by E1A expression was dependent on 
the mechanism of action for each drug. This effect was better observed at the 
highest viral dose used although cell death induced by virus alone also contributed 
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to the enhancement.  All E1A-mutant viruses tested induced a decrease in the 
EC50 value for both drugs at the highest viral dose tested (Fig. 40.B). 
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Fig. 40. Sensitisation to mitoxantrone and docetaxel in DU145 cells by AdE1A-mutant 
viruses. Dose-response curves to the drugs were constructed and EC50 values were 
determined and compared to that of drugs alone, expressed as % of EC50 for drug 
alone. Sensitisation was observed both at 10 and 100 ppc. The reduction in EC50 value 
for the AdE1A-1104 virus was not statistically significant at any dose used (A). 
Sensitisation was greater with 100 ppc although virus-induced cell death was very high 
at this concentration (B). Data represents the average and standard deviation of 5 
independent experiments, with t-test statistical analysis comparing each combination of 
drug and virus to drug alone, P<0.05 (*) and P<0.01 (**).  
A B 
 171 
            However, the AdE1A-1104 mutant failed to decrease the value for either 
drug to a degree statistically significant. There were no differences between the 
AdE1A-12S, AdE1A-1102 and AdE1A-1108 mutants at 100 ppc, although the 
two E1A mutant viruses were slightly more efficient at sensitising DU145 cells 
than the AdE1A-12S virus when 10 ppc were used (Fig. 40.A).  
  
 Three viral concentrations were tested in combination with mitoxantrone 
and docetaxel for similar studies in the PC3 cells. The observed degree of 
sensitisation correlated with increasing viral dose. As observed in DU145 cells, 
PC3 cells were more efficiently sensitised to mitoxantrone than to docetaxel (Fig. 
41.A). The AdE1A-1104 mutant was the least effective at inducing sensitisation 
to the drugs. This virus failed to sensitise PC3 cells to docetaxel at any viral 
concentration tested. It induced a small reduction in EC50 value for mitoxantrone 
only statistically significant at 50 ppc (Fig. 41.A). None of the tested viruses 
sensitised PC3 cells to docetaxel at 10 ppc. All mutants, with the exception of 
AdE1A-1104, significantly reduced the EC50 value for this drug when 100 ppc 
were used (Fig. 41.A). There were no differences between AdE1A-12S, AdE1A-
1102 and AdE1A-1108 at this dose in combination with docetaxel. Sensitisation 
to mitoxantrone was observed at all three viral doses with these viruses. AdE1A-
12S virus reduced the EC50 value for this drug by 40% at all doses: 10, 50 and 100 
ppc. The E1A-mutant viruses AdE1A-1102 and AdE1A-1108 were as efficient as 
AdE1A-12S. The AdE1A-1102 mutant was more efficient at 10 ppc, with a 50% 
reduction of EC50 for mitoxantrone at this viral dose. The AdE1A-1108 mutant 
was the best of the viruses tested at sensitising PC3 cells to mitoxantrone at the 
highest viral concentration of 100 ppc (Fig. 41.A). 
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Fig. 41. Sensitisation to mitoxantrone and docetaxel by AdE1A-mutants in PC3 cells.  Serial 
dilution of the drugs were combined with 10, 50 or 100 ppc of each virus. EC50 values were 
calculated and expressed as percentages of the value for each drug alone (A).  None of the viral 
doses used induced significant cell death in PC3 cells (<6%) (B). Sensitisation to mitoxantrone was 
observed with the three viral concentrations for all E1A-expressing viruses with the exception of 
AdE1A-1104 that only showed statistically significant sensitisation at 50 ppc (P<0.05). 
Sensitisation to docetaxel was proportional to viral dose although it only reached statistical 
significance at 100 ppc with all mutants, with the exception of AdE1A-1104.  Histograms represent 
an average of 3 experiments with standard deviation and t-test statistical analysis; P<0.05 (*), 
P<0.01 (**). 
A B 
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            In the 22Rv1 cells a lesser degree of sensitisation to mitoxantrone or 
docetaxel was observed with the new AdE1A12S-mutants in agreement with 
previous findings using the corresponding replication-selective mutants (Fig. 14). 
Sensitisation to docetaxel was only observed at 10 ppc, the highest of the three 
viral concentrations tested (Fig. 42.A). The EC50 value for docetaxel was reduced 
only by 20% with the AdE1A-12S virus, the only virus to show a statistically 
significant reduction at this dose. Sensitisation to mitoxantrone at the highest viral 
dose showed the same trend as in DU145 and PC3 cells; the AdE1A-1104 virus 
also failed to sensitise 22Rv1 cells to mitoxantrone even at 10 ppc while the 
AdE1A-1102 and AdE1A-1108 mutants reduced the EC50 value by 45% and 30% 
respectively (Fig. 42.A). The most efficient virus at this dose was the AdE1A-
12S, with a 60% reduction in EC50 value for mitoxantrone.  The lower viral doses 
used, 1 and 2.5 ppc, did not induce cell death in 22Rv1 during the length of the 
assay (Fig. 42.B). However, only the AdE1A-12S virus was able to sensitise 
22Rv1 cells to mitoxantrone at the lowest dose. Good senstitisation to 
mitoxantrone was observed with 2.5 ppc; at this dose, AdE1A-1102 and AdE1A-
1108 viruses reduced the EC50 value for mitoxantrone to the same level as the 
AdE1A-12S virus, to 60% of that of mitoxantrone alone (Fig. 42.A). 
    
 The data from the different cell lines strongly indicated that the E1A-1104 
protein was not able to sensitise prostate cancer cell lines to the cytotoxic agents 
currently used in the clinic. We also concluded that sensitisation was more 
efficient when viruses were combined with DNA-damaging agents like 
mitoxantrone than with cytoskeleton disrupting agents like docetaxel. It is 
possible that the mechanism by which E1A sensitises cells to drug involves 
pathways more closely related to DNA-damage than to microtubule organisation 
and therefore better sensitisation is achieved in combination with agents such as 
mitoxantrone.  
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Fig. 42. Sensitisation to mitoxantrone and docetaxel by AdE1A-mutants in 22Rv1 cells. Each 
drug was combined with 1, 2.5 and 10 ppc and EC50 values were calculated and expressed as 
percentages of the EC50 values for each drug alone (A). Sensitisation was proportional to viral 
dose. Statistically significant reduction in EC50 values at the lower viral dose was only observed 
for the AdE1A-12S virus in combination with mitoxantrone (P<0.05). Sensitisation to 
mitoxantrone was observed for the other mutants at higher doses, with the exception of the 
AdE1A-1104 virus, that failed to sensitise 22Rv1 to this drug. Statistically significant 
sensitisation to docetaxel was only observed in combination with the AdE1A-12S virus at 10 
ppc. However, cell death induced by virus alone at this concentration was too high (B). Data 
represent the averages of 3 independent experiments with SD and t-test; P<0.05 (*), P<0.01 (**). 
A B 
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 In addition, the degree of sensitisation varied among cell lines, suggesting 
that the individual status of each cell line and their gene mutations could play a 
role in determining the efficiency of sensitisation by E1A proteins. 
 
 
6.2 Expression of E1A increased in cells treated with 
mitoxantrone. 
 
 Previous experiments with replication-selective adenoviruses 
demonstrated increased E1A expression in the presence of mitoxantrone in 
chapter 3. Infection with GFP-expressing virus also demonstrated an increase in 
the number of infected cells in combination with mitoxantrone. Hence, E1A 
expression was assessed after infection with the new replication-defective 
E1A12S-expressing viruses in the presence or absence of the drug.  
  
 PC3, DU145 and 22Rv1 cells were treated with 100, 10 or 2.5 ppc 
respectively in the presence or absence of mitoxantrone at 50 nM. This 
concentration was selected based on previous qPCR data shown in chapter 3, 
showing a significant increase in E1A mRNA with this concentration of drug. 
Analysis of E1A proteins by western blotting showed an increase in E1A 
expression when cells were treated in combination with the drug. This increase in 
expression was observed at 24h in the three cell lines tested when virus was 
present throughout the experiment (Fig. 43). However, increase of E1A for all 
viral mutants in combination with drug was only observed in DU145 cells; the 
PC3 cell line showed small increases in E1A during combination treatments, only 
detectable for the AdE1A-1104 mutant. Similarly, increase in E1A levels in 
22Rv1-infected cells was only observed for the AdE1A-1108 mutant virus (Fig. 
43). 
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 In addition, we also detected hexon expression after infection with AdE1A-
1102 and AdE1A-1108 mutant viruses, indicating that late genes were expressed 
by these viruses, what could explain the observed reduced replication previously 
described in Fig. 38. 
Fig. 43. Changes in E1A expression after 24h of infection in the absence or presence of 
mitoxantrone at 50 nM. E1A levels increased for all mutants in the presence of drug in DU145 
infected cells, while smaller increases in E1A levels were detected for AdE1A-1104 in PC3 and 
for AdE1A-1108 in 22Rv1 cells. Hexon was detected after infection with AdE1A-1102 and 
AdE1A-1108. Virus and drug were present throughout the experiment. 
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 The observed increase in E1A expression could have been caused by an 
increase in infection by the AdE1A-12S virus or by an enhancement in viral gene 
transcription from the CMV promoter. An increase in GFP-expressing cells was 
observed when prostate cancer cells were infected with non-replicating AdGFP  
(Fig. 18). This was only observed when the virus was present throughout the 
experiment as opposed to being removed after 2h. Levels of E1A mRNA were 
quantified by RT-qPCR to verify that the effects seen with the AdGFP virus could 
also be observed with the AdE1A-12S mutant. 22Rv1, PC3 and DU145 cells were 
infected with AdE1A-12S virus in the presence or absence of mitoxantrone under 
two different conditions. In one set of cells, virus was removed from samples after 
two hours of infection; in another set, virus was left in the media during the length 
of the assay, as described previously for the AdGFP virus (Fig. 18). Levels of 
E1A mRNA were lower in cells infected for only 2h than for 24h as expected 
(Fig. 44). In 22Rv1 and PC3 cells treated with mitoxantrone after infection, E1A 
mRNA levels were similar to those in cells without drug treatment although 
reproducibly small increases in E1A mRNA with mitoxantrone were seen. 
However, mitoxantrone increased the levels of E1A mRNA in DU145 cells. 
  
 When AdE1A-12S was present in the medium throughout the study (24h) 
the levels of E1A mRNA were higher, as more cells were infected during the 
length of the assay (Fig. 44). Differences in mRNA expression between cells 
treated with virus alone or in combination with mitoxantrone were significant in 
the three cell lines tested. The smallest effect was observed in 22Rv1 cells, with 
twice more expression of E1A mRNA in cells treated with a combination of virus 
and drug. This increase was higher in PC3 and DU145 cells, in which expression 
of viral mRNA was 3.5 and 12 times higher, respectively, than in cells treated 
with virus only (Fig. 44). 
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Fig. 44. E1A mRNA levels in prostate cancer cell lines after infection with AdE1A-12S 
in the presence or absence of mitoxantrone at 50 nM. Cells were treated with virus and 
mitoxantrone for 24h in one condition; in a second condition, virus was replaced by 
medium only or containing mitoxantrone after 2h of infection. E1A mRNA level only 
increased significantly when virus and mitoxantrone were present for 24h, but not when 
virus was removed. Data represent the averages of 2 independent experiments with 
standard deviations. 
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 The smaller increases in E1A mRNA levels in 22Rv1 and PC3 cells 
compared to that in DU145 cells could explain the increase at the protein level 
that was clearly observed in DU145 cells but not in PC3 and 22Rv1 cells (Fig. 
43).  
  
 This data, together with data from chapter 3, showed that mitoxantrone 
induced an increase in E1A expression. This was likely to occur due to an 
increase in infectability over time since no significant increase was observed 
when virus was removed from the cells after 2h.   
  
  
6.3 The AdE1A-1104 mutant adenovirus failed to induce 
changes in cell cycle. 
  
 It is well known that E1A can induce S-phase in infected cells as a 
mechanism to achieve efficient viral replication while the cytotoxic drug 
mitoxantrone induces G2/M cell cycle arrest. We aimed to determine the effects 
on the cell cycle when the AdE1A-mutants were combined with mitoxantrone and 
whether potential changes correlated with the sensitising abilities of each mutant 
previously observed Fig. 40, Fig. 41 and Fig. 42. 
  
 Cell cycle progression was analysed in the three human prostate cancer cell 
lines to investigate changes in the cycle under combination of mitoxantrone at 50 
nM with the different E1A-expressing replication-defective adenovirus mutants. 
Viral doses were selected based on sensitisation studies: 2.5 ppc were used for 
22Rv1, 10 ppc for DU145 and 100 ppc for PC3 cells. Those were the doses that 
showed best sensitisation with minimal virus-induced cell death. Cells were 
treated with mitoxantrone, virus or in combinations for 24, 48 and 72 hours. 
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Propidium iodide and flow cytometry were used to quantify the number of cells in 
each phase of the cell cycle. 
  
 E1A expression at the viral doses used did not induce cell cycle changes in 
any of the cell lines tested. Replication-defective adenoviruses induced only small 
changes in the population of cells in each phase of the cell cycle that were never 
significative.  
  
 The effect of mitoxantrone on cell cycle progression varied among cell 
lines. The drug induced an increase in the sub G1 population and a decrease in the 
S-phase population in the 22Rv1 cells over time (Fig. 48). In the PC3 cells the 
drug initially increased the percentage of cells in S-phase but lwere later arrested 
in the G2/M phase. Mitoxantrone reduced the percentage of PC3 cells in G1-
phase compared to untreated cells and increased the G2/M population from 22% 
in untreated cells to 56% at 72h (Fig. 45). Combination of mitoxantrone with 
replication-defective viruses showed more cells in G2/M phase than treatment 
with mitoxantrone alone in PC3 (Fig. 46 and Fig. 47) and 22Rv1 cells (Fig. 50 
and Fig. 49), an increase that was only observed for those viruses that could 
sensitise the prostate cancer cells to mitoxantrone, the AdE1A-12S, AdE1A-1102 
and AdE1A-1108 mutants. The AdE1A-1104 mutant and AdGFP used as control 
virus, did not induce changes in phase distribution resulting in the same profile as 
mitoxantrone alone at all time points.  
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Fig. 45. Cell cycle analysis of PC3 cells at 24, 48 and 72h after treatment with viruses, 
mitoxantrone or combination of both. Viral infection did not induce changes in cell cycle at the 
doses used; mitoxantrone induced a progression in S-phase at early time points that resulted in 
G2/M arrest at 72h. E1A-mutant viruses that successfully sensitise PC3 cells to mitoxantrone 
increased the percentage of cells in G2/M after 72h in combination with the drug, while AdE1A-
1104 and the negative control virus AdGFP showed a similar profile to mitoxantrone alone when 
combined with this drug. Data are representative of 3 independent experiments. 
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Fig. 46. Analysis of cell cyle in PC3 cells 72h after infection with AdE1A-12S-mutants or AdGFP. 
This is a representative example of how the different cell cycle phases were gated in untreated cells 
to determine the percentage of cells in each phase after infection with viruses. Infection of PC3 
cells at 100 ppc had no effects on cell cycle with any of the viruses used. 
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Fig. 47. Flow cytometry analysis of PC3 cells after 72h of treatment with mitoxantrone alone or 
in combination with AdE1A-12S-mutants. Each phase was determined in cells treated with the 
drug alone and used to determine the proportion of cells in each phase after combination of drug 
and viruses. We observed a decrease in G1 after combination of mitoxantrone with AdE1A-12S, 
AdE1A-1102 and AdE1A-1108 viruses, compared to drug alone or in combination with AdE1A-
1104 or AdGFP. 
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Fig. 48. Cell cycle analysis of 22Rv1 cells after treatment with mitoxantrone, AdE1A-
mutant viruses or a combination of both agents. Similar to the results obtained in PC3 cells, 
viruses alone did not induce changes in cell cycle, but AdE1A-12S, AdE1A-1102 and 
AdE1A-1108 increased the percentage of cells in G2/M when combined with mitoxantrone 
after 72h. AdE1A-1104 and AdGFP, unable to sensitise cells to the drug, failed to induce 
changes in cell cycle in combination with mitoxantrone, compared to the dug alone. Data 
representative of 3 independent experiments. 
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Fig. 49. Flow cytometry analysis of 22Rv1 cells after 72h of treatment with AdE1A-12S-
mutants or AdGFP. Different cell cycle phases were gated in untreated cells and those gates 
were used to determine the percentage of cells in each phase for samples treated with viruses. No 
significant changes were observed with any of the viruses used at 2.5 ppc. 
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Fig. 50. Flow cytometry analysis of cell cycle in 22Rv1 cells 72h after treatment. This is a 
represenatative example showing how the different cycle phases were gated for 22Rv1 cells treated 
with mitoxantrone in the presence or absence of mitoxantrone. An increase in G2/M was observed with 
mitoxantrone combined wit AdE1A-12S, AdE1A-1102 and AdE1A-1108 viruses, compared to 
mitoxantrone alone. AdE1A-1104 and AdGFP combination with the drug resulted in a cell cycle profile 
similar to that of mitoxantrone alone. 
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Fig. 51. Cell cycle analysis of DU145 cells treated with 10 ppc of each AdE1A-mutant and AdGFP 
during 48h. Expression of E1A-deletion mutants did not have an effect in cell cycle of these cells at 
the dose used. Representative data of 3 independent experiments. 
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Fig. 52. Mitoxantrone alone or in combination with AdE1A-mutant viruses induced an arrest 
in G2/M phase in DU145 cells after 48h of treatment. Combination of mitoxantrone with 
viruses induced a greater arrest in G2/M and the formation of polyploidy; it was not possible 
to accurately identify each cell cycle phase in the profiles obtained after combination 
treatments. The AdE1A-12S and AdE1A-1102 mutants showed a greater number of cells 
cycling towards the G2/M than the other mutants. AdE1A-1104, AdE1A-1108 and AdGFP 
viruses showed a similar profile, although polyploidy was higher in cells treated with AdE1A-
1108 than with AdE1A-1104 or AdGFP in combination with mitoxantrone. Data 
representative of 3 independent experiments. 
 
Mitoxantrone 
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 In DU145 cells, as observed for the other prostate cell lines, viral infection 
did not affect the percentages of cells in each cell cycle phase (Fig. 51). However, 
changes induced by mitoxantrone in combination with viruses were greater than 
expected. The drug alone induced an arrest in the G2/M phase; the combination 
with viruses induced the formation of polyploidy and arrest in G2/M, although 
cells appeared to be in a transition between S-phase and G2/M, so accurate gating 
of the cells was not possible (Fig. 52). The AdE1A-12S and AdE1A-1102 viruses 
in combination with mitoxantrone induced a greater effect on the cell cycle in 
DU145 cells, while AdE1A-1104 and AdGFP showed similar profiles to that of 
mitoxantrone alone. The AdE1A-1108 virus induced changes in cell cycle in a 
similar manner as AdE1A-1104 although the percentage of polyploidy was 
greater for AdE1A-1108 than for AdE1A-1104. 
  
 These data showed that E1A mutants that successfully sensitised cells to 
mitoxantrone increased the percentage of cells in G2/M phase. Mitoxantrone 
induced G2/M arrest, so it is likely that enhanced cell killing by combination of 
drug and viruses enhanced the effects of the drug in these cells, inducing greater 
G2/M arrest. Supporting this hypothesis, viruses that did not sensitise prostate 
cancer cells to mitoxantrone did not induce a change in cell cycle profiles 
compared to the drug alone.  
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6.4 Mitochondrial membrane potential only changed in 
cells that were sensitised to cell death in response to the 
combination treatments. 
 
 Loss of potential of the mitochondrial membrane (mitochondrial 
depolarisation = ??) is associated with early induction of apoptosis. It is also 
known that E1A expression induces apoptosis hence, a possible mechanism of 
sensitisation by E1A to drugs could be through increased apoptotic activity. Cells 
were treated with all the replication-defective E1A-expressing mutant viruses in 
the presence or absence of mitoxantrone, at the concentrations described for the 
cell cycle analysis, followed by analysis of mitochondrial membrane potential by 
flow cytometry using TMRE and DAPI staining (Fig. 53.A). The newly generated 
replication-defective adenoviruses did not induce apoptosis at the concentrations 
tested in any of the cell lines used (Fig. 53.B). Mitoxantrone treatment increased 
the percentage of cells in early apoptosis; a higher percentage of apoptotic cells 
was observed after 24h in 22Rv1 cells, after 48h in DU145 and PC3 cells (Fig. 
53.B). The effects of the combination of mitoxantrone with each E1A- mutant 
virus were similar in DU145 and PC3 cells. Ad5-GFP and AdE1A-1104 mutants 
failed to increase the percentage of cells undergoing apoptosis.  
  
 On the other hand, AdE1A-12S, AdE1A-1102 and AdE1A-1108 viruses 
almost doubled the number of apoptotic cells when combined with the drug. In 
DU145 cells, the AdE1A-12S virus was the most efficient of the three viruses in 
enhancing apoptosis, followed by the AdE1A-1108 and AdE1A-1102 mutants.  In 
PC3 cells the AdE1A-1108 mutant induced the highest increase in apoptosis, 
starting at 72h (Fig. 53.B). 
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Fig. 53. Mitochondrial membrane depolarisation was assessed by a TMRE flow cytometry 
assay as an indication of activation of early apoptotic processes. Cells were treated with 2.5 
ppc (22Rv1 cells), 10 ppc (DU145 cells) or 100 ppc (PC3 cells) in the absence or presence of 
mitoxantrone at 50 nM. A) Flow cytometry analysis of DU145 cells after mitoxantrone 
treatment. Cells were divided into four quadrants, according to DAPI and TMRE staining. 
Quadrants I and II represent dead cells; quadrant III represent cells undergoing early apoptotic 
events; living cells are gated in quadrant IV. B) Viral infection did not induce apoptosis in 
human prostate cancer cells but viruses that sensitised cells to mitoxantrone increased the 
number of pro-apoptotic cells in combination with this drug compared to drug alone. 
Combination of mitoxantrone with AdE1A-1104 or AdGFP did not induce an increase in the 
percentage of pro-apoptotic cells in DU145 and PC3 cells although an increase in apoptosis 
was observed with AdE1A-1104 in combination with mitoxantrone in 22Rv1 cells. 
Representative data of 3 independent experiments. 
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 Combination of viruses and mitoxantrone did not increase the percentage of 
proapoptotic cells in 22Rv1. Mitoxantrone showed the same level of apoptosis 
induction alone as in combination with any of the viruses tested. This data was in 
agreement with previous observations, suggesting that this cell line was less 
sensitive to E1A-mediated sensitisation to cytotoxic drugs.  
  
 We observed that those viruses able to sensitise prostate cancer cell lines to 
mitoxantrone induced an increase in the percentage of proapoptotic cells in 
combination to mitoxantrone in comparison to the drug alone. This suggested that 
the supra-additive cell death observed in combination treatment could be due to an 
upregulation of proapoptotic pathways and that binding of E1A to p300 is critical 
to induce these pathways since AdE1A-1104 has no effect on ?? in combination 
with mitoxantrone. 
 
 
6.5 Inhibition of caspases resulted in increased survival 
and reduction of sensitisation to mitoxantrone by E1A. 
 
 TMRE analysis showed that early activation of apoptosis was increased 
with the AdE1A-12S mutants that successfully sensitised prostate cancer cell lines 
to mitoxantrone. To further investigate the role of apoptosis in sensitisation, 
human prostate cancer cell lines were treated with the pan-caspase inhibitor z-
VAD-FMK together with mitoxantrone and the AdE1A-mutant viruses, alone or 
in combination.  
  
 When the caspase inhibitor was added to cells treated with mitoxantrone 
and viruses the supra-additive effects of the combinations were inhibited in all 
cell lines (Fig. 54). The addition of inhibitor to cells treated with mitoxantrone 
alone also resulted in an increase of EC50 value for the drug.  
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Fig. 54. Caspase inhibition by z-VAD-FMK at 25 μM protected human prostate cancer cell lines 
to mitoxantrone-induced cell death and reversed sensitisation by E1A-expressing viruses. Cells 
were treated with increasing concentrations of mitoxantrone in combination with each virus (2.5 
ppc for 22Rv1, 10 ppc for DU145 and 100 ppc for PC3 cells) in the presence or absence of the 
caspase inhibitor. EC50 values  for mitoxantrone were calculates and expressed as a percentage of 
the EC50 value for mitoxantrone alone. Bars represent the average and standard error of 2 
independent experiments. 
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            When mitoxantrone and viruses were combined the EC50 value for the 
drug was reduced as seen previously (Fig. 40, Fig. 41, Fig. 42). However, when 
the caspase inhibitor was added the EC50 values increased for all combinations, 
preventing sensitisation. 
  
 The increase in EC50 value was different for each cell line. The PC3 cells 
showed the smallest increase in EC50 of the three cell lines tested. The increase in 
EC50 value in this cell lines was not higher than 40% in any combination and there 
was no increase in EC50 value for mitoxantrone in combination with AdE1A-12S 
virus (Fig. 54). In 22Rv1 cells the EC50 value for mitoxantrone was similar for the 
combinations with each virus in the presence of inhibitor, between 2.5 and 3 times 
the EC50 value of mitoxantrone alone for all combinations. DU145 cells showed a 
big increase in EC50 value for mitoxantrone when the inhibitor was combined 
with the drug up to 5 times higher in the presence of inhibitor (Fig. 54). There was 
also an increase in the EC50 for all the combinations when treated with the 
inhibitor although, not as high as for the drug alone, with exception of the 
combination of mitoxantrone with AdGFP. Caspase inhibition increased survival 
in all condition; however, this increase was not as high for combination treatments 
as for durg alone. Therefore, E1A-mediated sensitisation was not uniquely 
caspase sensitive; other caspase independent mechanisms might be involved in 
sensitisation of prostate cancer cells by E1A. 
 
 
6.6 Virus-induced cell death decreased after treatment 
with a caspase inhibitor. 
 
The expression of E1A-12S by the replication-defective viruses at the 
doses used during sensitisation studies did not induce apoptosis, as determined by 
TMRE analysis. However, it is known that high expression of E1A can induce 
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apoptotic responses. Additional dose-response studies to the mutant viruses were 
performed in the presence or absence of the pan-caspase inhibitor to examine the 
potential activation of apoptotic pathways.  
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Fig. 55. Inhibition of caspase activity protected DU145 and 22Rv1 from virus-induced cell 
death and reversed mitoxantrone sensitisation to viral toxicity. Dose-response curves to each 
virus were constructed in the presence or absence of mitoxantrone at 50nM, z-VAD-FMK 
caspase inhibitor at 25 μM or both. EC50 values were expressed as a percentage of EC50 
value for each virus alone. Presence of inhibitor protected DU145 cells to virus induced cell 
death by all viruses tested (red bars). An increase in EC50 value in the presence of caspase 
inhibitor was only observed for AdE1A-12S and AdE1A-1104 viruses in 22Rv1 cells. The 
caspase inhibitor reversed sensitisation to virus by mitoxantrone, resulting in EC50 values 
similar to virus and inhibitor in DU145 cells and to virus alone in 22Rv1 cells. Data 
represent averages with standard errors of 2 independent experiments. 
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             In addition, cells were also treated with the viruses in the presence of 
50nM of mitoxantrone, to determine whether an increase in EC50 values would be 
observed in response to caspase inhibitor, similar to the findings with the 
mitoxantrone EC50 values. 
  
 The EC50 value for each virus tested increased in DU145 cells in the 
presence of inhibitor (Fig. 55), indicating that expression of E1A induced caspase 
activation. The addition of mitoxantrone reduced the EC50 value for the virus in 
the absence of caspase inhibitor with the exception of the AdE1A-1104 virus. The 
addition of caspase inhibitor to the combinations of viruses and drug resulted in 
an increase of the EC50 value for the virus to a value similar to the EC50 value of 
the virus alone with inhibitor, except for the AdE1A-1108 virus that showed a 
greater increase (Fig. 55). 
  
 The effects observed in the 22Rv1 cells were different from those in the 
DU145 cells. The EC50 values only increased for the AdE1A-12S and AdE1A-
1104 viruses in the presence of caspase inhibitor while remaining the same for the 
AdE1A-1102 and AdE1A-1108 mutants (Fig. 55). EC50 values for all viruses 
were reduced in the presence of mitoxantrone at 50 nM, indicating that 
mitoxantrone induced sensitisation to viral toxicity of all mutants. Addition of 
caspase inhibitor to the combinations resulted in increased EC50 values compared 
to the combination treatment without inhibitor.  
  
 The values increased to a value similar to the EC50 value of the virus 
alone, but never reached the EC50 value of the virus in the presence of inhibitor, as 
observed in DU145 cells.  
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6.7 Expression of proteins involved in apoptosis changed 
during combination treatments. 
 
 The data presented supported the hypothesis of enhancement of apoptosis 
as a possible mechanism for chemo-sensitisation. Therefore, expression of 
proteins involved in apoptosis should be detectable by western blotting. Protein 
expression was analysis in the human prostate cancer cell lines PC3, DU145 and 
22Rv1. Cells were treated with viruses and mitoxantrone in combination as 
previously described for the TMRE studies. Proteins were harvested 48h after 
treatment. Activation of caspase 3 was first analysed since previous data using a 
pan-caspase inhibitor showed inhibition of sensitisation. Pro-caspase 3 was 
expressed in all three cells lines in its inactive configuration, as pro-caspase 3 of 
34 Kd. Cleaved caspase 3 was only detected at low levels in 22Rv1 cells (Fig. 
56). Mitoxantrone as single treatment did not induced cleavage of caspase 3 at 
48h in this cell line. Treatment with each AdE1A-12S mutant alone showed 
higher levels of cleaved protein than untreated cells. An increase in activated 
cleaved caspase was detected when mitoxantrone was combined with all mutants. 
Activation of caspase 3 was not detected in DU145 and PC3 cell with any 
treatment. 
  
 Expression of p53 was also analysed. Changes in p53 could only be 
studied in 22Rv1 cells since these cells express wild type p53. PC3 cells do not 
express p53 and DU145 cells express a non-functional p53 mutant. Expression of 
p53 in DU145 did not change with any treatment, showing levels of expression 
similar to untreated cells with any virus or combination with mitoxantrone (data 
not shown). Higher levels of p53 were observed 48h after cells were treated with 
mitoxantrone in 22Rv1 cells (Fig. 56). Infection with the replication defective 
adenoviruses also induced p53 expression, although AdE1A-1104 infection 
showed lower p53 levels than infection with the other mutants. This could suggest 
 199 
a role of p300/CBP interaction with E1A in p53 stabilisation. AdGFP infection 
also increased p53 levels. Combination of mitoxantrone and viruses further 
increased the levels of p53 compared to virus or drug alone. The Bcl-2 protein 
was also detected in 22Rv1 cells expressed at high levels in untreated cells. 
Treatment with mitoxantrone induced a decrease of Bcl-2 that was also observed 
when viruses and drug where combined, with the exception of the AdE1A-1104 
virus. Infection with this virus decreased BCL-2 expression, but it increased when 
this mutant was combined with mitoxantrone.  
  
 Another protein involved in cell cycle, p21, was studied in 22Rv1 cells. 
Although expression of this protein was high in untreated cells levels were 
 
 Fig. 56. Changes in expression of proteins regulating cell cycle and apoptosis in 22Rv1 
cells. Cells were treated with mitoxantrone at 50 nM and AdE1A-mutants at 2.5 ppc for 48h.  
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increased 48h after treatment with mitoxantrone (Fig. 56). Infection of 22Rv1 
cells with virus lowered the levels of p21 with the exception of AdE1A-1102. 
Combination of mitoxantrone and viruses resulted in levels of p21 similar to those 
of drug alone, with the exception of AdE1A-12S; p21 levels with this virus and 
mitoxantrone were higher than with virus alone but lower than the expression 
induced by mitoxantrone alone (Fig. 56). 
  
 It is known that E1A can antagonise the androgen receptor (AR); 
therefore, we analysed changes in the receptor levels to elucidate whether there 
was a relationship between E1A sensitisation and AR expression. The AdE1A-
1102 and AdE1A-1104 mutants failed to downregulate AR expression, while the 
other E1A-mutant viruses decreased its expression. The AdE1A-1102 mutant 
successfully sensitised cells to mitoxantrone, indicating that AR interactions with 
E1A might not be involved in chemosensitisation.  
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Discussion 
 
 
 
 
 
 
The data presented in this thesis showed that interactions of the CR1 of 
E1A are essential for E1A-mediated chemosensitisation of prostate cancer cells. 
In addition, we also reported that deletion of the CR1 containing the p300-binding 
region attenuated viral potency, while modifications of the pRb binding site did 
not affect the toxicity, viral replication or E1A-mediated sensitisation of 
adenovirus. Sensitisation to mitoxantrone was also dependent on the status of the 
mutations within each cell line, as not all cell lines tested showed equal 
semnsitivity to mitoxantrone or docetaxel. We also observed that other viral genes 
could be involved in the sensitisation, as combination of drugs with viruses unable 
to bind p300/CBP resulted in sensitisation. However, the use of replication 
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deficient E1A-expressing viruses showed that E1A-mediated sensitisation 
requires the region binding to p300/CBP at the CR1. This could require 
interactions with p300/CBP or other unkown interactions with cellular proteins 
within the CR1 of E1A. The data indicates that E1A regions interacting with 
p300/CBP within CR1 should not be deleted for the design of adenoviral vectors 
for the treatment of prostate cancer. 
 
Deletions of viral genes to confer cancer specificity to adenoviruses have 
been widely described (35, 44, 137, 142). The first adenovirus to be characterised 
was the dl1520 mutant, also known as ONYX-015 (183, 184). This virus did not 
express the E1B-55K protein that interacts with p53 to block p53-dependent 
apoptosis (41, 213). Hence, the hypothesis was that this virus would only be able 
to replicate in cells with mutated non-functional p53, a mutation of high 
occurrence in cancer cells. It was later shown by several groups that cancer 
specificity was not dependent on the p53 status of the tumour (185, 214, 215). In 
addition, deletion of the E1B-55K gene significantly attenuated viral potency 
(215, 216). Replicating adenoviruses with small deletions in E1A similar to those 
tested in this thesis were considered a promising alternative to achieve cancer 
selectivity without compromising viral toxicity. The replication selective viral 
mutants used in this thesis have been previously described (4, 139, 146). E1A 
mutations did not attenuate viral toxicity to levels similar to that of the dl1520 
mutant. In fact, all replicating E1A-mutant adenoviruses tested in this thesis were 
as potent as Ad5, with the exception of the dl1101 and the dl1104 mutants that 
were attenuated compared to Ad5.  
 
The attenuation observed for the dl1101 and dl1104 mutants could not be 
explained by a higher vp/pfu ratio, as all viruses tested showed similar ratios and 
consequently the specific deletions in E1A were responsible for the attenuated 
viral toxicity. These viruses are not able to bind p300/CBP complexes that are 
involved in activation of genes that regulate cell cycle progression and 
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differentiation (4, 146). In addition, the E1A-1101 protein does not bind the 26S 
proteasome (115), that results in longer half-life of this protein and failure to 
inhibit proteasomal degradation of cellular proteins such as p53. In fact, the 
dl1101 mutant does not stabilise p53, so no accumulation of p53 is observed in 
cells infected with this virus (100). This is because E1A must bind p300 to 
stabilise p53, so viruses unable to bind p300 fail to stabilise p53. Other reports 
have shown that E1A proteins produced by the dl1104 mutant are not stable and 
in consequence they are targeted for proteasomal degradation faster than wild type 
E1A (143). Even though we did not investigate protein stability or proteasomal 
degradation of E1A proteins in this thesis, we observed that levels of E1A-1104 
expressed by a replication deficient virus were lower than those of the other E1A 
mutants tested. Although protein stability and proteasomal activity are important 
factors during adenoviral replication, attenuation of toxicity of these two viruses 
is likely caused by the loss of binding to p300/CBP complexes.  
 
E1A-mediated transcriptional repression is essential for viral replication as 
it allows viral transcription and represses the expression of cellular genes that 
could interfere with the viral life cycle. Transcriptional repression by E1A-12S 
requires binding of E1A to p300 (93). Transient expression of p300 in 
combination with E1A does not completely restore transcriptional activity. More 
detailed studies have shown that both E1A-1101 and E1A-1104 fail to repress 
cellular transcription (92, 94). Single point mutations in amino acid residues 53 to 
56, not present in E1A-1104, were sufficient to lose E1A binding to p300/CBP 
and transcriptional repression activity (93), suggesting that binding to p300/CBP 
is required to repress transactivation. Binding to p300 is also required to stabilise 
p53 and to induce p53-dependent apoptosis (3, 42). Disruption of MDM2-p53 
complexes and acetylation of pRb by p300 are known to stabilise p53 and inhibit 
its degradation (78). We observed that replication of the dl1104 mutant in prostate 
cancer cell lines was influenced by their p53 status in the cells. This virus 
produced similar yields to Ad5 in the p53-null PC3 cell line and in DU145, which 
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expresses a non-functional p53. However, replication of this mutant in the p53 
wild type cell line 22Rv1 was significantly reduced. These data is in agreement 
with the hypothesis that p53 stabilisation through p300 is an important 
requirement for efficient viral replication, although this interaction is not required 
in p53 negative cells (217, 218). In the presence of functional p53, E1A 
interactions with p300/CBP repress p53-dependent transcription. Transcriptional 
activation by p53 possibly induces the expression of pro-apoptotic genes that 
could decrease the efficiency of viral replication. In contrast, a deletion in the 
CR2 had no effect in either viral toxicity or replication of the virus. We also 
determined the level of replication of dl1102, dl1104 and dl1108 mutants in PC3, 
DU145 and 22Rv1 cells both by the TCID50 method followed by viral genome 
quantification by qPCR, obtaining similar results. While these mutant viruses 
showed similar levels of replication in PC3 and DU145 cells, differences were 
observed in 22Rv1 cells. Viruses with mutations in the N-terminus of E1A, 
dl1102 and dl1104, showed an attenuated replication compared to Ad5 or the 
dl1108 mutant. The attenuation was more significant for the dl1104 mutant, 
indicating the importance of E1A-p300 interactions for viral replication. We also 
showed that disruption of pRb-E2F complexes by E1A does not play a role in 
adenoviral replication in prostate cell lines, as the dl1108 mutant was as effective 
as Ad5 in the three cell lines. It is possible that cellular mutations already present 
in these cell lines are sufficient to mimic the function of pRb-E1A interactions in 
the context of infection, while the repression of the transactivating activity of 
p300 is still a requirement for viral replication and toxicity. 
 
During viral infection, p300 stabilises p53 and prevents its degradation, a 
function that has been demonstrated to play an important role in viral replication 
(3). Failure to stabilise p53 and inhibit its degradation through p300-E1A 
interactions could explain the attenuation in replication in dl1104. In addition, 
22Rv1 was the only AR-positive cell line; there are reports that demonstrate a 
negative interaction between E1A and AR, with consequences for p300 activity 
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(25, 203). These reports showed that E1A represses AR-dependent transcription 
by indirect competition with AR activators. In addition AR negatively regulates 
p300, necessary for efficient virus-mediated entry into S-phase. Hence, AR 
interacts negatively with E1A and reduces viral replication. That hypothesis could 
also explain the attenuation of this virus and the lack of sensitisation in 
combination with chemotherapy, subject that will be discuss later in this chapter. 
 
The murine cell lines TRAMPC and RM1 showed high resistance to viral 
toxicity as previously shown in numerous publications that murine cells were not 
as permissive to human Ad5 infection as human cells (219, 220). In vitro studies 
in several murine cell lines have shown good E1A expression after adenoviral 
infection followed by efficient viral DNA synthesis (219, 220). However, there 
are reports that late structural proteins were not efficiently expressed in murine 
cell lines and consequently viral assembly did not occur in these cells (219, 220). 
Although we did not further investigate viral gene expression and replication in 
the two murine cell lines tested, our data showed that Ad5 failed to replicate in 
murine prostate cancer cells. Detection of GFP in these cells after infection with a 
non-replicating GFP-expressing adenovirus, AdGFP, excluded the hypothesis that 
viral internalisation and transport to the nucleus was ablated in the murine cells. 
Although TRAMPC and RM1 cells were poorly infectable by AdGFP, poor 
infectability alone could not explain the complete lack of replication. The human 
PC3 cells showed similar low infectability to the TRAMPC and RM1 cells but 
Ad5 could efficiently replicate in these cells in contrast to the murine cells. Our 
studies showed that Ad5 could infect the murine cell lines but viral replication 
was impaired. However, these data do not elucidate whether lack of replication 
was due to lower expression of late viral proteins or reduced packaging of viral 
particles, as previously suggested. 
 
In the context of adenoviral infection of prostate cancer cells, effects on 
androgen receptor and its interactions with E1A must also be considered. An 
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adenoviral mutant expressing a fusion protein E1A-AR was described as an 
alternative for targeting prostate cells and overcome AR-mediated decreases in 
viral replication (203). Our data showed that the AR positive 22Rv1 cell line was 
more sensitive to viral toxicity than DU145 and PC3 cells that are both AR 
negative. However, infection of 22Rv1 cells was more efficient than that of PC3 
cells, possibly explaining the differences in toxicity. DU145 cells showed similar 
levels of infection to those for 22Rv1 cells, and differences in toxicity between 
these two cell lines were not as dramatic as those observed for PC3 cells. AR 
expression was determined after infection with replication deficient E1A-
expressing viruses in the 22Rv1 cells. We observed that AdE1A-12S decreased 
AR expression, in agreement with previous studies showing negative regulation of 
AR by E1A (203). We also found that E1A deletions in the N-terminal region 
(AdE1A-1102 and AdE1A-1104 viruses) failed to downregulate AR expression in 
22Rv1 cells. A correlation between downregulation of AR and viral toxicity was 
not observed since the replication-selective dl1102 mutant induced cell death to 
levels similar to those of Ad5. In addition, AdE1A-1102, replication deficient, 
showed similar toxicity to that of AdE1A-12S. We concluded that attenuated of 
toxicity of the E1A-1104 expressing viruses, both replicating and non-replicating, 
was not due to interactions with AR but to a failure to interact with p300/CBP.   
 
Loss of AR expression has been associated with cancer progression and 
resistance to therapy; several groups have shown that this process might involve 
up-regulation of Bcl-2 in the absence of AR (7, 24, 203). We observed that the 
AR-negative cell line PC3 was more resistant to chemotherapy than 22Rv1 cells. 
However, 22Rv1 and DU145 showed similar resistance to both mitoxantrone and 
docetaxel. In addition, Bcl-2 was not detectable at basal levels in DU145 in spite 
of not expressing AR (205), indicating that sensitivity to cytotoxic drugs in 
prostate cancer cells might not only be associated with loss of AR and up-
regulation of Bcl-2. Even though we did not observe a correlation between 
downregulation of AR and viral toxicity, it is possible that AR status plays a role 
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in sensitisation of prostate cancer cells to chemotherapy. Interestingly, AR 
regulation is associated with p300 expression; down-regulation of p300 in 
prostate cancer cells depends on the presence of functional AR (25). As the 
disease progresses, AR decreases and p300 increases, inducing transcriptional 
activation of survival genes (24, 25). It has been reported that loss of AR activity 
increased p300 expression resulting in failure to arrest cells in G2/M (203). We 
observed that the population of 22Rv1 cells arrested in G2/M after mitoxantrone 
treament was not as pronounced as in PC3 cells, possibly due to a reduction in AR 
expression that was observed after mitoxantrone treatment could have induced 
p300 activity that would interfere with the regulation of the G2/M checkpoint. 
Hence only E1A proteins able to bind p300 would be able to induce a further 
increase of cells in G2/M. In AR negative cells, like PC3 cells, this androgen-
dependent regulation is absent, possibly contributing to a higher cycle arrest by 
mitoxantrone. 
 
 
We constructed replication-deficient adenoviruses expressing different 
E1A-mutant proteins in order to identify the effect of E1A expression in the 
absence of other viral genes. Adenoviruses used as vectors for transient or stable 
transfection of the cancer prostate cell lines was not successful. Prostate cancer 
cell lines have previously been shown to be difficult to transfect (221). We also 
observed that transfection efficiencies was not higher than 30% with most of the 
reagents tested, even the Mirus TransIT reagent, specifically designed to transfect 
prostate cells. The great cell death rate observed during transfection and the loss 
of E1A expression after passaging the cells made it necessary to find alternative 
expression vectors. Cell death and loss of E1A expression was probably due to 
two reasons, the effects of the transfection reagents on the cells and E1A-induced 
cell death. In addition, transfected cells had a doubling time that was longer than 
untreated cells. Even though we observed good sensitisation by E1A-12S in 
transiently transfected cells, the problems associated with the expression system 
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made the assays unreliable. Similar effects were observed when retroviruses were 
used although we did not further explore why prostate cancer cell lines were so 
poorly transducible by retroviruses.  
 
The use of replication deficient adenoviruses was a good alternative to 
induce E1A expression in prostate cancer cell lines. The use of replication 
deficient mutants lacking proteins involved in cell death inhibition or induction 
such as E1B or ADP respectively facilitated the study of E1A effects on cell death 
and chemosensitisation. In addition, expression of other viral early genes such as 
E4, are expected to be low as the E1A gene used for the construction of these 
viruses was based on E1A-12S cDNA, hence lacking the transactivation domain 
located in the CR3, only present in E1A-13S (42, 92).  The time course and level 
of expression of E1A was comparable to that of Ad5-infected cells. An additional 
advantage was that expression lasted longer due to the regulation by the CMV 
promoter and not by a viral promoter that could be repressed during progression 
of the viral cycle. The sensitivity of all three human prostate cancer cell lines to 
these viruses correlated with that of the replicating viruses, with PC3 cells being 
the most resistant to viral toxicity and the 22Rv1 cells the most sensitive. Similar 
to replication-selective viruses, the E1A-1104 expressing virus was less cytotoxic 
while the other mutants had similar toxicity. In any case, EC50 values for these 
viruses were higher than for Ad5 and replication studies using the TCID50 method 
confirmed that AdE1A-mutants failed to replicate in the cell lines. This indicated 
that E1A-mediated apoptosis was most likely the cause of cell death. However, 
qPCR analysis of hexon DNA amplification showed that the amounts of hexon 
increased over time for AdE1A-1102 and AdE1A-1108 viruses. It is possible that 
some recombination occurred during the production of these viruses, integrating 
E1B and possibly other E1A sequences in some viral particles. The recombination 
was low as E1A sequencing of these viruses showed that they were both 
expressing the correct E1A gene respectively, and E1A-13S sequences were not 
detected. To corroborate these results, we checked the presence of E1A in our 
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virus stocks. E1B was amplified at very low levels in these viruses when more 
than 35 PCR cycles were used. Recombination with the packaging cell line 
HEK293 is a difficult problem to avoid for replication-defective viruses; further 
purification of viruses or alternative production techniques might be necessary for 
other experimental settings or in a clinical trial situation, but we did not observe 
any effect on cell death or replication at the viral concentration used for our 
sensitisation studies. In addition, we can confirm that recombination was minimal, 
as otherwise the replicating properties of recombined viruses would have given a 
much lower EC50 value as a result of replication and spread to neighbouring cells. 
 
Since E1A expression has been associated with the induction of apoptosis 
(131, 222), we hypothesised that cell death observed with the AdE1A-mutant 
viruses was due to activation of apoptosis. Our toxicity data for replication 
deficient viruses in Chapter 5 indicate that E1A-mediated apoptosis is highly 
dependent on binding to p300/CBP, but not to pRb. E1A-mediated induction of 
apoptosis might be impaired due to the instability of this mutant protein, as 
previously discussed, or due to a lack of the repressional activity of E1A-
p300/CBP complexes. E1A-mediated apoptosis was thought to occur through 
activation of p53 after release of E2F (75, 78, 223). However, other studies have 
shown that induction of apoptosis by E1A can be p53-independent in pRb positive 
and negative cells (26, 83, 138). The proposed mechanism for E1A induced 
apoptosis involves activation of PUMA by p53-independent pathways (85). Sp1 
and different isoforms of p73 have been described as positive regulators of 
PUMA in p53-null cell lines (224, 225). PUMA is activated by p73 in a process 
that requires activation of Sp1, known to interact with p300. In addition p73 is 
regulated by Abl, although it can also be phosphorylated by Scr, known to interact 
with CR2 (130). It is possible that apoptosis can be induced by mechanisms 
involving p300 and/or pRb binding of E1A and that the pathway triggered after 
E1A expression depends on host balance of the proteins related to these pathways.  
 
 210 
The mechanisms involved in E1A-mediated apoptosis could also be 
responsible for the sensitising properties of E1A proteins to chemotherapy and 
radiotherapy. We studied combination of viruses with two different drugs 
commonly used in prostate cancer treatment, mitoxantrone and docetaxel. These 
drugs have different mechanisms of action; mitoxantrone binds to DNA and 
inhibits topoisomerase II, while docetaxel is a microtubule-binding agent. There is 
extended evidence that E1A can sensitise cancer cells to DNA damaging agents 
(89, 147, 150, 151, 157, 225-227); however, reports of interactions between E1A 
proteins and drugs with alternative mechanisms are contradictory. Our data 
showed that sensitisation of prostate cancer cell lines was efficient to both drugs 
used, although sensitisation to mitoxantrone was in all cases greater than to 
docetaxel. The interactions between virus and drugs were also cell line dependent 
but was not related to sensitivity to chemotherapy. PC3 cells were more resistant 
to both drugs and viruses than the other cell lines tested and yet showed better 
synergistic interactions in combination studies with replication selective 
adenoviruses and mitoxantrone. In contrast, antagonistic interactions were 
observed in 22Rv1 cells, despite being more sensitive to virus and drug toxicity 
when administered alone.  
 
Sensitisation was also dependent on the doses of both virus and drugs 
since no sensitisation was observed in 22Rv1 and PC3 cells when fixed 
concentrations of viruses and mitoxantrone were used but strong reduction of 
EC50 value for the drug was observed in combination with fixed concentrations of 
virus in both cell lines. Nevertheless, viral toxicity was higher than expected in 
the 22Rv1 cell line, possibly because these cells were already very sensitive to 
viral infection and small changes in viral dilutions or the cellular status at the time 
of infection could influence the final toxicity outcome. In contrast, TRAMPC 
cells could be successfully sensitised when treated with two fixed concentrations 
of both drug and viruses, despite a lack of significant synergistic interactions or 
reduction of EC50 value for the drug in other combination assays.  
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Interestingly, the combination of Ad5 with mitoxantrone and docetaxel 
significantly affected viral gene expression. Hexon expression could be detected 
by western blot at 24h only in combination treatment of Ad5 and docetaxel in 
DU145 and PC3 cells and also with mitoxantrone in PC3 cells but not in cells 
treated only with the virus. In addition, E1A mRNA levels increased in 
combination with mitoxantrone in PC3 cells. Infection with a non-replicating 
AdGFP virus showed that the number of infected cells increased significantly 
after 24h in the presence of mitoxantrone at 50 nM only when virus was not 
removed. Therefore we hypothesised that mitoxantrone increased the infection 
rate over time. A 2h infection with AdGFP did not change the percentage of 
infected cells, meaning that when using a replicating virus such as Ad5, once the 
first replication cycle is complete and new viral particles are released, more cells 
will be infected or a higher number of particles will enter each cell. However, we 
did not observe an increase in replication in the presence of drug. Further 
experiments are needed to fully understand the increase in infectability without an 
increase in replication, but we could hypothesise that the toxicity of the drug 
reduces the number of cells in which replication can occur. Hence, despite 
increasing the infectability of the cells, there would be less living cells available 
for further viral infection and replication. This would be further enhanced by the 
sensitising and bystander effects of E1A that in turn would sensitise both infected 
and uninfected cells to the actions of the drug. It is also possible that the 
molecular changes after drug treatment affect viral packaging or other late 
processes. 
 
Changes in E1A expression after viral infection in combination with 
mitoxantrone were very significant when using replication defective viruses 
expressing E1A. We observed a higher expression of E1A when virus was not 
removed. When we compared E1A mRNA levels in these samples with those 
infected with AdE1A-12S virus for 2h, we observed that E1A mRNA levels only 
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increased if the virus was not removed after 2h. Because AdE1A-12S did not 
replicate, we concluded that mitoxantrone induced an increase in infectivity over 
time that could not be observed if virus was removed, as previous infectivity 
assays describe. This indicates that mitoxantrone increased viral uptake by the 
cells; changes induced by mitoxantrone that favour infectivity must take more 
than two hours to occur.  
 
Other members of our team have reported that CAR levels are induced 
after mitoxantrone or docetaxel treatment, while integrin expression did not 
change (S. Radhakrishnan, manuscript in preparation).  This unpublished data is 
in agreement with the increase in infection described in this thesis. These findings 
could have relevance in the administration of combination therapies as they 
suggest that pre-treatment with mitoxantrone or docetaxel could improve the 
infectivity of prostate cancer cells. This could also improve sensitisation to the 
drug by E1A, as higher E1A expression would induce sensitisation the drug 
through bystander effects. Members of our team have shown that pre-treatment of 
cancer cells with mitoxantrone did not induce better synergistic interactions or 
influenced viral replication (S. Radhakrishnan, manuscript in preparation). 
However, we must consider that pre-treatment with mitoxantrone also induced 
cell death, so even if treated cells were more infectable the number of viable cells 
prone to infection was reduced by the action of the drug.  
 
Our results with replication-defective adenoviruses expressing E1A-
mutant proteins showed that E1A-1104 protein failed to sensitise prostate cancer 
cells to mitoxantrone or docetaxel. This mutant was also unable to induce and 
increase G2/M arrest or changes in mitochondrial membrane potential in 
combination with mitoxantrone compared to drug alone. Cell death observed 
during these sensitisation studies was caused by induction of apoptosis, as 
demonstrated by an increase in pro-apoptotic cells by TMRE staining. In addition, 
inhibition of caspase activity protected prostate cancer cell lines to mitoxantrone-
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induced cell death and to viral sensitisation. Based on the expression profiles of 
the cell lines used, we hypothesise that induction of apoptosis was independent of 
p53 status in PC3 and DU145 cells but not in 22Rv1 since this is the only cell line 
expressing functional wild type p53. In this cell line, total p53 levels were 
increased after infection with the replication defective E1A-expressing mutants 
AdE1A-12S and AdE1A-1102, both able to bind pRb and p300/CBP. However, 
increases in p53 were not as high with the AdE1A-1108 and AdE1A-1104 and it 
is likely that these mutants did not stabilise p53 as efficiently as AdE1A-12S or 
AdE1A-1102. E1A interactions with pRb can upregulate p53, so less p53 could be 
expected after expression of E1A-1108, and a second interaction of E1A with 
p300/CBP further stabilises p53 (83, 99, 100, 223). Possibly, E1A-1104 and E1A-
1108 are less effective at stabilising p53 due to the deletions in the binding site of 
either cellular factor. The p53-antagonist Bcl-2 protein was decreased in the 
presence of mitoxantrone and when combined with all mutants with the exception 
of AdE1A-1104. The lack of sensitisation by the AdE1A-1104 virus in this cell 
line could partially be due to Bcl-2 antiapoptotic properties. It is possible that the 
downregulation of antiapoptotic proteins like Bcl-2 is involved in sensitisation; 
the E1A-1104 was not able to downregulate the levels of Bcl-2 in the presence of 
mitoxantrone, partially explaining why we did not observed supra-additive effects 
after the combination of this mutant with the drug. 
 
 Toxicity of AdE1A-12S mutant viruses was due to activation of 
apoptosis, as inhibition of caspases significantly attenuated viral toxicity. 
However, the viral doses used for sensitisation studies did not induce apoptosis 
and mitochondrial depolarisation, therefore we suggest that E1A expression 
upregulated mitoxantrone-induced apoptosis. The main cellular proteins involved 
in E1A-mediated regulation are pRb and p300/CBP.  We did not find any 
relationship between the pRb pathway and the enhancement of apoptosis during 
combination treatments, not only because the AdE1A-1108 virus does not bind 
pRb, but also because good sensitisation was observed in DU145 despite the lack 
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of pRb expression in this cell line. Sensitisation by E1A-12S was thought to be 
dependent on pRb binding and consequent release of E2F (138). This would 
activate several transcription factors, resulting in p53-dependent apoptosis. 
Previous studies showed that induction of apoptosis by E1A-12S and sensitisation 
to chemotherapy and radiotherapy were independent of binding to pRb (126). 
Additional studies demonstrated that even though dissociation of pRb-E2F 
complexes is mainly through E1A sequestering of pRb, transcriptional activation 
of E2F1 is also dependent on binding to the N-terminus of CBP. E1A can also 
stimulate E2F1 transcription by directing CBP to the E2F promoter although this 
activation has only been demonstrated in vitro (103). Regulation of E2F1 
transcriptional activity is regulated by acetylation mainly by CBP and, to a lesser 
extent by p300, through a mechanism that is negatively regulated by pRb (103). 
E2F release from pRb has also been described after expression of E4-6/7 
adenoviral proteins (47). 
 
Binding of p300/CBP to E1A is also known to be the mechanism 
responsible for the observed downregulation of p21 induction after p53 
stabilisation, proposed by some groups as a mechanism for the induction of 
apoptosis in DNA-damaged cells (42, 89).  Our data, however, demonstrate that it 
is possible to enhance drug-mediated apoptosis independently of p21 inactivation 
in prostate cancer cell lines. E1A can regulate p21 activity by direct or indirect 
interactions with TRRAP and p400 (106). We observed that p21 levels did not 
decrease after infection with AdE1A-1102 that is unable to bind p400 although no 
effect on sensitisation was detected. We should consider that p21 is mainly 
involved in cell cycle arrest and senescence (41) by inhibiting cyclin E/cdk2 
(103). This cannot be considered a survival mechanism since under those 
conditions survival pathways are inhibited and cell viability is compromised.  
Another issue to consider when investigating apoptosis induction is the host 
status. Interaction of p400 and myc have been reported to induce apoptosis (113), 
however, myc is commonly deregulated in cancer cells and so is the regulation of 
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cyclin dependent kinases controlling cell cycle checkpoints (228). More 
importantly, E1A expression also influences expression of cyclins and cdks to 
force entry into S-phase (3, 42, 222). Cyclin E/cdk2 are negative regulators of 
p300, providing a checkpoint that regulates the G1/S transition (103). 
Interestingly, other groups have proposed that cyclin E/cdk2 can phosphorylate 
CBP and increase HAT activity, as observed when bound to E1A (103).  
 
It was suggested that p400 binding was required for sensitisation, as myc–
defective cell could be lines less efficiently sensitised by E1A, due to reduced 
expression of caspase-7 (113). However, myc expression is regulated by E1A 
through p400 interaction, possibly to overcome cycle arrest (42). Myc expression 
is often deregulated in cancer cells, so E1A interaction with p300/CBP and p400 
might be more important to control the different cell cycle checkpoints after 
infection than interactions with p400.  
 
In order to postulate a hypothesis that is in agreement with our 
observations, we must consider the effects of the drugs on the prostate cancer 
cells tested and how sequestering of p300 by E1A can enhance them. 
Mitoxantrone is a drug classified as a topoisomerase II inhibitor and a DNA-
intercalating agent that induces DNA damage by DNA double strand break (13). 
There is evidence that E1A can regulate the activity of the topoisomerase II 
promoter in E1A-expresing cells (229) and that topoisomerase I is increased in 
cells infected with dl922-947 or Ad2 (230). In addition, exogenous expression of 
topoisomerase II can sensitise cells to topoisomerase II inhibitors such as 
etoposide (231). It is then likely that E1A-sensitisation of prostate cancer cells to 
mitoxantrone was caused by upregulation of topoisomerase II after infection and 
that the process requires binding of E1A to p300/CBP. The use of the 
topoisomerase II inhibitor TAS-103 in a range of cancer cell lines showed that 
susceptibily to this inhibitor was dependent on p300 expression and that over-
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expression of p300 sensitised these cell lines to TAS-103 but not to cisplatin 
(232).  
 
One protein that has been described to play a role in topoisomerase II 
transcriptional activation and E1A expression is p38 (233). This protein belong to 
the family of mitogen-activated protein kinases, involved in both proliferative and 
apoptotic activities. Inhibition of p38 by the specific inhibitor SB203580 
correlated with a decrease in topoisomerase II expression (233). Activation of p38 
also occured during late G2/M phase by topoisomerase II and histone deacetylase 
activity, inducing the inhibition of the cdc25B phosphatase and phosphorylation 
of cdc2; this results in a decrease of cyclin A/cdk2 and arrest in G2/M (234, 235). 
It is well known that E1A alters host HDAC activity and mitoxantrone inhibits 
topoisomerase II (13), hence it is reasonable that during combination therapies of 
these two agent we observe G2/M arrest as a consequence of p38 phosphorylation 
and a decrease in p300 activity. Our data showed that when sensitisation to 
mitoxantrone was successful with replication-deficient viruses, a higher 
proportion of cells were arrested in G2/M. In contrast, AdE1A-1104 in 
combination with the drug showed the same cell cycle profile as cells treated only 
with mitoxantrone. It is possible then that E1A-p300/CBP complexes increase 
HAT activity, accompanied by a repression in HDACs, to stimulate p38-
dependent G2/M arrest. Failure of the E1A-1104 protein to sequester p300/CBP 
would result in a failure to overcome G2/M arrest, as we have observed. When it 
comes to cell cycle analysis, we must also consider the effects that E1A could 
have in progression through it; it is well established that E1A promotes entry into 
S phase, and alters the cyclin/cdks balance to favour viral replication (3, 41, 42, 
222); those effects could interfere with the arrest induced by mitoxantrone. 
However, no effect on the cell cycle was observed under the condition used in this 
thesis, so we conclude that alteration in cell cycle distribution is a consequence of 
drug treatment and E1A-mediated sensitisation to this treatment.  
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Combination of replication deficient adenoviruses expressing E1A-mutant 
proteins with mitoxantrone in the presence of the broad pan-caspase inhibitor z-
VAD-FMK resulted in abrogation of E1A-mediated sensitisation and protection 
against mitoxantrone-induced cell death. Similar effects were observed when a 
sub-optimal concentration of the drug was combined with different viral 
concentrations. This suggested a strong interaction of the caspase pathway in the 
cell death observed. However, cleavage of caspase-3 was weakly observed in 
22Rv1 cells and not detected in DU145 and PC3 cells, even though procaspase-3 
levels were slightly decreased. It would be interesting to detect caspase-3 
activation by more sensitive methods, such as flow cytometry with specific 
antibodies, to further elucidate the involvement of caspase-3 in mitoxantrone-
induced cell death. The levels of active caspase-3 detected in 22Rv1 cells were 
similar in all combinations, including the sensitisation-deficient mutant AdE1A-
1104. However, the changes in mitochondrial transmembrane potential strongly 
suggest that this mutant failed to increase the proapoptotic effects of 
mitoxantrone. Low levels of transmembrane potential lead to cytochrome c 
release and consequent caspase activation, leading to apoptosis (236). However, 
mitochondrial transmembrane potential can be altered by other mechanisms, such 
as increases in K+ permeability not related to apoptosis (236).  
 
We should consider the possibility that mitochondrial activation of 
apoptosis could be both caspase dependent and independent; recent findings have 
shown that apoptosis induced after excision of chromatin loop domains 
upregulates caspase-independent apoptosis, involving topoisomerase II, p38 and 
mitochondrial loss of potential (235). In this model, DNA cleavage would activate 
p38 that would induce BAX translocation to the mitochondrial membrane, 
reducing its permeability. This would favour the release of apoptosis inducing 
factor (AIF) and the formation of a positive feedback loop with topoisomerase II, 
inducing apoptosis in a caspase-independent manner. This would also allow the 
release of cyt c and activation of caspase-dependent apoptotic pathways that 
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would work in parallel with caspase-independent pathways. These researchers 
proposed a model in which caspase-dependent apoptosis is dispensable in the 
apoptotic pathway associated with the excision of DNA loop domains, but not 
when internucleosomal DNA fragmentation occurs. Interestingly, caspase-2 is 
regulated by topoisomerase I and II and it is involved in G2/M checkpoint arrest 
(237, 238), although it has been shown to have both pro- and anti-apoptotic 
effects, which could partially explain the antagonism observed between 
topoisomerase II inhibitors and other chemotherapeutic agents (14).  
 
The antiapoptotic Akt protein, also known as PKB, is also involved in p38 
regulation (156). Decreased Akt phosphorylation has been demonstrated after 
chemotherapy-induced apoptosis with agents like cisplatin and taxol (155, 156, 
205). In all cases, downregulation of Akt correlates with activation of p38, PARP 
cleavage and caspase activation. Akt activity is downregulated by removal of 
phosphate groups by PTEN and PP2A/C, both enzymes having recognised 
tumour-suppressive functions (155). Good correlation has been observed between 
PTEN/Akt status of prostate cancer cell lines and their resistance to chemotherapy 
(205); PC3 cells express non-functional PTEN and have been described to be 
more resistant to taxol and cisplatin than other cell lines (205). Our data with 
docetaxel and mitoxantrone is in agreement with this hypothesis, as PC3 cells 
were more resistant to these agents than the other cell lines tested. 
 
Other groups have shown that upregulation of PP2A/C is required for 
chemosensitisation and that its activity is significantly increased in E1A stable-
transfected cell lines (155). However, these changes in host proteins that induce 
chemosensitisation are not similar in the context of a replicating adenovirus. Even 
though PP2A/C and p38 activation and subsequent Akt dephosphorylation have 
been documented in E1A-transfected cells, opposite results were observed when 
replicating viruses were used (239). E4-ORF1 and E4-ORF4 viral genes can 
actually control activation of the MEK/ERK pathway and replication seems to be 
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dependent on it (47, 51, 240); use of ERK inhibitors results in decrease of 
replication in Ad5-infected cells. Control of this pathway is probably upstream of 
ERK, as the E4-ORF4 region can specifically bind to PP2A and reduce its 
functions, hence increasing activated Akt and ERK1/2 that will activate the 
mTOR and MAKP signally pathway (240). Viral mutants unable to bind PP2A 
failed to phosphorylate p70S6K, downstream of ERK, impairing S-phase entry. 
Under this condition, viral protein expression and viral production was decreased 
by 50% (240). Involvement of ERK1/2 in viral replication could partially explain 
the resistance observed in PC3 to viral toxicity and replication, as p-ERK1/2 is 
not detected in PC3 cells (205). Lack of p-ERK in these cell lines could also 
account for the sensitisation observed in spite of their known resistance to 
chemotherapy, as lack of activated ERK would have a downstream effect on p38, 
increasing its activity. 
 
 MAPK is also relevant in p300/CBP upregulation of HAT activity. CBP 
is associated in vivo with ERK1 and phosphorylated by ERK2 to induce HAT 
activity, possibly mediating the ability of CBP to mediate the transcriptional 
activity of Elk1 (103). There is also strong evidence of increased phosphorylation 
of p38 in E1A-expressing cell lines that promotes phosphorylation by activated 
p38 of several transcription factors that bind to p300/CBP and E1A, such as 
CREB, Sp1, c-Fos, c-Jun and Elk-1 (241, 242). E1A and E4 possibly regulate the 
activity of all these transcription factors to ensure efficient viral replication (47).  
 
It seems as if E1A-induced changes in cellular pathways are different and 
opposite to viral replication; one example of this is the strong induction of 
proapoptotic signals observed during E1A expression, including p53 stabilisation 
and p21 activation. However, these alterations are later counteracted by other viral 
genes such as E1B. A similar mechanism could involved the MAPK family of 
proteins; E1A could induce activation of MAPK-dependent pro-apoptotic 
signalling in a similar fashion to p53 stabilisation, to repress other cellular 
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pathways that might reduced efficiency of replication. At the same time, the 
balance of E1A-12S and E1A-13S levels could be important, as E1A-12S lacks 
the transactivation domain and hence is involved in transcriptional repression, 
while E1A-13S favours transcription (93, 243). The CR3 domain, unique in E1A-
13S protein, binds to several transcription factors to allow successful transcription 
of viral proteins and the host proteins needed for viral cycle progression. This 
domain might actually be essential for efficient activation of the MEK/ERK 
pathway, as other groups have shown that the induction of Akt phosphorylation 
and PI3K pathway is only observed in E1A-13S-transformed cells, but not when 
E1A-12S was used (244). If E1A-12S expression maintain p-Akt at lower levels 
than E1A-13S, then E1A-mediated sensitising combination therapies should be 
designed with E1A-12S viruses for those drugs affecting this cellular pathway.  
 
Interestingly we observed that synergistic interactions between 
mitoxantrone and AdE1A-12S obtained lower CI values than combinations of the 
drug with Ad5.  Taking into account that combinations with a replicating virus 
also resulted in virus-induced cell death, we expected synergy with a non-
replicating virus to be less efficient in vitro. The results observed could be 
explained by several factors. First, the replication deficient virus only expressed 
E1A-12S, inducing a stronger transcriptional repression than Ad5. Secondly, 
E1A-12S was constantly expressed after infection while E1A in Ad5-infected 
cells was expressed in the context of viral cycle progression. Last, we must also 
take into consideration that the bystander effects of E1A expressed by AdE1A-
12S were possibly greater due to constant strong expression in infected cells. In 
order to obtain a low CI value both virus and drug must work in synergy with one 
another; in most cases when replicating viruses were used, EC50 value decrease 
for the drug was observed, but virus dose-response curve were less affected in 
each combination. This indicates that viral toxicity is not greatly affected by 
combination with drugs, but viral proteins sensitised cancer cells to the apoptotic 
actions of the chemotherapy. 
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The improvement in the synergistic interactions was greater for 
mitoxantrone than for docetaxel, possibly because E1A can better sensitise cells 
to apoptotic pathways that are upregulated by mitoxantrone but not by docetaxel. 
Docetaxel is a taxane that bind to ß-tubulin monomers by stabilising microtubules 
and arresting their depolymerisation (17). This leads to inactivation of Bcl-2 and 
apoptosis. It has also been proposed that docetaxel induces cell death through a 
mechanism different from apoptosis termed mitotic catastrophe that is dependent 
on caspase-2 activation (17, 238, 245). If docetaxel-inducted cell death was 
triggered by the same caspases as mitoxantrone, we would expect similar 
sensitisation to the taxane as to the DNA-damaging agent. Although we observed 
sensitisation to docetaxel, the viral concentration needed was higher than for 
mitoxantrone. In addition, synergy between AdE1A-12S and docetaxel was not as 
efficient as with mitoxantrone. We also observed that E1A-1104 failed to sensitise 
prostate cancer cells to docetaxel. So it is possible that the mechanisms underlying 
E1A-mediated sensitisation are similar for both DNA-damage and cytostatic 
agents and that both agents activated similar proapoptotic proteins that target 
different signalling pathways. Maybe this only applies to mitoxantrone, as one 
report indicates that mitoxantrone could inhibit microtubule assembly in addition 
to its known DNA-damaging properties, being a drug that works by two 
distinctive mechanisms (15).  Caspase-2 would be a good candidate to regulate 
the apoptotic processes with both drugs; apoptosis induced by cytoskeletal 
disruption is highly dependent on caspase-2 activation of the mitochondrial 
apoptotic pathway, as caspase-2
-/-
 cells are resistant to taxane-induced cell death 
(245). This would induce translocation of Bax, release of cyt c and upregulation 
of caspase 10, 9, 8 and 3, as described after docetaxel or taxol treatment. 
Topoisomerase II inhibitors, on the other hand, can activate caspase-2 dependent 
apoptotic pathways in both a cytochrome c dependent and independent manner 
(235). We hypothesise that E1A can upregulate both mechanisms, although it 
might be more efficient at sensitising cells to drugs affecting apoptosis involving 
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DNA-damage. In addition, little is known about the effects in tubulin and 
cytoskeleton during combination treatments; tubulin expression is downregulated 
after adenovirus infection and tubulin specific chaperones are upregulated (246), 
possibly promoting tubulin degradation. In addition, the cytoskeleton shows 
changes in configuration after infection that could alter, positively or negatively, 
the effects of cytostatic agents.  
 
These findings have implications in the future design of adenoviral vectors 
for prostate cancer therapy. The E1A mutations chosen to design new viruses 
should retain the CR1 region binding to p300/CBP in order to maintain the 
sensitising potential of E1A, in addition to retaining the same toxicity as Ad5 in 
cancer cells. On the other hand, viruses unable to bind the pRb family members 
are a better option, as they maintained sensitising potential and viral toxicity 
similar to Ad5. These results also suggest that the use of DNA-damaging agents 
in combination with adenovirus therapy may be more efficient than the use of 
cytostatic drugs, as these did not synergise with viral therapy as efficiently as 
DNA-damaging agents. We also showed that mitoxantrone treatment increased 
the infectability of the cells, and future work will aim to investigate the 
advantages of drug treatment prior to adenoviral infection, in order to maximise 
the number of infected cells. Further research will also aim to elucidate the role of 
other viral genes in sensitisation; a careful examination of the effects of viral gene 
expression on chemosenstitisation would lead to the construction of much more 
efficient viruses for the use in the clinic. 
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8Chapter 8 
 
 
 
 
Future directions 
 
 
 
 The data discussed in this thesis show that binding to p300/CBP is 
essential to efficiently sensitise prostate cancer cell lines to both mitoxantrone and 
docetaxel. The great number of differences in the survival and apoptotic pathways 
in the cell lines tested helped us identify that E1A binding to p300/CBP sensitised 
prostate cells by p53 and pRb independent mechanisms. Further research is 
needed to identify the molecular mechanisms of the observed sensitisation. The 
molecular changes after drug treatment must be better understood, together with 
the involvement of p300/CBP. Based on the literature and the available evidence 
discussed in the previous chapter, the effects of the combination treatment on 
certain promoters, like the topoisomerase II promoter, involves cofactors such as 
Sp1 that are modified and regulated both by p300/CBP and the p38 pathway, also 
suggested to be involved in sensitisation. It would be interesting to use new E1A 
mutants deleted in the CR1 domain binding to pRb, to fully understand the 
involvement of pRb in sensitisation of pRb-positive cells and alternative 
mechanisms of sensitisation in cells with mutated pRb. Understanding how E1A 
regulates the transcription of cellular factors could also determine why 
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sensitisation to mitoxantrone was more effective than to docetaxel. As discussed 
previously, this could be due to a double sensitisation by E1A in combination 
with mitoxantrone, both at apoptotic pathways and at the promoter level of genes 
that are not affected by docetaxel treatment. The identification of the mechanisms 
of sensitisation to DNA-damaging and cytoskeleton disruption agents could lead 
to the discovery of common targets of E1A and the design of therapies that 
maximise sensitisation by targeting those proteins.  
 
The cancer specificity of the E1A-deletion mutants should be further 
analysed. The data in this thesis has focused on the sensitising abilities of the 
different E1A mutations. However, in order to use these findings for the 
construction of new viruses, we must assess the impact of the E1A modifications 
on replication and toxicity in normal cells. We observed that E1A-1102 and E1A-
1108 retained the sensitising ability of wild type E1A, but further research should 
elucidate whether one of these mutations confers better cancer selectivity in the 
context of a replicating virus. Replication and toxicity of the replication selective 
E1A-mutant adenoviruses used in this thesis should be evaluated; this would 
allow the determination of the optimal E1A mutation for the construction of new 
replicating viruses for prostate cancer treatment. In addition, the sensitising 
abilities of these E1A-mutant proteins should also be compared in vivo. The use 
of the replication deficient viruses in animal models night not result in significant 
tumour regression, since these viruses do not replicate and viral particles could 
also be rapidly cleared. However, in combination with chemotherapy, we might 
obtain interesting results even in the absence of replication as previously shown 
(145). We must consider these viruses as a tool to understand the effects of E1A 
both in vitro and in vivo, rather than good candidates for the use in the clinic. 
Nevertheless, new evidence from in vivo studies together with data from normal 
cells would be useful to finally choose the best E1A mutations for evaluation in 
the clinic.  
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New replication-selective adenoviruses could then be constructed 
expressing the selected E1A mutant. In addition, the same mutant could be 
inserted as a transgene to obtain expression of E1A at a late phase of infection. 
We observed that synergy with both docetaxel and mitoxantrone was more 
efficient with AdE1A-12S than with replication competent viruses. This suggest 
that a constant expression of the E1A mutant, not controlled by the self-regulation 
of E1A during the early phase of infection, might be more efficient at sensitising 
prostate cancer cells. Hence, the expression of E1A as a transgene could improve 
the sensitising efficiency of replicating viruses. The construction of viruses 
overexpressing E1A would imply new research to fully determine the 
consequences of E1A expression as a transgene. These viruses should be 
characterised: analyse the effect of E1A in replication, their toxicity and 
sensitising abilities in vivo and in vitro, compared to the already available E1A-
mutated replication selective and defective viruses. 
 
The data presented in this thesis and the future work that would arise from 
it will contribute to a more efficient design of adenoviruses for the treatment of 
prostate cancer, maximising toxicity, selective replication and sensitising 
potential. 
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9Chapter 9 
 
 
 
Appendix 
 
 
 
 
 
9.1 PCR verification of the viruses used in this thesis. 
 
The following figures show the PCR products of E1A, E1B and E3 in the 
viruses used in this thesis. E1A was amplified in all viruses to check size 
compared to Ad5 E1A. An E1B fragment was amplified to check presence of this 
gene in the replication competent viruses and its absence in the AdE1A-mutant 
viruses. In addition, the deletion in the dl1520 mutant is reflected by a small size 
of the amplified product. Amplification of E1B in AdE1A-1102, AdE1A-1104 
and AdE1A-1108 was observed after 35 cycles of PCR. The band obtained was 
fainter than that obtained for the replication competent viruses. It is possible that 
recombination between the viral plasmid and the HEK293 cells genome took 
place, resulting in a small proportion of virus carrying E1B. The AdE1A-1102 
and AdE1A-1108 viruses showed defective replication and a toxicity similar to 
AdE1A-12S, what suggests that if recombination took place, it only resulted in a 
minor proportion of virus carrying E1B. A fragment of the E3 gene was also 
amplified to check the absence in the AdE1A-mutants. 
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Fig. 57. E1A PCR amplification for each replication competent E1A-mutant vadenovirus. 
As expected, the dl312 mutant did not show any band for E1A and the mutant viruses 
showed bands smaller than that of Ad5, as these mutants only expressed the E1A-12S 
protein and not E1A-13S. PCR was run as described in materials and methods using 
primers for the whole E1A gene; the sequence of the primers can be found in the 
materials and methods chapter. 
Fig. 58. E1A amplification on AdE1A-mutant viruses. The AdE1A-12S virus contained 
a bigger E1A fragment, as it carried the whole E1A-12S cDNA without any deletions. 
The E1A DNA amplified on the other viruses was slightly smaller than the band for 
AdE1A-12S. This indicated the absence of the deleted region, what was also confirmed 
by sequencing.  
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Fig. 59. E1B amplification. Primer set 6, described in materials and methods, was used to detect 
the presence of the E1B gene in each virus used. All replication competent viruses contained the 
E1B gene. The dl1520 mutant showed a smaller band than Ad5, as it is deleted in the E1B-55K 
gene. E1B was not present in the AdE1A-12S virus; amplification was observed in the other 
AdE1A-mutant viruses. This could be due to recombination with the cellular genome during the 
production of the viruses, resulting in a small proportion of viruses containing E1B. The bands for 
E1B in these viruses were faint compared to their replication compentent equivalents, indicating, 
that presence of E1B is reduced to a small proportion of virus. 
Fig. 60. E3 amplification for each virus used. E3 was amplified using the primer set 7 described in 
the materials and methods chapter. E3 was detected in all replication competent viruses but not in 
the replication deficient AdE1A-mutant viruses. 
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9.2 Sequence verification of the E1A mutant cDNAs used 
in this thesis. 
  
All E1A cDNAs used in this thesis were sequenced by the Genome Centre 
(Institute of Cancer). First, the E1A-12S cDNA sequence was compared to the 
consensus sequence of E1A-13S cDNA, to observe the lack of the region 
corresponding to the CR3 (Fig. 61). All E1A-mutant sequences were aligned 
against the consensus sequence for E1A-12S cDNA. The E1A-1102 mutation 
lacked 30 nucleotides corresponding to amino acids residues 26 to 35 (Fig. 62); 
E1A-1104 also showed the correct deletion of 39 nucleotides (Fig. 63) and E1A-
1108 lacked the 12 nucleotides that code for the amino acid residues 124 to 127 
(Fig. 64). 
 
 
Fig. 61. Alignment of the E1A-12S cDNA obtained to construct the AdE1A-12S virus to the 
consensus sequence of E1A-13S. 
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Fig. 62. Alignment of E1A-12S sequence (on top) against the sequence of the E1A-1102 mutant 
used in this thesis (bottom sequence). The deleted region in the E1A-1102 mutant corresponded to 
the deletion of residues 26 to 35, indicating that the E1A-1102 constructed would produce the 
correct mutant protein. 
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Fig. 63. Alignment of E1A-12S (top) against the E1A-1104 constructed (bottom). The deletion in 
E1A-1104 corresponded to the sequence coding for amino acid residues 48 to 60, verifying the 
identity of the E1A-1104 mutant. 
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Fig. 64. Alignment of E1A-12S (top) against E1A-1108 (bottom). The small deleteion observed in 
the E1A-1108 cDNA constructed corresponded to the residues missing in the E1A-1108 consensus 
sequence. 
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